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ABSTRACT 
 
Quantitative Imaging in Epilepsy (PET) 
NMDA and Opioid Receptor Availability in Focal Epilepsy 
 
Introduction 
Epilepsy is a heterogeneous collection of neurological diseases characterised clinically by 
recurrent seizures. Pre-clinical models implicate derangements in ligand-gated receptor-
mediated neurotransmission in seizure generation and termination. In this thesis, the author 
quantified activated N-methyl D-aspartate- and opioid peptide receptor availability in adults 
with focal epilepsy.  
 
Methods 
This thesis consists of three positron emission tomography (PET) studies of adults with focal 
epilepsy, using [18F]GE-179 (activated NMDA receptors) and [11C]diprenorphine (DPN; 
opioid receptors) radioligands. A novel resolution-recovery technique, Structural Functional 
Synergistic – Resolution Recovery (SFS-RR), was applied to pre-existing paired [11C]DPN 
PET datasets acquired from adults with temporal lobe epilepsy (TLE). Activated NMDA 
receptor availability was quantified in adults with frequent interictal epileptiform discharges 
(IEDs), by regional compartmental modelling and model-free voxelwise analyses. Statistical 
parametric mapping was used to identify significant differences in volumes-of-distribution 
(VT) between populations.  
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Results 
[18F]GE-179 had good brain extraction with a relatively homogeneous distribution and 
moderately-paced kinetics in grey matter. The two brain compartments, four rate-constants 
model best described the radioligand’s kinetics in grey matter. Global increases in [18F]GE-
179 VT were seen for seven of 11 participants with frequent IEDs. Focal increases in [
18F]GE-
179 VT of up to nearly 24% were also identified for three of the 11 participants. A post-ictal 
increase in [11C]DPN VT was identified in the ipsilateral parahippocampal gyrus.  
 
Discussion 
This first-in-man evaluation of [18F]GE-179 evidenced several properties that are desirable in 
PET radioligands, but the specificity of binding requires further characterisation. The results 
suggest focal increases in activated NMDA receptor availability in participants with 
refractory focal epilepsy, and also post-ictal increases in opioid peptide availability in the 
parahippocampal gyrus in TLE. Both findings may have pathophysiological relevance, and 
illustrate the potential of quantitative ligand PET with advanced post-processing to investigate 
changes in inhibitory and excitatory receptor systems in the epilepsies in vivo.  
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PREFACE 
__________________________________ 
‘Epilepsy’ is a common neurological problem that is characterised by recurrent, unprovoked 
seizures. Despite much progress in recent years, the pathophysiology of the epilepsies is not 
completely understood. Pharmacotherapy entails side-effects, and the treatment response is 
unsatisfactory for a large minority of people with epilepsy. Resective surgery is not without 
risk, but can result in seizure-freedom.   
 Investigative modalities such as electroencephalography (EEG), 
magnetoencephalography (MEG), magnetic resonance imaging (MRI) and single-photon 
emission tomography (SPECT) can be used to assist the diagnosis epilepsy, to facilitate the 
localisation of epileptogenic brain tissue, and to provide insights into the pathophysiology of 
the condition. These modalities are complementary, and each has its own limitations.    
This thesis presents data generated via positron emission tomography (PET), a 
versatile nuclear medicine imaging modality that is safe, minimally-invasive, and used 
clinically for the investigation of refractory epilepsies (and other conditions). A novel PET 
radioligand, [18F]GE-179, was used in an attempt to measure activated N-methyl D-aspartate 
(NMDA) receptor availability in participants with epilepsy. Success in this regard would 
highlight an investigation capable of providing novel in vivo data of potential 
pathophysiological and clinical relevance, for both epilepsies and other neurological and 
psychiatric conditions. A novel PET post-processing method, Structural and Functional 
Synergistic Resolution – Recovery (SFS-RR) was also used to analyse previously-acquired 
[11C]diprenorphine ([11C]DPN) data, in an attempt to accurately quantify opioid peptide 
receptor (OPR) availability in temporal lobe epilepsy (TLE). Success in this regard would 
provide additional insights into the relevance of OPR-based neurotransmission to the 
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pathophysiology of epilepsy, and also highlight an approach to derive more informative data 
from PET scans in general.        
 
Research Objectives 
The overall objectives of the research reported in this thesis were: 
1. To evaluate the potential of a novel PET radioligand, [18F]GE-179, to quantify 
activated NMDA receptor availability in humans in vivo 
a.In healthy control participants;  
b.In participants with frequent interictal epileptiform discharges (IEDs). 
2. To apply a novel partial-volume effect (PVE) correction technique to previously-
acquired [11C]DPN data 
a.To quantify OPR availability in participants with refractory TLE. 
 
Author’s Contributions 
The author was responsible for: 
 Data processing and analyses 
 Publication and dissemination of findings 
The author was also responsible for the following, specific to the [18F]GE-179 studies: 
 Acquiring approval from regulatory authorities (National Health Service (NHS) local 
ethics committee, NHS Research and Development Departments, the Administration 
of Radioactive Substances Advisory Committee (ARSAC)). 
  Participant identification, liaison, and recruitment including 
o Attendance at outpatient epilepsy clinics 
o Visits to inpatient epilepsy and telemetry units  
 Data acquisition including: 
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o Informed consent 
o Arterial and venous cannulation 
o EEG data acquisition 
o Radioligand administration 
The author was also responsible for the following, specific to the [11C]DPN study: 
 Adaptation and correction of existing MATLAB (.m) scripts 
 Creation  of novel MATLAB scripts 
 
Thesis Structure 
This thesis presents a substantial body of work addressing the objectives specified above. The 
thesis is organised as follows:  
1. Chapter 1 presents a concise summary of the state of the art, describing the various 
forms of the epilepsies, with a review of existing investigative (particularly 
neuroimaging) methodologies and receptor systems of relevance to the thesis.   
2. Chapter 2 summarises common materials and methods used in the research. Aspects 
that are specific to particular studies are discussed in the context of the individual 
study later in the thesis. 
3. Chapter 3 characterises [18F]GE-179 PET in healthy control participants, detailing the 
cohort demographics, methodology, results achieved and research implications. 
4. Chapter 4 reports the application of [18F]GE-179 PET imaging to participants with 
frequent IEDs, detailing the cohort demographics, methodology, results achieved and 
research implications. 
5. Chapter 5 describes the implementation and application of SFS-RR to paired 
[11C]DPN PET datasets, detailing the methodology, results achieved and research 
implications. 
  
28 
6. Chapter 6 presents an overall discussion of the research, and reviews the main 
findings, implications and limitations.  
7. Chapter 7 presents suggestions for further work, identifying the next logical steps in 
the development of the research. 
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CHAPTER 1 
INTRODUCTION and BACKGROUND 
__________________________________ 
1 INTRODUCTION AND BACKGROUND 
1.1 The Epilepsies  
‘Epilepsy’ defines a number of different syndromes whose cardinal feature is a predisposition 
to recurrent, unprovoked seizures (Chang and Lowenstein, 2003, Duncan et al., 2006, Beghi, 
2007). A common neurological problem worldwide, conservative estimates suggest 
approximately 5% of the general population will have the condition during their lifetimes, 
with a prevalence of approximately 5 per 1000 people and an incidence of approximately 50 
per 100,000 people per year (Sander, 2003, Forsgren et al., 2005). Epilepsy can occur in 
people of all ages and has a wide range of causes, presentations, and associated co-
morbidities.  
In developed countries, up to one third of patients fail to achieve seizure remission 
(Sander, 2003), i.e. develop chronic (refractory) epilepsy (Kwan and Sander, 2004). Epilepsy 
is also strongly associated with neurological (Zaccara, 2009), psychiatric (Gaitatzis et al., 
2004b), cognitive and behavioural (Hermann et al., 2008) co-morbidity. People with epilepsy 
have a reduced life expectancy (Lhatoo et al., 2001, Gaitatzis et al., 2004a). 
Despite several attempts to introduce a revised system (Engel, 2006, Berg et al., 
2010), epilepsies are still classified and described in accordance with the 1989 schema of the 
International League Against Epilepsy ((ILAE; (ILAE, 1989)). The major distinction is 
between ‘localisation-related’, ‘partial’, or ‘focal’ epilepsies [herein referred to as ‘focal’ 
only], ‘in which seizure semiology or findings at investigation disclose a localised origin of 
  
30 
the seizures’; and ‘generalised’ epilepsies ‘in which the first clinical changes indicate initial 
involvement of both hemispheres’ and ‘the ictal encephalographic patterns initially are 
bilateral’.  
 Focal epilepsies are the most common seizure disorder in adults. This introduction 
will describe the investigation of focal epilepsies, particularly frontal and temporal, in adults 
only, although the findings might additionally be applicable to generalised epilepsies and 
younger populations.  
 
1.1.1 Temporal lobe epilepsy (TLE) 
Temporal lobe epilepsy (Engel Jr, 1996) is the most common of all adult, focal epilepsies, 
accounting for approximately 60-70% of cases (Duncan, 2007). TLEs can be described in 
terms of aetiology or localisation (see Figure 1 for a depiction of cortical anatomy). The major 
subtype of TLE is medial (mTLE; also known as mesial or mesio-basal) temporal lobe 
epilepsy, which is associated with the presence of hippocampal sclerosis (mTLE-HS; for 
review see: (Malmgren and Thom, 2012)); however, other symptomatic (resulting from a 
‘known or suspected disorder of the central nervous system’ (ILAE, 1989)) or cryptogenic 
epilepsies (presumed symptomatic but of unknown cause) are seen in the medial temporal 
lobe. Lateral (also known as neocortical) TLE is also commonly encountered, and can be 
symptomatic or cryptogenic (Engel Jr, 1996, Theodore, 2004, Walczak, 1995). 
Epileptic seizures are classified and described according to latest ILAE-endorsed 
schema (ILAE, 1981). ‘Simple’ seizures are those with retention of consciousness, whereas 
‘complex’ is used to describe those in which consciousness is impaired (ILAE, 1981). 
‘Secondarily generalised’ is used to describe seizures characterised by focal discharges on 
electroencephalography (EEG) that are later seen over most of the brain. 
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FIGURE 1: Functional anatomy of the cerebral cortex.  
Frontal lobe is shown in orange/red, temporal lobe in yellow/purple, parietal lobe in blue, occipital lobe in green. Top – lateral view of left hemisphere; bottom – medial 
view of right hemisphere. (Taken from (Crossman and Neary, 2010)). 
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1.1.1.1 Clinical features of TLE 
Simple medial temporal lobe seizures are characterised by a sensation of epigastric rising, 
emotional symptoms (e.g. usually fear), and sometimes olfactory or gustatory hallucinations 
(Engel Jr, 1996). Where impairment of consciousness follows (a ‘complex’ seizure), there is 
usually motionless staring, altered responsiveness, oro-alimentary and gestural automatisms, 
and later reactive automatisms lasting a couple of minutes (Engel Jr, 1996). Postictal amnesia 
of the event, and disorientation for several minutes, is common. Secondarily generalised 
seizures are relatively rare.   
 The onset of seizures in those with mTLE is usually between five and ten years of age. 
Initially responsive to treatment, the seizures often recur in the teenage years (Berg et al., 
2003, Berg et al., 2006) (the  ‘stuttering course’) and frequently, i.e. in approximately 25% of 
cases, become refractory to medical treatment, more so than in other epilepsies (Semah et al., 
1998). The neurological examination is usually unremarkable; however, formal 
neuropsychological testing typically reveals material-specific memory deficits.  
The clinical features of lateral temporal lobe seizures show considerable overlap with 
those of medial TLE (Williams et al., 1987). Auras commonly herald seizure onset, and are 
typically hallucinatory (especially auditory, but also gustatory, olfactory, or visual). 
Consciousness may be preserved until later in the seizure, after which motionless staring and 
automatisms ensue. The latter may have more prominent motor manifestations than in medial 
temporal lobe seizures. Similar post-ictal phenomena to that of medial temporal lobe seizures, 
such as amnesia for the event, are commonly observed.   
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1.1.2  Frontal lobe epilepsy (FLE) 
The term ‘extra-temporal lobe epilepsy (ETLE)’ describes a heterogeneous collection of focal 
epileptic syndromes of origin outside the temporal lobe. In particular, this term refers to the 
focal adult-onset epilepsies, frontal lobe epilepsy (FLE), the parietal (PLE) and occipital 
(OLE) lobe epilepsies. ETLE excludes severe paediatric epilepsy syndromes, febrile 
convulsions, ‘benign’ childhood seizure susceptibility syndromes, and the idiopathic 
generalised epilepsies. 
 Frontal lobe epilepsy (FLE) is the most common ETLE, representing approximately 
20-30% of recurrent/refractory focal seizures (Manford et al., 1992, Rasmussen, 1991); for 
review: (Duncan, 2007, O'Muircheartaigh and Richardson, 2012, Ryvlin et al., 2006). The 
condition has been less well studied than TLE, and both clinical and electroencephalographic 
classification remains challenging (ILAE, 1989).  
 
1.1.2.1 Clinical features of FLE 
 Frontal lobe seizures are typically short events that occur without warning and are 
followed by a very rapid recovery. These seizures commonly occur in sleep, often in clusters 
of five or more per night. A wide variety of seizure patterns is seen in FLE, though typically 
highly stereotyped in each individual patient. Various attempts have been made to categorise 
the seizure types (Geier et al., 1977, Rasmussen, 1983, Manford et al., 1996) since the 6-site 
onset scheme proposed by the ILAE (ILAE, 1989), such as the following: 
 
(a) Unilateral/focal clonic seizures.  
This includes the classical, hemiclonic Jacksonian march. 
 
 
  
34 
(b) Bilateral asymmetrical tonic seizures. 
These seizures are characterised by turning of the head and eyes, and posturing of the arms 
and legs. Seizures arising from the supplementary motor area are classically manifest by the 
‘fencing posture’, with the contralateral arm abducted at the shoulder, externally rotated, and 
flexed at the elbow. Motor automatisms may occur, particularly in seizures arising from the 
premotor cortex.  
 
(c) Complex motor seizures. 
These seizures are manifest as ‘hypermotor’, ‘gestural’ or ‘repetitive’ patterns of complex 
motor activity. They may have frontopolar, anterior cingulate, opercular insular or 
orbitofrontal origin. The presence of aura leads to their confusion with temporal lobe seizures. 
Autonomic (such as facial flushing or pallor, incontinence of urine) and motor automatisms 
are common. Post-ictal dysphasia may occur.   
 
 In summary, however, the ictal semiology in frontal lobe epilepsy is inconsistently 
and only partly explained by the site of seizure onset. The most likely explanation for this is 
the activation of the same specific brain circuits by seizures of differing site of onset by 
means of propagation.  
 
1.1.3  Parietal and occipital lobe epilepsies (PLE, OLE) 
Epilepsies arising from the posterior cortices (i.e. parietal and occipital lobes; Figure 1) are 
comparatively rare. Somatosensory epilepsy has been reported in only1.4% of people with 
epilepsy (Mauguiere and Courjon, 1978), and most often to describe PLE (Salanova et al., 
1995, Siegel, 2003).  
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 The prominent ictal manifestations of parietal lobe seizures are elementary sensory 
phenomena at seizure onset. These may be positive (such as paraesthesiae) or negative, and 
are usually perceived contralateral to the hemisphere of origin. Pain can be an ictal symptom, 
and less commonly, thermal perceptions (such as a burning sensation), sexual phenomena, 
ideomotor apraxia (a feeling of being unable to move part of the body), and disturbance in 
body image. Visual illusions have been described in PLEs of the non-dominant lobe, in 
association with lesions close to the occipital lobe. The simplest illusions involve objects that 
are perceived as enlarged or reduced in size, compressed, wavy, or colourless (Bender et al., 
1968). Consciousness is often preserved in parietal and occipital lobe seizures, or at least until 
late in the evolution of the seizure.  
 Occipital lobe epilepsies (OLEs; for review see: (Adcock and Panayiotopoulos, 2012)) 
can be broadly divided into symptomatic (Kuzniecky, 1998) or cryptogenic/idiopathic 
conditions. OLE and also symptomatic OLE have both been reported to have a prevalence of 
8% in focal epilepsy (Gibbs and Gibbs, 1952, Andermann et al., 1993); whilst the precise 
incidence and prevalence of OLE is not known, it is generally considered rare. OLE, 
particularly idiopathic, has a much higher incidence in paediatric populations – these 
syndromes are not considered here. Additional parietal syndromes of childhood, 
migraine/epilepsy syndromes involving the parietal and occipital lobes, and relevant 
encephalopathies are not described here (for review see: (Sveinbjornsdottir and Duncan, 
1993)). 
OLE manifests ictally as elementary visual hallucinations, although these are not 
unique to seizures with onset in the occipital lobe (Ludwig et al., 1976). The hallucinations 
are usually crude sensations of white light, and can take a variety of shapes such as a line, a 
zigzag of lines, circles, etc. They may occur in one hemifield or the entire visual field, and 
have been associated with discharges from the lateral occipital cortex (Russell and Whitty, 
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1955). Other ictal semiology of OLE includes complex visual hallucinations, such as pictures 
of animals, peoples, scenes, numerals or letters, associated with parieto-occipital lesion 
(HORRAX and PUTNAM, 1932). 
 
1.2 Aetiology of focal epilepsies 
1.2.1 Aetiology of TLE 
Temporal lobe epilepsy is associated with HS, more than any other pathology (Margerison 
and Corsellis, 1966), which itself has been associated with prolonged complex febrile 
convulsions in childhood (VanLandingham et al., 1998, Scott et al., 2003).  
It is debated whether hippocampal sclerosis in mTLE represents the cause or a 
consequence of repeated seizures. In favour of the former, removal of the sclerosed 
hippocampus from humans can be curative. In addition, bilateral hippocampal atrophy was 
actually seen prior to prolonged febrile convulsion in two children (VanLandingham et al., 
1998). In contrast, recurrent seizures in animals (baboons) result in hippocampal damage that 
is similar to HS (Meldrum et al., 1974). Interestingly, hippocampal atrophy has been seen in 
unaffected first-degree relatives of individuals with a familial form of TLE, suggesting HS in 
isolation is insufficient to cause seizures (Cendes et al., 1998).  
 Other pathologies that may give rise to TLE include benign tumours such as 
dysembryoplastic neuroepitheliomas (DNETs; Figure 2), cavernous angiomas, gliomas, 
malformations of cortical development including focal cortical dysplasias (FCDs), and gliosis 
secondary to cerebral infection (meningitis or encephalitis) (Duncan, 2007).  
 
1.2.2 Aetiology of FLE 
In a large cohort of 250 patients treated surgically for FLE, nearly 31% were related to head 
injury, approximately 25% were related to cerebral tumour, approximately 10% to birth 
  
37 
trauma, and nearly 6% to gliosis (from abscess, haematoma etc.; (Rasmussen, 1963)). In 
nearly 12% of cases the cause remained unknown. Other series have reported similar (20 – 
30%) prevalence of cerebral tumour (Wolf et al., 1993, Frater et al., 2000). Focal cortical 
dysplasia (Figure 3) is a frequent cause (Marusic et al., 2002); in one surgical series, 58% of 
patients were diagnosed with a malformation of cortical development (MCD) on the basis of 
post-operative histology (Janszky et al., 2001).  
The spectrum in non-surgical FLE is probably less dominated by tumours, and may 
include malformations (especially FCD) and vascular anomalies. A very small proportion of 
focal (including frontal) lobe epilepsies are caused by single-gene defects, such as autosomal 
dominant nocturnal frontal lobe epilepsy, which is associated with mutations in subunits of 
the nicotinic receptor.  
 
1.2.3 Aetiology of PLE, OLE 
The aetiology of parietal and occipital lobe epilepsies, other than for the syndromic subtypes 
listed above, is largely as for that of frontal and temporal lobe epilepsies. Focal parietal and 
occipital lobe seizures may occur in reflex to specific stimuli, such as phototic stimuli, 
patterns, and mental activity (Goossens et al., 1990) such as reading (Bickford et al., 1956) 
and mathematical calculations, and have been proposed to result from diminished inhibition 
in dysfunctional parietal (Goossens et al., 1990) and occipital lobes.  
 
1.3 Investigations in the epilepsies 
1.3.1 Magnetic resonance imaging  
Magnetic resonance imaging (MRI) is the method of choice used in the evaluation of adult, 
focal epilepsies to identify structural abnormalities that might be the cause of the epileptic 
seizures (for review see (Craven et al., 2011)). For example, (Griffiths et al., 2005) identified 
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abnormalities in 26% of adults with focal epilepsy with MRI; in those with refractory 
epilepsy, the yield can be much greater (Urbach et al., 2004, Von Oertzen et al., 2002). MRI 
is particularly valuable in the evaluation of those with refractory focal epilepsies prior to 
respective surgery. Epilepsy-tailored protocols typically included a high-resolution, gradient 
echo three dimensional (3D) T1-weighted volume (MPRAGE or SPGR), T2, and coronal 
fluid-attenuated inversion recovery (FLAIR) sequences, ideally on a 3T scanner (Craven et 
al., 2011, Deblaere and Achten, 2008). 
MRI is sensitive to malformations of cortical development, including perisylvian (i.e. 
frontal) polymicrogyria, but also heterotopia (clusters of normal grey matter in abnormal 
locations), lissencephaly (shallow sulci), and hamartomas. Focal cortical dysplasia is seen as a 
region of thickened (>4mm) cortex, with indistinct grey-white matter boundary, and increased 
white matter (T2 or FLAIR) signal (Craven et al., 2011, Deblaere and Achten, 2008). They 
are usually extratemporal, and often difficult to differentiate from tumours. In tuberous 
sclerosis (TS), multiple tubers are seen (best on T2 and FLAIR) in both cortical and sub-
cortical tissue, often with a predilection for the frontal lobes. 
 Vascular malformations such as arteriovenous malformations and in particular 
cavernomas (cavernous angiomas) are associated with focal epilepsies. The former are 
described as ‘a black bag of worms’ on T2 images, whereas the latter have a nodular or 
‘popcorn’ appearance with mixed-intensity core a low-signal haemosiderin ‘ring’ (Deblaere 
and Achten, 2008). Other potentially epileptogenic abnormalities that can be identified with 
MRI include sequelae of central nervous system (CNS) infections such as encephalitis and 
intracranial tuberculosis, gliosis resultant from infarction or head trauma, and encephalocoele 
(herniation of the cortex through a bone defect) (Craven et al., 2011).  
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FIGURE 2: Dysembryoplastic neuroepithelioma (DNET).  
T2-weighted coronal imaging reveals hyperintense signal in the right temporal lobe, FLAIR imaging shows high signal in the solid element of the tumour. T1-weighted 
coronal imaging post-gadolinium does not show contrast enhancement. (Taken from (Craven et al., 2011)).     
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FIGURE 3: Focal cortical dysplasia.  
T1-weighted coronal inversion recovery shows low signal in the right temporal lobe white matter underlying an area of thickened cortex, T2-weighted imaging shows 
abnormal high signal, as does FLAIR imaging. (Taken from (Craven et al., 2011)).   
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The most common finding in TLE is mesial temporal sclerosis, evident on T1 images 
as loss of hippocampal volume, with increased signal intensity on T2 and FLAIR, and a loss 
of internal structure (Craven et al., 2011, Deblaere and Achten, 2008). The gliosis is often 
better appreciated on T2/FLAIR images. Visible atrophy corresponds to a decrease in volume 
of 15-35%, relative to the contralateral hippocampus and healthy controls (Cendes et al., 
1993, Fuerst et al., 2003). Histopathological examination has confirmed the existence atrophy 
in cases of MRI abnormality (Cascino et al., 1991). However, few newly diagnosed cases 
have detectable hippocampal atrophy (Van Paesschen et al., 1997, Briellmann et al., 2002). 
Hippocampal sclerosis is often associated with atrophy extending beyond the hippocampus 
(HS+) or other focal pathology such as tumour (+HS; for review see: (Malmgren and Thom, 
2012)). Tumours such as gangliomas, dysembryoplastic neuroepithelial tumours (DNETs) 
and low-grade astrocytomas are also frequently observed in TLE in isolation. In contrast, 
oligodendrogliomas are more frequently identified in the frontal lobes.  
 
1.3.1.1 Magnetic resonance spectroscopy  
Magnetic resonance spectroscopy (MRS) quantifies specific proton- (1H ) or phosphorous- 
(31P) containing metabolites in the brain in vivo. The technique detected metabolic 
abnormalities in the epileptogenic hemisphere of nearly all patients of several extra-temporal 
lobe epilepsy cohorts (e.g. (Garcia et al., 1995)). However, the changes had a much wider 
distribution than the presumed epileptogenic zone (Stanley et al., 1998, Li et al., 2000), and 
the technique appears to be of limited localising value. 
 
1.3.1.2 Diffusion tensor imaging 
Diffusion tensor imaging (DTI) measures directionality of water diffusion and can be used to 
provide a measure of white matter integrity (for review see: (Yang et al., 2011, Tournier et al., 
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2011). The value of DTI in frontal lobe epilepsy is yet to be evaluated in a large cohort. 
(Rugg-Gunn et al., 2001) revealed alterations in anisotropy and/or diffusivity in 10 of 30 
patients with normal MRI. Of the 30, six had been diagnosed with FLE on the basis of video 
and EEG telemetry; the contribution of these six patients to the total of ten patients with DTI 
abnormalities was not directly reported. However, three of six patients with both ictal and 
interictal EEG abnormalities in the frontal lobe had significant increases in mean diffusivity 
in the same regions (Rugg-Gunn et al., 2001). Rugg-Gunn et al also reported an area of 
increased diffusivity in a patient with refractory FLE and normal MRI (Rugg-Gunn et al., 
2002).    
Significantly reduced anisotropy and increased diffusivity was seen in ten of ten 
patients with MRI evidence of past acute and non-progressive cerebral injury; of these, five 
had interictal epileptiform activity in the frontal lobe(s) (Rugg-Gunn et al., 2001). In all 
patients, the areas of increased diffusivity corresponded to the abnormalities evident on the 
conventional MRIs. The same group evaluated DTI in 22 patients with partial seizures and 
malformations of cortical development (MCD; (Eriksson et al., 2001)). Ten of these 22 
patients had one or several MCDs in the frontal lobe(s). DTI revealed alterations in anisotropy 
and/or diffusivity within the MCD region in all 10 of these patients. In addition, in four 
patients, areas of decreased anisotropy and, in six patients, areas of increased diffusivity were 
detected outside the margins of the lesions seen on T1- and T2-weighted
 images (Eriksson et 
al., 2001). (Wieshmann et al., 1999) described DTI in 18 patients with partial epilepsy and a 
structural abnormality on standard T1- and T2-weighted MRI. Of these, three had an 
abnormality of the frontal lobe(s). Anisotropy was significantly reduced in all structural 
abnormalities, but mean diffusivity was increased in only two of the three patients with 
frontal lobe abnormality. The authors did not examine outside the regions of interest (ROI) 
(for example, using parametric mapping).  
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1.3.2 Electroencephalography 
Electroencephalography (EEG) is the graphical representation of the difference in voltage 
between two different cerebral regions plotted against time (Olejniczak, 2006). Synaptic 
activity is the most significant source of EEG potentials, which are in the microvolt (µV) 
range (Olejniczak, 2006). Fast action potentials are usually too short-lived to make a 
significant contribution to the signal. The exception to this rule is during synchronous firing, 
as occurs during sleep and in epileptic cortex. Combined synchronous activity of 
approximately 108 neurons in 6cm2 is required to produce scalp EEG; 20cm2 of cortex may be 
required to produce interictal spikes (Olejniczak, 2006).  
 EEG fields are primarily generated by pyramidal neurons of cortical layers III, V, and 
VI. The dorsal thalamus is considered the chief sub-cortical EEG rhythm generator, i.e. the 
pacemaker that synchronises populations of neocortical neurons (Timofeev and Chauvette, 
2011, Buser, 1964, Hughes and Crunelli, 2005).   
 The alpha rhythm (8 – 13 Hertz; Hz), a main rhythm seen at rest and with the eyes 
closed, is generated in several cortical areas (Hughes and Crunelli, 2005), although the 
occipital contribution is dominant. The beta (>13 – 30Hz; (Kozelka and Pedley, 1990)) and 
gamma rhythms (>30 Hz; (Whittington et al., 2011)) are fast waking rhythms that arise from 
cortex. During sleep, the GABA-mediated inhibition projects from the thalamus and inhibits 
these cortical generators and sleep spindles and high-amplitude delta waves are seen. Delta 
waves (<4 Hz; (Brigo, 2011)) result from potassium fluxes at voltage-gate thalamic and 
cortical ion channels. The theta rhythm, (5 – 7 Hz) has been associated with working memory 
functions (Sauseng et al., 2010). 
 EEG remains, with MRI, a primary investigative tool in the diagnosis and localisation 
of focal epilepsy. (Scalp) EEG provides a two-dimensional representation of three-
dimensional cortical neuronal activity; hence the location of the signal generator is 
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challenging and an active field of research (for review see: (Plummer et al., 2008, Michel et 
al., 2004)).  
Interictal (i.e. not occurring during a seizure) epileptiform discharges (IEDs) can occur 
in the absence of epilepsy; this, however, is rare (approximately 0.5 – 0.65% (Bennett, 1967, 
Gregory et al., 1993)) and there is a strong genetic component in the occurrence of IEDs 
without epilepsy. In contrast, repeated and/or sleep EEG reveals IEDs in approximately 80% 
of people with epilepsy (Binnie, 1996);  they are less common in patients with seizures arising 
from the frontal, parietal or occipital lobes than in temporal lobe epilepsy.  
Ictal (i.e. occurring during seizure(s)) EEG patterns are distinguished from IEDs in 
that 1) they evolve in terms of frequency and amplitude, and 2) they are associated with 
clinical symptoms. The most distinctive EEG feature of focal seizures is their evolution to 
high-amplitude activity with slower frequencies; however, over 70% of simple focal seizures 
do not have a clear correlate on scalp recordings.  
In contrast to mesial TLE, interictal and ictal discharges in neocortical temporal lobe 
epilepsy often extend beyond the anterior temporal electrodes to parasagittal regions 
(Foldvary et al., 1997, Gil-Nagel and Risinger, 1997). An identifiable EEG correlate is more 
frequently absent with this condition, ictal activity is usually slower, and may have a 
parasagittal maximum amplitude.  
 
1.3.2.1 EEG features of temporal lobe epilepsy  
The interictal scalp EEG in mTLE usually shows anterior or mid-temporal spikes and spike-
wave discharges, which may be unilateral or bilateral and independent (Engel Jr, 1996), and 
often propagate to frontopolar or posterior temporal electrodes (Emerson et al., 1995). 
Sphenoidal electrodes assist detection in medial TLE, and intermittent or persistent temporal 
slow waves may also be seen in this subgroup. Simple partial seizures are usually associated 
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with cessation of interictal spikes only. At the onset of loss of consciousness (i.e. in a 
complex partial seizure (ILAE, 1981)), characteristically low-voltage fast (five to seven 
Hertz) rhythmic activity is observed in one sphenoidal electrode (Risinger et al., 1989).  
In lateral TLE spikes are often maximal over the entire temporal lobe, and maximal 
along the lateral convexity (Duncan, 2007). In contrast to those of mTLE, the spikes of lateral 
TLE are usually smaller, and less prominent on sphenoidal electrodes.   
 
1.3.2.2 EEG Features of frontal lobe epilepsy  
The scalp EEG is of limited value in frontal lobe epilepsy. IEDs are only seen in 65 – 70% of 
patients, even with repeated examinations. Ictal correlates of clinical seizures are also 
frequently absent. When present, interictal and ictal discharges are commonly bilateral spike 
and wave, which may give the false impression of generalised seizure onset (Salanova et al., 
1993).  
The limited spatial resolution of scalp EEG hampers discharge localisation in FLE. 
Furthermore, distant, mesial, and deep gyral discharges are often undetectable due to signal 
attenuation (Laws et al., 1970).  Ictal EEG is often uninterpretable due to the extent of motor 
manifestation-related muscle artifact (Lee et al., 2000). One large study found scalp EEG to 
correctly localise 65% of seizures with onset in the lateral frontal lobes, as judged by seizure-
free post-surgical outcome (Foldvary et al., 2001). Moreover, mesial frontal lobes seizures 
were accurately localised in only 12%. Another study found localising patterns in only one 
third of patients with FLE (Bautista et al., 1998).  
Interictal epileptiform discharges, whilst present in 60 – 80%, are of limited localising 
value; they can be bilateral, multilobar, or generalised (Laskowitz et al., 1995). Indeed 
bilateral spikes have been reported as the most common interictal finding in this population 
(Quesney, 1991). The lateralisation derived from interictal EEG may be misleading (Blume 
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and Oliver, 1996). Even on intracranial recordings, the interictal discharges are often widely 
distributed, and may occur distant to the site implicated on scalp recordings (Salanova et al., 
1993). In contrast, interictal rhythmical midline theta, which is seen in approximately half of 
all FLE patients, does have localising value (Beleza et al., 2009). 
 Intracranial depth EEG (Guenot et al., 2001, Surbeck et al., 2011), where employed, 
has the limitation of only detecting discharges in the extreme vicinity of the electrodes. 
Subdural plates and arrays of subdural pegs (Surbeck et al., 2011, Blume et al., 2001) allow 
more extensive sampling, but sampling is restricted to the superficial cortex only.   
 
1.3.2.3 EEG Features of parietal and occipital lobe epilepsy  
The interictal scalp EEG in PLE is often discordant with clinical features, or is normal 
(Williamson et al., 1992a). Alternatively focal slowing may be seen, particularly in 
symptomatic cases. Widespread discharges are commonly observed (Williamson et al., 1992a, 
Cascino et al., 1993, Gibbs and Gibbs, 1952). 
 The interictal EEG in symptomatic OLE is frequently abnormal but often misleading; 
discharges are most frequently localised to posterior temporal electrodes, and strictly occipital 
in only 20% (Adcock and Panayiotopoulos, 2012). (Williamson et al., 1992b) reported that 
IEDs were confined to the occipital lobes in only two of a 25-strong surgical OLE cohort; 
similar findings were described for other symptomatic cohorts (Blume et al., 1991, Salanova 
et al., 1992). Secondary bilateral synchrony (lower amplitude epileptiform discharges over 
homologous regions and bilateral epileptiform activity are frequently observed (Salanova et 
al., 1992, Gibbs and Gibbs, 1952). 
 The semiology in both PLE and OLE commonly fails to consistently localise ictal 
discharges to a single brain region (Sveinbjornsdottir and Duncan, 1993). Ictal scalp EEG 
recordings of simple parietal seizures often resemble interictal recordings, or may show 
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diffuse suppression or abnormality which may be followed by parietal sharp waves 
(Williamson et al., 1992a). Subdural and depth electrode recordings do not seem to hold great 
localising value in this population (Williamson et al., 1992a).  
 Ictal scalp EEG in OLE is often unremarkable (Adcock and Panayiotopoulos, 2012) or 
fails to suggest an occipital lobe onset, especially in symptomatic cases (Salanova et al., 1992, 
Williamson, 1994). The most commonly identified ictal features are paroxysmal fast activity 
and/or fast spiking, with gradual anterior spreading (Takeda et al., 1969, Bancaud, 1969). 
Depth electrodes can reveal the occipital onset and the route of discharge spread/propagation 
(Williamson and Spencer, 1986). 
 
1.3.3 Single photon emission computed tomography  
Single photon emission computed tomography (SPECT) is a nuclear medicine technique in 
which the participant is injected with a ligand labelled with a photon-emitting radionuclide, 
such as technetium-99m (99mTc) or iodine-123 (123I) (for review see: (Accorsi, 2008, O'Brien, 
2000)). Gamma cameras detect an 140keV γ-ray emitted via radiodecay; a collimator lets pass 
only those that approach at certain angles; thus each point on the detector is associated with a 
line in space along which the radiodecay occurred.      
 SPECT is widely available and relatively inexpensive. On-site synthesis of the 
radioligand is not required, owing to the half-life of the commonly used radioisotopes. 
Radioligands used to image regional cerebral blood flow (rCBF) do not redistribute within the 
first two hours of initial uptake, allowing for off-site injection. However, the technique is of 
limited spatial resolution (e.g. approximately 10 mm full-width at half maximum (FWHM) 
which is worse than that of positron emission tomography), and sensitivity (less than 
approximately 0.01% of emitted photons contribute to the image) (Accorsi, 2008). Moreover, 
quantitative analysis is challenging (Beekman et al., 2001). In epilepsy research, subtraction 
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ictal SPECT and statistical comparison with a database of controls is increasingly performed 
alongside side-by-side ictal:interictal visual assessment (Lee et al., 2006, O'Brien et al., 1998, 
McNally et al., 2005).  
 SPECT is most widely used in epilepsy to estimate rCBF with 
[99mTc]hexamethylpropyleneamine-oxime ([99mTc]HMPAO) or [99mTc]ethyl cysteinate dimer 
([99mTc]ECD). Interictal SPECT imaging is a relatively insensitive localising and lateralising 
tool (Spanaki et al., 1999, Devous et al., 1998, Zaknun et al., 2008). Ictal SPECT, in contrast, 
more often reveals hyperperfusion that can be indicative of the epileptogenic zone. (Lee et al., 
2005) reported ictal-interictal subtraction [99mTc]HMPAO SPECT in 56 participants with 
refractory focal epilepsy associated with normal MRI. The predominant hyperperfusion was 
localised to the subsequently-resected lobe for 10 of 24 participants (42%) who achieved 
seizure-freedom. However, this was also the case for 13 of 32 participants (41%) who did not 
have a seizure-free outcome. 18 of the seizure-free 24 participants (75%) were lateralised by 
the technique, compared with 17 of the 32 participants (53%) of those with persistent seizure. 
Thus, the predictive value of localised or lateralised hyperperfusion, as visualised by ictal-
interictal subtraction [99mTc]HMPAO, for seizure-free (Engel class I) surgical outcome was 
reported as non-significant. However, the authors assumed that the largest and most intense 
(i.e. with the highest Z score) foci of hyperperfusion should be used to localise the 
epileptogenic zone, whereas in actual fact this is often more indicative of propagation than 
seizure onset (Dupont et al., 2006).  
 In the study described above, for the ictal scans (Lee et al., 2005) injected the 
radioligand with mean delay of 29 ± 17 seconds after seizure onset. The radioligand takes a 
further 30 seconds, approximately, to reach the brain; its concentration  peaks within 2 
minutes; and only around 70% is extracted during the first pass (Van Paesschen et al., 2007). 
Thus erroneous or inadequate localisation might be explained by depiction of the 
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epileptogenic (ictal onset) zone and seizure propagation in the ictal image. (Lee et al., 2006) 
have associated radioligand injection within 20 seconds of seizure described two SPECT 
patterns consistent with propagation for 10 of 15 participants (67%) with refractory focal 
epilepsy and MRI-visible FCD by (Dupont et al., 2006). In contrast, the predominant 
hyperperfusion localised to the FCD in only four cases (27%).  
 Smaller studies have described greater success, for example (O'Brien et al., 1998, 
O'Brien et al., 2000). (O'Brien et al., 2004) found that localisation with SISCOM was 
predictive of surgical outcome, for a cohort of 17 participants with FCD that subsequently had 
surgical resection. However, localisation was less strictly-defined than that of (Lee et al., 
2005) as hyperperfusion spanning more than one lobe, e.g. temporo-parietal could be 
considered localising if partially overlapping with the site of resection. Moreover, the 
‘excellent outcome’ group included participants with persistent, but ‘non-disabling’ seizures. 
Of the eight participants with such outcome, Subtraction ictal SPECT co-registered to MRI 
(SISCOM) was concordant with site of resection in four (50%); whereas SISCOM was 
concordant with the site of resection in four of the remaining nine participants (44%) with 
‘improved’ or ‘poor’ outcome.    
 Interestingly, ictal hypoperfusion of the frontal lobe (as assessed with [99mTc]ECD 
SPECT was been reported for all 11 participants with TLE-HS, in addition to ipsilateral 
temporal lobe hyperperfusion (Nelissen et al., 2006). Thus ictal SPECT has been 
hypothesised to visualise frontal ‘surround’ inhibition in addition to seizure onset on 
propagation.  
  
1.3.4 Positron emission tomography  
Positron emission tomography (PET) is a nuclear medicine technique in which the subject is 
injected with a ligand labelled with a positron-emitting radionuclide, such as fluorine-18 (18F) 
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or carbon-11 (11C) (Blokland et al., 2002, Frackowiak, 1989). PET cameras are used to 
simultaneously detect a pair of 511 keV γ-rays, which are released on each collision 
(annihilation) of the emitted positron with a nearby electron.  
 PET systems are exquisitely sensitive, and can provide absolute (quantitative) data. 
Radioligands that are indistinguishable from their non-labelled counterparts can be generated 
using carbon, nitrogen, or oxygen isotopes. The longer half-life of fluorine-18, approximately 
110 minutes, allows for off-site radioligand production and commercial distribution, whereas 
the short half life of carbon-11 (approximately 20.3 minutes) entails a low effective dose for 
the subject.  
[18F]fluoro-deoxyglucose ([18F]FDG) PET is used in the pre-surgical evaluation of 
subjects with refractory focal epilepsy, to image interictal cerebral metabolism. Zones of 
hypometabolism, compared with surrounding cortex, or compared with a database of normal 
controls, can help identify the presumed epileptogenic zone (Henry and Votaw, 2004). 
Additional radioligands designed to image benzodiazepine receptors, cannabinoid receptors, 
the D2 and D3 dopamine receptors, glutamate receptors, opioid receptors, serotonin receptors, 
and the serotonin transporter have also been described (Zimmer and Luxen, 2012).  
 The major limitation of PET is the need for a cyclotron and radiochemistry laboratory 
for radioligand synthesis (although for fluorine-labelled compounds this can be off-site and 
commercial distribution systems exist). The effective dose entailed by longer-lived isotopes 
such as fluorine-18, and the less-commonly used copper-64, iodine-124, is modest, in the 
range of 5-10 milliSieverts for a typical acquisition. Of the radiotracers discussed in this 
chapter, only [18F]FDG has found widespread clinical use. In addition, for many 
neurotransmission systems, a radioligand of suitable specificity and reliability is yet to be 
identified. Another limitation is the restricted spatial limitation (about 4-5 mm full-width at 
half maximum for most current PET systems; (Lee et al., 2005)). 
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1.3.4.1 Positron emission tomography in temporal lobe epilepsy  
Interictal [18F]FDG PET reveals ipsilateral temporal lobe hypometabolism in approximately 
60-90% of those with TLE (Henry et al., 1993b, Rugg-Gunn, 2009, Gaillard et al., 1995). 
Hypometabolism has also been reported in the ipsilateral insula (Bouilleret et al., 2002). A 
recent study found the technique lateralised 87% of those with TLE and normal MR imaging 
(Carne et al., 2004). However, localisation is less reliable; for example, (Hajek et al., 1993) 
were unable to demonstrate a clear relationship between the location of the epileptogenic 
focus as defined by EEG and the degree of hypometabolism. The diffuse hypometabolism is 
taken to represent widespread dysfunction of non-epileptogenic temporal lobe (Engel Jr, 
1996). 
 [11C]flumazenil (FMZ) PET shows reduced binding in the ipsilateral temporal lobe, 
which is less widely distributed than the hypometabolism in TLE seen with [18F]FDG (Savic 
et al., 1993, Henry et al., 1993a, Szelies et al., 1996, Debets et al., 1997, Juhasz et al., 2000), 
but not necessarily confined to sclerotic hippocampi in mTLE (Hammers et al., 2001). 
Moreover, [11C]FMZ binding in the hippocampus in vivo, which may be bilateral (Koepp et 
al., 1997), has shown good correlation with autoradiographic [3H]FMZ studies (Hand et al., 
1997, Koepp et al., 1998a). One series of 100 surgical candidates did not find [11C]FMZ PET 
superior to [18F]FDG PET in localising the seizure onset (Ryvlin et al., 1998); clinical utility 
is additionally limited by the need for on-site synthesis.    
(Kumlien et al., 1999) attempted to quantify activated N-methyl D-aspartate (NMDA) 
receptor availability in eight patients with medial TLE using the antagonist, [11C]ketamine. 
Reduced binding was seen on the ipsilateral temporal lobe; it is unclear whether this relates to 
hypoperfusion or tissue loss, rather than decreased NMDA receptor activation. 
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The mu opioid receptor agonist [11C]cartenafil showed increased binding in the (ipsi-) 
lateral temporal neocortex of those with TLE (Mayberg et al., 1991). Post-ictal increases in 
opioid receptor availability, relative to the interictal state and controls, in the ipsilateral 
temporal pole and fusiform gyrus were identified using [11C]diprenorphine ([11C]DPN; 
(Hammers et al., 2007a)). Additionally, left posterior temporo-parieto-occipital binding 
decreases have been associated with reading-induced seizures in humans, in vivo (Koepp et 
al., 1998b).  
[11C]alpha-methyl-L-tryptophan (AMT) PET has been used to quantify serotonin 
synthesis in the epileptogenic tubers of patients with tuberous sclerosis (Chugani et al., 1998). 
In general, the radioligand has shown high specificity, but low sensitivity, relative to 
[18F]FDG PET. (Natsume et al., 2003) found increased [11C]AMT uptake in the ipsilateral 
hippocampus of each of their seven participants with TLE in association with normal 
hippocampal volume, relative to those with hippocampal sclerosis and in controls. [11C]AMT 
uptake was negatively correlated with [18F]FDG uptake. Concordant [11C]AMT increases 
were also seen in two of three participants with temporal or fronto-temporal seizure onset (as 
judged by prolonged (scalp) video-EEG (Fedi et al., 2001).  
 
1.3.4.2 Positron emission tomography in frontal lobe epilepsy 
[18F]FDG PET frequently identifies abnormalities in FLE, however specificity is lacking, and 
the area of hypometabolism is usually more widespread than the EEG seizure-onset zone or 
structural lesion, if present (da Silva et al., 1997). (Kim et al., 2002 reported ‘exact 
localisation’ of epileptogenic foci by hypometabolism on [18F]FDG PET in 36% (five of 14) 
of MRI-normal patients with refractory FLE. In contrast, exact localisation was possible in 11 
of 15 patients (73%) with FLE and structural abnormality on MRI. Here, the term ‘exact 
localisation’ refers to the site indicated by clinical history, neurologic examination, prolonged 
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ictal  and inter-ictal scalp EEG, video telemetry, and good post-surgical outcome (Engel class 
I or II) after a mean follow-up of 20 months. (Ryvlin et al., 1998) similarly reported 
localisation in approximately 75% of patients with abnormal MRI, whereas, similar to other 
results (Hamer et al., 2002), [18F]FDG PET localised only approximately 35 – 45% of MRI-
normal patients with FLE.  
The localising ability of [18F]FDG PET has been similarly evaluated in cohorts of 
patients with intractable seizures and focal cortical dysplasia (FCD). Focal hypometabolism 
concordant with the MRI-visible lesion was visually identified for two of five participants 
with frontal lobe FCDs in a series reported by (Goffin et al., 2010). However, extra-lesional 
hypometabolism was identified for the remaining 3 participants. [18F]FDG PET has also been 
evaluated participants with FCDs but normal or near-normal/doubtful MRI, of whom eight 
had frontal FCDs. Focal hypometabolism was seen in nine cases; however, the proportion of 
these with frontal FCDs was not reported.  
Three of 19 patients reported by (Kim et al., 2000) had an exclusively frontal lobe 
MRI abnormality. Focal cortical hypometabolism was revealed for both patients who had 
[18F]FDG PET. In both cases, the extent of the lesion was judged by visual assessment to be 
significantly larger on PET than on MRI. Focal hypometabolism was evident in the frontal 
lobes of two of a further nine MRI-normal patients with surgically proven FCD. EEG data 
was not reported.  
[11C]FMZ PET has been evaluated as a complementary investigation in FLE. Early 
and subsequent results suggested decreased FMZ binding was evident in a more 
circumscribed region than the hypometabolic area demonstrated with [18F]FDG PET (Ryvlin 
et al., 1998, Savic et al., 1995). However, the high diagnostic yield reported by Savic et al. 
(1995) was not replicated in a later study (Ryvlin et al., 1998); moreover discordant and 
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multifocal decreases are common (Hammers et al., 2003c). [11C]FMZ PET is not routinely 
used in the clinical setting. 
 
1.3.4.3 Positron emission tomography in parietal and occipital lobe epilepsies 
It is generally accepted that parietal and occipital lobe epilepsies share many common 
features with FLE and TLE; hence much of the preceding paragraphs are applicable to these 
conditions.  
 Few studies that were explicitly designed to evaluate [18F]FDG PET in PLE or OLE 
have been published. (Lee et al., 2005) reported [18F]FDG PET in 11 participants with PLE 
and 11 participants with OLE, all with normal MRI. One of the three participants with PLE 
who became seizure-free (Engel class I) after surgery was correctly localised; four of the 
seven with OLE who became seizure-free after surgery was correctly localised. Localisation 
was judged ‘correct’ if concordant with the site of resection.  
 (Kim et al., 2004) reported 38 participants with refractory PLE, of whom 14 had a 
parietal lobe lesion visible on MR imaging. [18F]FDG PET demonstrated localised 
hypometabolism for 11 participants (29%), and lateralised the epileptogenic zone for 15 
(40%). Ictal SPECT localised the epileptogenic zone for seven of 25 participants (25%), and 
lateralised for 15 (54%). The exact criteria that was used to distinguish between ‘localised’ 
and ‘lateralised’ was not provided. A trend towards favourable outcome (>90% reduction in 
seizure frequency) was observed for localised PET hypometabolism only, although formal 
statistical analyses were not possible.    
 (Binder et al., 2009) reported ipsilateral hypoperfusion for each of five participants 
with refractory symptomatic PLE who had (presumably interictal) SPECT. Imaging 
methodology, localisation of hypoperfusion, and post-operative outcome for this subgroup 
were not provided.   
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 (Kim et al., 2001) reported that nine of 15 participants with OLE were correctly 
localised by visual analyses of-, and asymmetry indices derived from, interictal [18F]FDG 
PET. All were seizure-free (Engel class I) after surgery; localisation was judged ‘correct’ if 
concordant with the resected occipital lobe. A further five participants were correctly 
lateralised, but incorrectly localised. Seven of the nine participants who also had an occipital 
structural lesion on MRI were correctly localised; whereas two of the six MRI-normal 
participants were correctly localised.   
 
1.4 Receptor systems in the epilepsies 
1.4.1 Glutamate receptors 
L-glutamate (glutamic acid) is the major excitatory neurotransmitter used in the CNS. 
Glutamate receptors can be sub-divided into metabotropic (for review see: (Nicoletti et al., 
2011)) and ionotropic receptors (for review see: (Traynelis et al., 2010, Bowie, 2008, Mayer, 
2011)).  
 
1.4.1.1 Metabotropic glutamate receptors 
Metabotropic glutamate (mGlu) receptors are a family of eight widely-expressed G-protein 
coupled receptor subtypes receptor (for review see: (Nicoletti et al., 2011, Niswender and 
Conn, 2010)). Group I includes mGlu1 and mGlu5; group II includes mGlu2 and mGlu3; 
group III includes mGlu4 and mGlus6-8. Group I receptors are coupled to Gq/G11 proteins, 
the activation of which promotes synthesis of inositol-1,4,5-triphosphate and diacylglycerol. 
All other subtypes are coupled to Gi/Go proteins (Nicoletti et al., 2011, Niswender and Conn, 
2010), activation of which inhibits adenylyl cyclase. 
 The mGlu receptors possess a large, extracellular N-terminal domain known as the 
Venus flytrap domain, (VFT; (Kunishima et al., 2000, Tsuchiya et al., 2002)), which contains 
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the glutamate-binding site. Two VFDs dimerise in the receptor, back-to-back (Jingami et al., 
2003). Each VFD is attached to seven transmembrane rhodopsin-like domains via the 
cysteine-rich domains (CRDs), which are stabilised by disulphide bridges (Muto et al., 2007). 
Binding of glutamate to the VFDs induces a conformational change that is sufficient for G-
protein activation (Pin et al., 2003, Goudet et al., 2004); guanosine 5′-triphosphate is 
exchanged for (GTP) for guanosine 5′-diphosphate within the alpha subunit. The activated G 
protein subunits then modulate the function of various effectors and secondary messenger 
molecules such as ion channels.   
 Group I mGlu receptors are predominantly localised to postsynaptic sites. Activation 
of these receptors produces a cell depolarisation and an increase in excitability via modulation 
of ion channels (Batchelor et al., 1997). Activation also mediates synaptic plasticity, via both 
long–term depression (LTD; (Palmer et al., 1997); for review see: (Kano et al., 2008)) and 
long-term potentiation ((Manahan-Vaughan et al., 1999); for review see: (Kullmann and 
Lamsa, 2008)).  
 Group II mGlu receptors are diffusely expressed in the CNS (Nicoletti et al., 2011), 
mGlu2 localised to the pre-terminal region of the axon (Lujan et al., 1997, Tamaru et al., 
2001), and mGlu3 to pre- and postsynaptic sites and on glia (Ohishi et al., 1993, Petralia et 
al., 1996). The major functions of pre-synaptic mGlu2 and mGlu3 receptors are inhibition of 
neurotransmitter release and the induction of LTD of excitatory synaptic neurotransmission 
(Yokoi et al., 1996, Robbe et al., 2002, Nicholls et al., 2006, Manahan-Vaughan, 1998).  
 The mGlu6 receptor is expressed in the dendrites of ON-bipolar cells of the retina 
only (Nomura et al., 1994, Vardi et al., 2000). The remaining Group III  mGlu receptors (4, 7 
and 8) are predominantly localised in pre-synaptic terminals, and, like Group II mGlu 
receptors, their activation negatively regulates glutamate release ((Xi et al., 2003); for review 
see: (Cartmell and Schoepp, 2000)).  
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 Metabotropic glutamate receptors are increasingly implicated in the epilepsies (for 
review see: (Ure et al., 2006, Alexander and Godwin, 2006, Tang et al., 2009)). For example, 
increased expression of group I mGlu receptors was observed in cerebral tissue resected from 
participants with refractory focal epilepsies (Aronica et al., 2003, Notenboom et al., 2006). 
These findings are complemented by pre-clinical data that evidences induction of seizures on 
activation of group I receptors (Tizzano et al., 1995, Chapman et al., 2000).   
 
1.4.1.2 Ionotropic glutamate receptors 
Ionotropic receptors are described as AMPA-, KA (L-α kainic acid) or NMDA receptors 
based on their antagonist. Each receptor assembles as a dimer of dimers (Tichelaar et al., 
2004, Midgett and Madden, 2008), i.e. a tetrameric complex of subunits (Laube et al., 1998, 
Rosenmund et al., 1998, Sobolevsky et al., 2009). Receptor subunits are consist of four 
discrete domains; the extra-cellular amino terminal domain, the extracellular ligand-binding 
domain, the transmembrane domain, and the intracellular carboxyl-terminal domain 
(Traynelis et al., 2010). 
 AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid) receptors are 
tetrameric heteromers that are formed from combinations of GluA1 – GluA4 subunits 
(Dingledine et al., 1999). The receptors are complexed with transmembrane AMPA receptor 
regulatory proteins (TARPs), which influence receptor expression and trafficking ((Tomita et 
al., 2003); for review see: (Jackson and Nicoll, 2011)). 
 AMPA receptors have rapid gating kinetics, are weakly permeable to Ca2+ ions, and 
mediate the vast majority of fast excitatory synaptic neurotransmission in the CNS. Binding 
of glutamate triggers a brief, rapidly rising conductance that decays rapidly (within 1 -2 
milliseconds; (Mott et al., 2008, Traynelis et al., 2010)). They are often co-localised with 
NMDA receptors. The addition or removal of AMPA receptors is believed to strongly 
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influence synaptic plasticity (for review see: (Malinow and Malenka, 2002, Shepherd and 
Huganir, 2007)).  
 AMPA receptors are associated with epilepsy (for review see: (Rogawski and 
Donevan, 1999, Rogawski, 2013)); for example, a number of selective AMPA antagonists 
have demonstrated anticonvulsant properties in animal models (Chapman et al., 1991, Smith 
et al., 1991, Durmuller et al., 1994).   
 Like AMPA receptors, KA receptors are tetrameric heteromers that are formed from 
combinations of GluK1 – GluK5 subunits (Traynelis et al., 2010). KA receptors are prevalent 
throughout the CNS (Monaghan and Cotman, 1982), although present at fewer synapses than 
AMPA receptors, and are believed to have a neuromodulatory role.  
 KA receptors have a slow-decaying time course (e.g. approximately 100 
milliseconds) and are only activated after short bursts of pre-synaptic activity (Traynelis et al., 
2010). In addition to their ionotropic role, they also signal via G-protein-coupled secondary 
messengers (a metabotropic function) to decrease gamma-Aminobutyric acid (GABA) release 
(Rodriguez-Moreno and Lerma, 1998) and reduce slow potassium after-hyperpolarisation 
current, thereby increasing excitability (Melyan and Wheal, 2011, Melyan et al., 2002).  
 KA receptors have been repeatedly associated with epilepsy and excitotoxicity (for 
review see: (Vincent and Mulle, 2009)). For example, systemic or intracerebral injection of 
kainate (KA) in rodents induces epileptiform seizures; this is exploited as the KA model of 
TLE (Nadler, 1981, Ben-Ari, 1985). 
NMDA receptors, and their association with focal epilepsies, are described 
subsequently in this Chapter; please see Section 1.4.1.3. 
 Orphan ionotropic glutamate receptor subunits GluD1 and GludD2 (also known as 
δ1 and δ2) have been additionally been described, but are poorly understood as they do not 
form functional ion channels.  
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1.4.1.3 NMDA receptors in focal epilepsies  
NMDA receptors are ion-channel receptors for L-glutamate, the major excitatory 
neurotransmitter in the CNS (Monaghan et al., 1989, Zhong et al., 1995, Wollmuth and 
Sobolevsky, 2004). Excitatory synaptic transmission via these receptors is believed to mediate 
neuroplasticity, and to be necessary for cognition, memory, and neuronal survival.  In certain 
circumstances, however, NMDA receptor over-activation is associated with cell death (Sattler 
et al., 1999).  
 NMDA receptors are protein complexes that are both ligand- and voltage- gated, and 
typically comprise four subunits ((Furukawa et al., 2005); Figure 4).  At resting potential, an 
Mg2+ ion is bound within the channel pore, blocking the flow of Ca2+, K+ and Na+ ions.  On 
membrane depolarisation in the presence of both glycine (Nakanishi and Masu, 1994, 
Dingledine et al., 1999) and glutamate, Mg2+ is expelled from the channel pore in the centre 
of the protein complex, allowing cation influx (Wollmuth and Sobolevsky, 2004, Paoletti et 
al., 2007, Banke and Traynelis, 2003). 
 Excessive NMDA receptor activation mediates excitotoxic neuronal injury following 
acute cerebral insults (Leker et al., 2002, Waterhouse and Waterhouse, 2003a). It is also 
thought to contribute to chronic neurodegenerative diseases (e.g. Alzheimer’s, Huntington’s); 
and disorders of neuronal hyperexcitability (epilepsy and neuropathic pain syndromes;  
(Dingledine et al., 1999, Waterhouse and Waterhouse, 2003a, Waxman et al., 2005, Kalia et 
al., 2008)); and various mental health disorders (e.g. schizophrenia; (Lau et al., 2007)). 
Hence, there is continued interest in the development of radioligands to allow assessment of 
NMDA receptor expression and function in humans in vivo. 
 Following injury, damaged neurons release excess glutamate into the extracellular 
space, resulting in excessive NMDA receptor activation (Leker et al., 2002, Bramlett et al., 
2004), which has been proposed to contribute to epileptogenesis. Blockade of NMDA 
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receptors prevents paroxysmal depolarisation shifts, the intracellular correlate of IEDs 
(Matsumoto and Marsan, 1964, Anderson et al., 1986, Mody et al., 1987); blocks the 
development of kindling (Croucher et al., 1988, Sato et al., 1988, Vezzani et al., 1988, 
Croucher and Bradford, 1990, Croucher et al., 1992, Croucher et al., 1995); and is 
neuroprotective (Brandt et al., 2003).  
Quantification of NMDA receptor availability in kindling models has yielded mixed 
results, with several studies suggesting increased availability in the hippocampus and cerebral 
cortex (Savage et al., 1982, Yeh et al., 1989, Burnashev et al., 1995). Autoradiography of 
human epileptogenic temporal lobe tissue has identified increased  NMDA receptor 
availability in the parahippocampal gyrus, in contrast to decreased availability in the 
hippocampi, particularly in sclerotic regions (Geddes et al., 1990, Hosford et al., 1991, 
Kumlien et al., 1993). Human in vivo microdialysis studies have revealed marked elevations 
in extracellular glutamate concentration preceding and during seizures (Hamberger et al., 
1991, Carlson et al., 1992, During and Spencer, 1993). Receptor activation, however, can 
only be shown in vivo. 
 Imaging NMDA receptor expression or function in humans in vivo has been a 
challenge because of low brain uptake, low affinity for the NMDA receptor, high rates of 
dissociation, rapid metabolism, and non-specific binding of the radioligands studied. To date, 
only six of more than 60 radioligands designed for in vivo imaging of the NMDA receptor 
system (Sobrio et al., 2010) have progressed to PET or SPECT studies in humans (see Table 
1).Of these, five bind at the phencyclidine (PCP)-recognition site (Waterhouse and 
Waterhouse, 2003b) which lies within the NMDA ion channel pore, and hence require 
receptor activation to allow binding. These ’pore-blocker’ ligands could potentially allow 
imaging of the NMDA receptor in the active/open state using PET. 
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 The diarylguanidine antagonist, CNS 5161 (i.e. ]N-[2-Chloro-5-(2-
methylsulfanyl)phenyl]-N’-methyl-N’-(3-methylsulfanylphenyl) guanidine), is one such 
ligand that demonstrated high uptake in the putamen and thalamus in human studies in vivo 
(Asselin et al., 2004, Hammers et al., 2004). Quantification of [11C]CNS 5161 was difficult, 
radiochemical yield low, and metabolism fast; it was not pursued as a PET radioligand. 
CNS 5161 labelled with fluorine-18 ([18F]GE-179 (i.e. [18F]N-[2-chloro-5-(2-
fluoroethylsulfanyl)phenyl]-N’-methyl-N’-(3-methylsulfanylphenyl) guanidine); (Robins et 
al., 2010, Brown J et al., 2011)) has similar affinity for the intra-channel site of the rat NMDA 
receptor (KD = 2.35 +/- 0.2 nM (Robins et al., 2010)). In vitro, [
18F]GE-179 displaces 
[3H]tenocyclidine from the PCP-site with a KI of 2.4nM (similar to that seen with [
3H]MK-
801 and CNS 5161 (Hu et al., 1997)). No significant affinity for any of 60 other CNS 
receptors, channels, or transporters was seen at 10 nM (nanomolar; i.e. 10 x 10-9 mol/L = 1 x 
10-5 µmol/ml; GE Healthcare, unpublished data, on file). [For reference, a typical radioligand 
injection for PET in humans is 40 x 10-5 µmols in total; 2.4% of the injected dose was 
observed in rodent brains at 30 seconds post-injection (GE Healthcare, unpublished data, on 
file)].  
Incorporation of [18F]GE-179 into the cell membrane of teratocarcinoma 2 (NT2) 
cells, differentiated to express human NMDA receptors, that were incubated with glutamate 
was completely reversed with co-incubation with high concentrations of the use-dependent 
NMDA receptor antagonist MK-801 (GE Healthcare, unpublished data, on file). GE-179 has 
a distribution coefficient (log D7.4) of 2.49 ± 0.1 (Robins et al., 2010), indicative of moderate 
lipophilicity, similar to that of CNS 5161 (log P = 1.92 ± 0.26; (Biegon et al., 2007)).  
 In this thesis, the author reports the first use of [18F]GE-179 PET in humans (healthy 
controls), and subsequently in people with  frequent interictal epileptiform discharges. Several 
favourable properties of the radioligand are identified, and the author subsequently identifies 
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FIGURE 4: Structure of the NMDA receptor.  
Membrane topology of the NMDA receptor subunit (top) and depiction of crystal structure of the NMDA 
receptor crystal structure (bottom; front and back subunits removed). Glu – glutamate; Gly – Glycine; M1 – 4 – 
Hydrophobic subunits; S1S2 – Ligand binding complex. (Adapted from (Wollmuth and Sobolevsky, 2004)). 
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increased [18F]GE-179 VT in a proportion of evaluated participants with IEDs. Thus, this 
thesis provides the first evidence in humans in vivo of increased activated NMDA receptor 
availability in association with epileptiform discharges.  
 
1.4.2 Clinical evidence for the role of glutamate receptors in (focal) epilepsies 
The efficacy of several anti-epileptic drugs (AEDs) in humans, in vivo suggests that excitatory 
neurotransmission via ionotropic glutamate receptors may be excessive in a proportion of 
individuals with focal epilepsies, as antagonism of receptor function is associated with 
reduced seizure frequency. Perampanel is a novel AED that exerts its primary mode of action 
via non-competitive antagonism at the AMPA receptor; it is not known to have significant 
affinity for any other CNS targets (for review see: (Rektor, 2013)). Responder rates of 
approximately 34% of participants with refractory focal epilepsy have been observed in phase 
III clinical trials, which differed significantly from that of placebo-treated participants 
(approximately 14 – 18%; (French et al., 2013, Krauss et al., 2012)).  
 Several other AEDs are believed to exert their anticonvulsant effect in part via 
glutamatergic receptors (for review see: (Rogawski and Loscher, 2004)); phenobarbitone acts 
at AMPA receptors when administered in at least moderately-high doses, whereas felbamate 
and topiramate cause inhibition of KA and NMDA receptors.   
 Domoic acid is a neurotoxic, cyclic amino acid that can accumulate in shellfish 
(Jeffery et al., 2004). The symptoms of domoic acid neurotoxicity are gastrointestinal upset, 
headache, amnesia, and can include seizures (Perl et al., 1990). Kainic acid and domoic acid 
are potent agonists at KA receptors (Hampson et al., 1992, Darvas et al., 2004). They also 
have moderate and weak affinity for AMPA and NMDA receptors, respectively. The toxicity 
of domoic acid is attributed to activation of KA receptors, which leads to depolarisation with 
the release of glutamate and subsequent activation of AMPA and NMDA receptors (for 
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review see: (Pulido, 2008)). The activation of the ionotropic glutamate receptors results in 
Ca2+ influx, which triggers excitotoxic neuronal cell degeneration mediated through reactive 
oxygen species and enzymes such as nitric oxide synthase. This mechanism of action of 
domoic acid neurotoxicity also suggests that excitatory neurotransmission via ionotropic 
glutamate receptors may be excessive in individuals with epilepsies, as agonism of receptor 
function is associated with seizures. 
 Anti-NMDA receptor encephalitis is a recently-described neuro-autoimmune 
syndrome in which antibodies formed in response to stimuli such as tumour or infection 
cross-react with the NR1 subunit of the NMDA receptor ((Dalmau et al., 2007); for review 
see: (Peery et al., 2012)). Clinical features include a “psychotic and/or seizure phase” 
characterised by behavioural and emotional disturbances, decreased cognition, psychosis, 
dyskinesias and seizures (commonly generalised tonic – clonic). The syndrome is attributed to 
the presence of auto-antibodies targeted against the N-terminal of the NR1 subunit of NMDA 
receptors (Dalmau et al., 2008). Auto-antibody exposure promotes NMDA receptor 
internalisation, resulting in decreased NMDA receptor surface density and decreased NMDA 
receptor-mediated currents (Hughes et al., 2010). The mechanism of action of anti-NMDA 
receptor encephalitis suggests that NMDA receptor hypofunction might be evident in 
individuals with epilepsies. This seemingly counter-intuitive conclusion might reflect that 
antagonism of NMDA receptor function has been suggested to result in an overall state of 
disinhibition, due to decreased stimulation of inhibitory, particularly GABAergic (Grunze et 
al., 1996, Drejer et al., 1987), neurotransmitter systems.    
 
1.4.3 Opioid receptors and temporal lobe epilepsy  
The opioid peptide receptor (OPR) system comprises μ (MOP), δ (DOP), κ (KOP) and 
nociceptin/orphanin FQ (NOP; also known as ORL-1) opioid peptide receptors (for review: 
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(Satoh and Minami, 1995, Dhawan et al., 1996)), which bind endogenous opioids known as 
enkephalins and endorphins. Additional subtypes have been proposed for each of the three 
main classes (DOP, KOP, MOP; (Alexander et al., 1999)). 
The endogenous opioid peptides are derived from four gene products, pro-
opiomelanocortin, pro-enkephalin, pro-dynorphin, and pro-nociceptin (Alexander et al., 
1999). Pro-opiomelanocortin gives rise to beta-endorphin; pro-enkephalin to several 
enkephalins such as [Met]enkephalin; pro-dynorphin to three dynorphins and several 
endorphins, and pro-nociceptin to orphanin FQ/nociceptin. 
The opioid peptides are stored in large vesicles, the release of which (exocytosis) is 
dependent on calcium influx (Bayon et al., 1978) via high-frequency stimulation of the 
neuron (Wagner et al., 1991). Opioid peptides reduce the excitability of surrounding neurons 
(Drake et al., 1994). Degradation is via carboxypeptidases and aminopetidases (Pleuvry, 
1991).  
 The opioid peptide receptors are G-protein coupled receptors of approximately 370 
amino acids, which consist of seven hydrophobic transmembrane domains (Chaturvedi et al., 
2000). The domains are connected by several short intra- and extracellular loops. Humans are 
characterised by abundant kappa and paucity of delta receptors, relative to rodents (Pfeiffer et 
al., 1982, Pilapil et al., 1987, Hiller and Fan, 1996, Peckys and Landwehrmeyer, 1999). 
[3H]diprenorphine, a partial delta, kappa, and mu receptor agonist, has been used to estimate 
opioid receptor binding over the entire brain. Via subtype-selective blocking, it was seen that 
DOP receptor binding accounted for only 20%, approximately, whereas KOP and MOP 
receptor binding were both approximately 40%. However, in the medial temporal lobes, 
kappa binding dominates at approximately 60%; MOP binding is lower at less than 30%, and 
DOP below 20% (Pfeiffer et al., 1982). In contrast, reduced kappa binding has been reported 
in the temporal basal neocortex (Pilapil et al., 1987).    
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DOP receptors are most numerous in the striatum and the occipital (striate) cortex, but 
are found throughout the neocortex (Pfeiffer et al., 1982, Pilapil et al., 1987). DOP mNRA 
expression is moderate to dense in the dentate gyrus of the human hippocampus, and weak to 
moderate in the hippocampal subfields CA1-4 (cornu ammonis 1-4; (Peckys and 
Landwehrmeyer, 1999)). Similarly, moderate DOP receptor binding has been reported in the 
hippocampus (Hiller and Fan, 1996), although lower estimates also exist (Pfeiffer et al., 
1982). 
KOP receptors are most numerous in the hippocampus, amygdala, and neocortex, and 
sparsely distributed in the striatum (Pilapil et al., 1987). Hippocampal KOP receptor 
messenger ribonucleic acid (mRNA) expression is moderate to dense in the dentate gyrus of 
the hippocampus, and weak to moderately dense in CA1-4. Whilst KOP opioid receptor 
binding dominates over DOP or MOP binding in the most of the hippocampus (Pfeiffer et al., 
1982), little binding is seen in the dentate gyrus (Hiller and Fan, 1996, de Lanerolle et al., 
1997).  
Activation of the mu opioid receptor has effects that may be both pro-convulsant 
(Tortella et al., 1987) and anti-convulsant (post-ictal suppression; (Albertson et al., 1984, 
Tortella and Long, 1985); for review, see (Tortella, 1988)). Pre-clinical studies using the non-
selective opioid receptor antagonist naloxone provide additional support for a ‘bi-directional’ 
influence of opioid receptor stimulation on seizure susceptibility (Rocha et al., 1991). In 
interpreting pre-clinical work, it is worth noting that human brains have relatively more kappa 
and conversely less delta opioid receptors than the rat brain (Pfeiffer et al., 1982, Peckys and 
Landwehrmeyer, 1999).  
Activation of hippocampal kappa opioid receptors in the guinea pig by pro-dynorphin-
derived opioid peptides reduces glutamate release (Rusin et al., 1997) and long-term 
potentiation (Wagner et al., 1993). 
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TABLE 1: PET and SPECT studies of the NMDA receptor to date in humans (in vivo; overleaf). 1c2k – One brain compartment, two rate-constants model; 2c3k – Two-
compartments, three rate-constants (irreversible binding) model; 2c4k – Two brain compartments, four rate-constants model; BP – Binding potential; bv – variable blood 
component; CC – Normalised to calcarine cortex; NR – NMDA receptor subunit; Ref – Reference region; RS-ESA – Rank-shaping regularisation of exponential spectral 
analyses; VT – Volume-of-distribution.  
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Authors Year Radioligand Participants Outcome measure(s) Conclusion(s) 
(Hartvig et al., 1995) 1995 
(S)-[N-methyl-
11C]ketamine 
5 healthy BP (2c4kRR); BP reduced by up to 19.4% with (S)-ketamine 
(Owens et al., 1997) 1997 [123I]MK-801 
5 cerebral ischaemia; 5 
healthy 
Uptake High uptake in cerebelli and white matter 
(Brown et al., 1997) 1997 [123I]MK-801 
5 Alzheimer’s disease; 
5 healthy 
Uptake/CC Non-significant differences in elimination 
(Kumlien, 1999) 1999 
(S)-[N-methyl-
11C]ketamine 
8 medial TLE 
BP (2c4k); uptake 
asymmetry 
Reduced uptake in epileptogenic temporal lobes 
(Ametamey et al., 2002) 2002 [18F]memantine 5 healthy VT (1c2k; 2c4k) Highly perfusion-dependent uptake 
(Erlandsson et al., 2003) 2003 [123I]CNS 1261 7 healthy VT (1c2k; 2c4k) 1c2k model optimal 
(Asselin et al., 2004) 2004 [11C]CNS 5161 3 healthy 
VT (1c2kbv; 2c3kbv; 
2c4kbv) 
?2c3kbv or 2c4kbv optimal 
(Bressan et al., 2004) 2004 [123I]CNS 1261 7 healthy VT (pseudo-equilibrium) Pseudo-equilibrium model comparable to 1c2k 
(Hammers et al., 2004) 2004 [11C]CNS 5161 6 healthy VT (2c4kbv) Correlation between hippocampal VT and memory 
(Matsumoto et al., 2007) 2007 [11C]AcL703 6 healthy BP-Ref Low brain uptake; NR2C-selective binding 
(Ahmed et al., 2011) 2011 [11C]CNS 5161 
18 Parkinson’s disease; 
5 healthy 
VT (RS-ESA) Increased VT in dyskinetic participants 
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There is evidence for an anticonvulsant effect of endogenous opioids, mediated 
through kappa opioid receptors (Loacker et al., 2007). These authors found that pro-dynorphin 
knockout mice (i.e. mice deficient of kappa-preferring endogenous opioid peptides) exhibited 
a reduced seizure threshold, which was returned to normal levels using the kappa-selective 
agonist U-50488. In contrast, mu agonists had little effect, and a delta-selective agonist 
decreased seizure threshold in wild–type and pro-dynorphin deficient mice. In support, low-
expression alleles of the pro-dynorphin promoter have been associated with an increased risk 
of TLE, albeit inconsistently (Stogmann et al., 2002). Moreover, pro-dynorphin RNA 
(ribonucleic acid) is increased in the ipsilateral hippocampi of those with refractory TLE 
(Pirker et al., 2009), particularly in those with recent seizures. 
There is growing evidence for an anticonvulsant action of endogenous peptides 
(Pleuvry, 1991), in a ‘tonic antiepileptic’ system that is hypothesised to limit the spread of 
electrical activity within the temporal lobe (Mayberg et al., 1991, Hammers et al., 2007a, 
Pirker et al., 2009). The most convincing evidence implies a role for opioid peptides in post-
ictal seizure inhibition (Pirker et al., 2009, Engel Jr et al., 1981). 
PET studies of opioid-receptor mediated neurotransmission in epilepsy have provided 
evidence for a dynamic relationship between opioid peptide receptor availability and seizures. 
Interictal studies (i.e. those performed when the participant is not having a seizure) suggest 
increased MOP and DOP receptor availability in the ipsilateral temporal lobe during the 
interictal period in temporal lobe epilepsy (Frost et al., 1988, Mayberg et al., 1991, Madar et 
al., 1997). Ictal studies of reading-induced and absence seizures suggest decreased opioid 
MOP-, DOP- and KOP receptor availability occurs during seizures (Bartenstein et al., 1993, 
Koepp et al., 1998b). Post-ictal (i.e. within 24 hours after a seizure) opioid peptide receptor 
binding is increased in the ipsilateral temporal lobe in TLE (Hammers et al., 2007a). In 
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contrast, in vitro studies revealed down-regulated mu receptor signal transduction in the 
ipsilateral temporal neocortex of those with refractory TLE (Rocha et al., 2009)   
All PET studies to date have failed to demonstrate significant alteration of 
hippocampal or parahippocampal gyrus opioid peptide receptor binding (interictal or post-
ictal) in TLE. This is surprising, given the longstanding association of these regions with 
TLE. Moreover, increased hippocampal mu opioid receptor mRNA expression and binding 
was documented in humans with refractory TLE ex vivo (Cuellar-Herrera et al., 2012). These 
findings suggest that the opioid binding per neuron is actually upregulated in these sclerotic 
regions. It should be noted that [11C]DPN VT is quite low in the hippocampus, when 
compared with that of surrounding regions; hence, the ability to reliably detect significant 
alterations in binding in this region may be reduced. However, variable anatomical alterations 
in mTLE could result in different degrees of partial-volume effect (PVE; see below) affecting 
the ability to measure such alterations. This possibility has not yet been assessed. 
 
1.4.4 Clinical evidence for the role of opioid receptors in (focal) epilepsies 
Clinical evidence for the role of opioid receptors in (focal) epilepsies is scant. Opioid 
analgesic overdose is characterised by respiratory depression (apnoea), stupor and miosis (for 
review see: (Boyer, 2012)). Seizures, however, have been additionally associated with 
overdose of the opioid analgesics tramadol (Talaie et al., 2009), dextropropoxyphene and 
pethidine/meperidine (Kaiko et al., 1983). Chronic and high-dose administrations of morphine 
and hydromorphine have also been associated with myoclonic jerking (Parkinson et al., 1990, 
Sjogren et al., 1994, Sjogren et al., 1993), whereas rapid dose escalation of these drugs was 
additionally associated with (convulsive) seizures (Hagen and Swanson, 1997). However, 
overall the number of patients described in studies pertaining to morphine and 
hydroxymorphine are small, and EEG reports are lacking. Hence, there is limited clinical 
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evidence to suggest that opioid-peptide receptor mediated neurotransmission is excessive in 
individuals with epilepsies, as agonism of the µ receptor in particular is associated with 
clinical features that are consistent with seizures.    
 
1.5 Correction for the partial-volume effect 
The PVE has been defined as “the loss in apparent activity that occurs when an object 
partially occupies the sensitive volume of the imaging instrument” (Hutton and Osiecki, 
1998). The ‘object’ normally refers to a small region of interest of grey matter, and the 
‘sensitive volume’ refers to the volume defined by instrument resolution of the PET camera 
photon detector.  
 Partial-volume effects are spatial-resolution-related effects that result from the 
blurring of an ideal PET activity distribution by a ‘point spread function’ (PSF). The PSF is 
equivalent to the image of a point source, and can be modelled by a Gaussian function of 
known FWHM. Signal from regions with a high intensity signal tend to ‘spill in’ to 
surrounding low intensity signal regions, and vice-versa. A consequence of this ‘intensity 
diffusion’ is the under- and over-estimation of regional concentrations of radioactivity 
(Meltzer et al., 1996, Aston et al., 2002, Erlandsson et al., 2012).  
 Numerous approaches to partial volume effect correction have been published (for 
review see: (Erlandsson et al., 2012)), with little attempt to compare performance (but see: 
(Hutton et al., in press)). The methods can be broadly divided into those that are applied 
during image reconstruction, and those that applied to reconstructed images. ‘Structural and 
Functional Synergistic - Resolution Recovery’ (SFS-RR; (Shidahara et al., 2009, Shidahara et 
al., 2012) is a novel partial-volume effect correction method that is an example of the latter, 
and has been evaluated in simulations and in human [18F]FDG and [11C]raclopride PET 
studies. 
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 In this thesis, the author reports the application of SFS-RR, a novel partial volume 
effect correction method, to post- and interictal [11C]diprenorphine PET data acquired from 
participants with refractory temporal lobe epilepsy. The author identifies a novel post-ictal 
increase in (ipsilateral) parahippocampal [11C]DPN VT, thus providing further evidence in 
humans in vivo for opioid peptide receptor derangements in association with epileptic 
seizures.  
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CHAPTER 2 
COMMON MATERIALS AND METHODS 
__________________________________ 
2 COMMON MATERIALS AND METHODS 
To avoid repetition, common aspects of subject recruitment, data collection and analyses are 
described below, and referred to in subsequent sections. Methods more specific to each study 
are described in the relevant sections. 
 
2.1 Regulatory issues 
The studies were approved by Imperial College Healthcare NHS Trust and University College 
London Hospitals NHS Foundation Trust, and by the Administration of Radioactive 
Substances Advisory Committee (ARSAC) of the UK. All participants provided written, 
informed consent according to the Declaration of Helsinki prior to participation in the study. 
 
2.2 Participant recruitment and screening 
Participants with epilepsy were recruited from the epilepsy clinics of the National Hospital for 
Neurology and Neurosurgery, Queen Square, London, United Kingdom (UK), and the 
Epilepsy Society, Chalfont St. Peter, Buckinghamshire, UK. Their diagnosis was based on 
prolonged and repeated interictal and ictal EEG recordings and magnetic resonance imaging 
MRI data. Clinical data and results of previous investigations were obtained from the 
participant’s hospital records. Current seizure frequency and time since last seizure at 
scanning were obtained from the participant and/or carers.  
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 The ideal control population is identical to the cohort of interest in all aspects other 
than disease status; this allows minimisation of confounds and maximum inference on the 
results of the analyses. In practice, this is difficult to achieve, particularly within the context 
of recruitment difficulties, the time constraints of a study with a finite budget, and the 
scheduling demands of busy PET and MRI scanning centres. Every attempt was made to 
match the participant groups, primarily in terms of age and gender; this was partially-
successful.  All control participants denied a history of neurological or psychiatric disorder, 
usage of regular medication, regular- or recent use of recreational drugs. Each potential 
participant’s GP was informed and encouraged to contact the investigators if he/she believed 
any of the exclusion criteria were met.  
 In this thesis, healthy control participants were recruited via friends, colleagues, and 
acquaintances, and local advertising. The study budget did not allow for screening procedures 
such as blood tests, EEG recordings, and review and examination by an experienced 
neurologist and psychiatrist. Therefore it is feasible that the participants could have had a 
relevant disease that they chose not to disclose, or alternatively of which they were unaware. 
It was not possible to match the participant groups on socio-economic and educational status; 
this limitation is most relevant to the [11C]DPN study, in which several of the investigator’s 
colleagues participated as controls. (The investigator’s colleagues are likely to have obtained 
higher socio-economic status and greater educational achievement than the participants with 
TLE, many of whom were unable to work and study due their frequent seizures).  
 All participants provided a urine specimen for urine drug screen cassette test for 11-
nor-∆9-tetrahydrocannabinol, morphine, amphetamine, benzoylecgonine, methamphetamine 
and oxazepam (Monitect©; BMC, California, United States of America) prior to PET 
scanning.  Furthermore, all female patients of childbearing age underwent a urine pregnancy 
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test. All participants with positive tests were excluded, other than participants with epilepsy 
who tested positive for prescribed benzodiazepines.  
  
2.3 Radioligand synthesis and administration 
The radioisotopes were produced on site by Hammersmith Imanet Limited in the Cyclotron 
Building site, Hammersmith Hospital, London, UK and then incorporated in GE-179 and 
diprenorphine, respectively, for injection. Each preparation was analysed by high-
performance liquid chromatography (HPLC) to determine the specific activity of the 
radioligand and the radiochemical purity. The presence of pathogens was excluded. Each 
radioligand was injected intravenously through a 22-guage cannula inserted into an 
antecubital fossa vein prior to the emission scan. The radioligand was injected and flushed 
thirty seconds after the start of the dynamic scan as a smooth bolus over the subsequent 15s 
seconds, followed by a flushing over a further 15 seconds.  
 
2.4 Specific activity of the radioligands at the time of injection 
The specific activity at the time of injection was computed as the coefficient of injected 
radiation to co-injected mass in relation to the relative molecular mass (RMM) of the 
radioligand, as in Equation 1:  
 
 
(1) 
 
2.5 PET data acquisition 
All PET scans were performed at the Hammersmith Imanet Limited, Cyclotron Building site, 
Hammersmith Hospital, London, UK. All scans were acquired in 3D mode. Participants were 
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placed in the centre of the scanner, as the resolution of the scanners decreases towards the 
periphery of the field of view. The images were acquired in a quiet, dimly-lit room without 
background noise.  
 
2.6 Head positioning and transmission scans 
In order to minimise movement during the scan, the participant’s head was rested in foam 
head moulds secured with straps. The participants were marked on the skin over the forehead 
and over the maxillary bones, aligned with projected laser lines, and subsequently monitored 
throughout the scan via a camera and monitor. Correct positioning was verified with a two-
minute transmission scan, which was followed by a five- (SFS-RR study) or ten-minute 
([18F]GE-179 studies) transmission scan using a 137Cs point source to allow emission scans to 
be corrected for attenuation. If significant movement was noticed during the emission scan, 
subjects were repositioned and would undergo a second transmission scan at the end of the 
dynamic scan.   
 
2.7 Continuous electroencephalographic monitoring  
All participants with epilepsy were monitored by simultaneous electroencephalography (EEG) 
during the PET scan. EEG electrodes were situated in caps (large and medium sizes were 
available) according to the international 10/20 system of electrode placement. An additional 
reference electrode was placed on the participant’s earlobe. The EEG recordings were used to 
detect possible sub-clinical epileptiform activity during the PET scans. The participants with 
epilepsy (and controls) were additionally observed directly and via a monitor for evidence of 
seizures.  
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2.8 Derivation of parent plasma radioligand input function 
Each participant had a 22-gauge cannula inserted into a radial artery prior to the PET scan, 
after checking patency of the ulnar anastamosis with a modified Allen’s test (Cable et al., 
1999, Allen, 1929) and local anaesthesia with 0.5% bupivicaine (or similar).  
 Continuous arterial blood sampling at a rate of 5 millilitres (ml) per minute was 
performed from t = 0 - 15 minutes and radioactivity measured in a bismuth germanate on-line 
(BGO) detection system (Ranicar et al., 1991, Jones et al., 1994). Discrete arterial blood 
(10ml) samples were taken with heparinised syringes at baseline and over the course of the 
emission scan. All samples were subsequently used for cross-calibration, determination of the 
partition of radioactivity, and determination of the parent radioligand fraction (Luthra et al., 
1993).  
 Continuous decay-, and metabolite-corrected parent plasma input functions were 
generated for all subjects using CLICKFIT versions 1.6 and 1.7 (in-house software, 
Cunningham et al., 2006) running in MATLAB 6.5 (The MathWorks Inc), as described 
previously (Jones et al., 1994, Hammers et al., 2007b). Briefly, the continuous on-line time 
course of radioactivity concentration in whole blood was first interpolated over intervals 
where data was missing due to regular flushing with saline. Subsequently the continuous time 
course was calibrated against the radioactivity concentration measured in the four 
corresponding discrete blood samples. The plasma:whole blood ratio was calculated from the 
discrete blood samples and fitted to a function with four free-parameters ([18F]GE-179 
studies; defined in Section 3.3.4) or a straight line ([11C]DPN studies). The final input 
functions were generated by multiplication of the calibrated time course of radioactivity in the 
blood with the fits to the plasma:blood ratios and correction for parent radioligand fraction. 
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2.9 Motion correction  
A post hoc frame-by-frame realignment method (Hammers et al., 2007a) implemented in 
Piwave 8.0 (Turkheimer et al., 2000, Turkheimer et al., 2008) was used to compensate for 
head movement during dynamic scans. The datasets were initially denoised using wavelets 
(Turkheimer et al., 1999). The denoised frames were then realigned using a mutual 
information – based method (mpr; (Studholme et al., 1997)). For each participant, an early 
frame with high signal-to-noise ratio and little evidence of movement was selected as the 
reference frame. Frames 1 to 4 ([11C]DPN study) or 1 to 6 ([18F]GE-179 studies) were not 
realigned due to low signal-to-noise. The remaining frames were automatically re-sliced and 
reconstructed into a new dynamic image.  
 
2.10 Summation images and mask images 
All summation images were created using Receptor Parametric Mapping version 6 (RPM6; 
(Gunn et al., 1997, Aston et al., 2001)) running in MATLAB 5.0, and were weighted relative 
to frame duration. Each participant’s summation image was used to create a binary whole-
brain mask that encompassed all grey- and white matter, in addition to a perimeter 
surrounding the cortical surface of approximately 10 mm (Hammers et al., 2007a), using the 
‘Extract region’ tool implemented in Analyze© 8.1 software (Mayo Clinic 2002). The masks 
were used to inform exponential spectral analyses (ESA) (Cunningham and Jones, 1993) 
and/or rank-shaping regularisation of spectral analyses (RS-ESA; (Turkheimer et al., 2003)).  
 
2.11 Spatial transformations 
All spatial transformations were performed using SPM software, versions 5 (SFS-RR study) 
or 8 ([18F]GE-179 studies; Statistical Parametric Mapping, Wellcome Trust Centre for 
Neuroimaging, UCL, London, www.fil.ion.ucl.ac.uk/spm) running under MATLAB 7.4 (The 
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MathWorks Inc., Natick, MA, USA). PET images were transformed to the same participant’s 
MRI space (or vice-versa) using the ‘Coregister’ tool in SPM (Collignon et al., 1995). 
Optimisation was by normalised mutual information (Maes et al., 1997) and 7th-degree B-
spline interpolation was used. Co-registered PET images (i.e. in MRI space) were transformed 
to standard space (i.e. the Montreal Neurological Institute 152 / International Consortium for 
Brain Mapping [MNI152/ICBM] template image) in SPM by applying the warp matrix that 
was calculated by (tissue-class) segmentation of the MRI. 
 
2.12 Tissue-class segmentation of MR images 
All MR images were segmented into grey matter, white matter, and cerebrospinal fluid 
components by unified segmentation (Ashburner and Friston, 2005), as implemented in the 
‘Segment’ tool of SPM5 and 8. Individual grey matter and white matter component images 
were thresholded at a probability of 0.5 using Analyze© 8.1 software (Mayo Clinic 2002). 
These images were transformed to PET space using the ‘Coregister’ tool as described above. 
 
2.13 Regional/anatomical segmentation of MR images  
T1-weighted images were anatomically segmented using multi-atlas propagation with 
enhanced registration and decision fusion (MAPER: (Heckemann et al., 2010b)). In this 
method, high-dimensional registrations of 30 MRI data sets (associated with manually derived 
atlases of 83 regions each in stereotaxic MNI152/ICBM space (Hammers et al., 2003a, 
Gousias et al., 2008)) are propagated to a target brain; this model’s 30 atlases segmentations 
are fused later on in the target spaces (Heckemann et al., 2006). 
 Individualised, MAPER-derived Hammersmith atlases were transformed to the 
participants’ native PET by applying the inverse of the warp matrix that was calculated by 
(tissue-class) segmentation of the MRI, using nearest-neighbour interpolation.   
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2.14 Extraction of PET data from regions-of-interest 
Data (mean, standard deviation) were extracted (‘sampled’) from regions-of-interest (ROIs) 
within attenuation-, scatter-, and motion-corrected dynamic images, summation images, and 
VT images using the ‘sample images’ tool, part of the ‘ROI’ tool of Analyze
© 8.1 software.  
 To allow quantification of percentage of increase or decrease, data was extracted from 
statistically significant clusters of difference in radioactivity concentration or VT using the 
MarsBar toolbox (Brett M et al., 2002). Such data is presented scaled (adjusted) relative to the 
global radioactivity concentration or VT of the participants with frequent IEDs, as relevant. 
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CHAPTER 3 
ACTIVATED NMDA RECEPTOR AVAILABILITY IN 
HEALTHY CONTROL PARTICIPANTS 
__________________________________ 
3 ACTIVATED NMDA RECEPTOR AVAILABILITY IN HEALTHY 
CONTROLS 
[18F]GE-179 is a novel PET radioligand that selectively binds within the ion channel pore of 
activated/open NMDA receptors (see Chapter 1 for further details). In this Chapter, the author 
describes the first-in-man evaluation of [18F]GE-179 PET. The following properties were 
defined as desirable in a PET radioligand (Pimlott, 2005, Laruelle et al., 2003): 
 Moderate affinity for the target  
o I.e. low – medium KD  
 Low non-specific binding 
o I.e. high selectivity for the target only 
o I.e. low affinity for other receptors, transporters, etc. 
o I.e. regional cerebral distribution consistent with known receptor density 
 Low plasma protein binding 
o I.e. high plasma free-fraction 
o I.e. high plasma-over-whole blood ratio 
 Rapid plasma clearance 
o I.e. rapid peripheral metabolism 
 Low toxicity 
 Adequate brain penetration 
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o I.e. low – moderate lipophilicity, Log P 
 Absence of radiolabelled metabolites in brain 
 Low between-subject coefficient of variation in healthy controls 
 Low test – re-test variability in healthy controls 
 
3.1 Objectives 
The objectives of the study were as follows: 
1. Evaluate the kinetic behaviour of [18F]GE-179 in vivo in the normal human brain. 
2. Quantify [18F]GE-179 binding/distribution in vivo in the normal human brain (in terms 
of influx trapping constant (KI) or volume-of-distribution (VT)). 
 
3.2 Hypothesis 
The primary hypothesis was: 
1. The two brain-compartments, four-rate constants (reversible binding; 2c4kbv) model 
would best-described the kinetic behaviour of [18F]GE-179 in vivo in the normal 
human brain. [This was based on evaluation of [11C]CNS 5161 (Asselin et al., 2004) 
and the rapid washout of [18F]GE-179 from the rodent brain (GE Healthcare, 
unpublished data, on file)].  
 
3.3 Materials and methods 
This study was approved by the Royal Marsden Hospital Research Ethics Committee, and the 
previously described regulatory authorities (see Section 2.1).  
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3.3.1 Study population 
The inclusion criterion was as follows: 
 Age between 25 and 80 years on the day of the PET scan 
The exclusion criteria were as follows: 
 History of neurological, psychiatric or other relevant medical disease 
o Including claustrophobia 
 Regular medication intake 
 Standard MRI exclusion criteria (e.g. ferromagnetic implants) 
 Advice from the participant’s GP against participation 
 Inability to provide informed consent 
 Regular (i.e. on five or more occasions) or recent (within the preceding three months) 
recreational drugs use, other than cannabis-containing substances 
 Positive urinary drugs-of-abuse screen (other than cannabis-containing substances; 
Monitect©; BMC, California, USA.) on the day of the PET scan 
 Pregnancy; a positive (urinary) pregnancy test on the day of the PET scan 
 Unsatisfactory modified Allen’s test (Cable et al., 1999, Allen, 1929) on the day of the 
PET scan 
 Relevant abnormality on MR imaging  
 Fourteen participants were enrolled into the study, of which 13 could eventually be 
scanned. One individual was not scanned  as the result of the modified Allen’s test (Cable et 
al., 1999, Allen, 1929) was unsatisfactory. Of the remaining 13, one individual was found to 
have evidence on MRI of a large post-natal infarct; another was unable to remain still during 
the PET scan; a third was subsequently reported by his family doctor to have a history of 
benzodiazepine abuse; a fourth was found, unexpectedly, to be unsuitable for 3T MRI (due to 
the presence of an implant inserted during stapedectomy, which had been evaluated at 1.5T 
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only). These participants were excluded. The demographic and descriptive data for the nine 
remaining healthy participants, who were without history of neurological or psychiatric 
illness, are presented in Table 2.  
 
3.3.2 Radiochemistry  
[18F]GE-179 was synthesised by Hammersmith Imanet Limited as previously described 
(Robins et al., 2010, Brown J et al., 2011) and administered also as previously described (see 
Section 2.3). Details of the injectate are presented in Table 2.  
 
3.3.3 PET image acquisition 
Images were acquired using a Siemens/CTI ECAT EXACT3D HR+ (962) PET camera 
(Siemens, Erlangen, Germany) with a 15.5 centimetre (cm) axial and 58.0 cm transaxial field 
of view (FOV), a spatial resolution of 4.8 ± 0.2  mm, and sensitivity of 69  cps/Bq/ml (Brix 
et al., 1997). Ten-minute 2D transmission scans were acquired for attenuation- and scatter 
correction, prior to dynamic image acquisition, using a single rotating external photon [137Cs] 
point source. Each subject had a 90-minute dynamic emission scan with a median smooth 
bolus intravenous injection of 187 MBq [18F]GE-179 administered 30 seconds after 
commencing image acquisition (t = 0.5 minutes; details of the injectate are presented in Table 
2). Thirty-four frames of increasing duration were acquired (1 x 30 seconds [background 
frame], 6 x 10 seconds, 3 x 20 seconds, 3 x 30 seconds, 4 x 1 minute, 6 x 2 minutes, 8 x 5 
minutes, and 3 x 10 minutes). Data were reconstructed using the Fourier rebinning algorithm 
(FORE; (Defrise et al., 1997)) and 2D filtered back-projection (FBP; Ramp, kernel 2.0mm 
FWHM). The voxel size of the reconstructed images was 2.092mm × 2.092mm × 2.42mm. 
 The images were acquired in a quiet, dimly-lit room without background noise. Foam 
padding was used to hold the subject’s head in a comfortable position. Head position was 
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monitored throughout with the camera’s laser light; if a major movement was noticed, the 
subject was repositioned and had a second transmission scan at the end of the dynamic scan. 
Continuous arterial blood sampling at a rate of 5 millilitres (ml) per minute was performed 
from t = 0 - 15 minutes. Discrete arterial blood samples were taken at baseline and t = 3, 5.5, 
10.5, 15.5, 25.5, 35.5, 50.5, 70.5, and 90.5 minutes and were subsequently used to generate 
plasma:whole blood activity ratios and determine metabolite levels. The plasma radioactivity 
concentration in each sample was obtained from an aliquot that had been rapidly centrifuged 
prior to measurement in a Nal(TI) well counter. The plasma radioactivity concentration in 
whole blood was measured separately. HPLC was used to quantify radiolabelled metabolites 
in the plasma.  
 
3.3.4 Adverse or serious events 
As this was not a (phase I) clinical drug trial (as confirmed by the Medicines and Healthcare 
Products Regulatory Agency of the UK; MHRA), a formal monitoring and reporting standard 
operating procedure for the detection and documentation of serious and adverse events was 
not implemented. Pre-clinical toxicology studies of GE-179 and human, in vivo studies of 
close analogues, detailed below, had suggested that adverse or serious events were very 
unlikely with administration of tracer does of [18F]GE-179. Participants were closely observed 
during scan sessions, left the scan centres feeling well, and were encouraged to contact the 
author immediately should they have any concerns. 
 
3.3.4.1 GE-179 pre-clinical toxicology1  
GE-179 had no effect on any cardiovascular parameters (including QT interval) in conscious 
dogs up to doses of 50 µg/kg (a no-observed-effect-limit, NOEL, equivalent to 168-fold the 
                                                          
1 Source: GE Healthcare plc, unpublished data, on file.  
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expected maximum human clinical dose). GE-179 was also evaluated in a modified expanded 
acute toxicity in vivo study in rats, with a no-observed-adverse-effect-limit, NOAEL, of 316 
µg/kg (equivalent to 306-times the expected maximum human clinical dose).  
GE-179 induced mutations in two of the five Salmonella strains in an in vitro reverse 
mutation (Ames) assay.  However in vivo, GE-179 did not cause any increase on the 
frequency of micronuclei in bone marrow up to doses of 1033 µg/kg (equivalent to 1000 
times the expected maximum human clinical dose).   
 
3.3.4.2 Human, in vivo toxicology – analogues of GE-179 
CNS 5161, a close analogue of GE-179, was administered to 24 patients in doses up to 4.5mg 
(intravenous over 20 h) without any dose-limiting toxicity observed (Paion AG, press release 
9th April 2009).  Doses of up to 2 mg CNS 5161 have been also been administered to healthy 
volunteers (Walters et al., 2002), and of up to 500 mg in participants with neuropathic pain 
(Forst et al., 2007). Transient increases in blood pressure and heart rate were the most 
commonly reported side effects, with mild headaches and mild visual disturbances also 
reported by some patients. There were no changes in the electrocardiographic parameters 
measured, including the QT interval.  
[11C]CNS 5161 and another analogue of GE-179, [123I]CNS 1261, have also been 
administered clinically as an NMDA receptor tracer to healthy volunteers (Erlandsson et al., 
2003, Bressan et al., 2004, Stone et al., 2006, Stone et al., 2008, Ahmed et al., 2011, Asselin 
et al., 2004, Hammers et al., 2004), participants with dyskinesia (Ahmed et al., 2011) and 
schizophrenia (Bressan et al., 2005, Bressan et al., 2003);  no tracer-related adverse events 
were reported. 
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3.3.5 MRI data acquisition 
3D Volumetric T1-weighted coronal SPGR MRI sequences were acquired to exclude relevant 
intracranial structural abnormality and for co-registration with the PET images, using a GE 
Signa 3T HDx system (General Electric, Waukshua, WI, U.S.A.) with a voxel size of 0.938 
mm x 1.100 mm x 0.938 mm. Coronal T2 and FLAIR were also acquired for each participant. 
MR images were reviewed by an experienced neuroradiologist. 
 
3.3.6 Metabolism of [18F]GE-179 
For each participant, the plasma-over-blood ratio of [18F]GE-179 was fitted to the following 
function with four free parameters using CLICKFIT version 1.7 (Cunningham et al., 2006; in-
house software) running in MATLAB 6.5 (The MathWorks Inc., Natick, MA, USA). 
 
 (2) 
 
[Where t is the scan time; x1 ... x4 are the model parameters; y plasma-over-blood ratio of 
[18F]GE-179 at scan time t]. 
 For each participant, the fraction of plasma radioactivity attributable to the parent 
[18F]GE-179 was fitted to a sigmoidal function with four free parameters using the following    
equation to generate a metabolite model for each participant.  
 
 
(3) 
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 [Where ts = t/3600 seconds, the normalised scan time; x1 ... x4 are the model parameters; y(t) is 
the fraction of parent [18F]GE-179 remaining in the plasma at scan time t]. 
The area under the metabolite model curve (AUCmetabs) was used as a measure of the 
rate of metabolism for each individual. Correlations between the AUCmetabs and age, weight, 
and body-mass index (BMI) were examined by Spearman’s rank (ρ) correlation coefficient 
using SPSS for (Microsoft) Windows version 16.0 (SPSS Inc., IBM Corporation, Somers, 
New York, USA). The threshold of statistical significance for these correlations (p < 0.05) 
was corrected for multiple comparisons using Bonferroni’s method ((Dunn, 1961, Tukey, 
1977) i.e. 0.05/3 = 0.01657).    
The AUCmetabs was compared across genders and smoking status by a univariate 
general linear model (GLM) in SPSS.  
 The analyses did not account for potential penetration of radiolabelled metabolites 
across the blood-brain barrier.  
 
3.3.7 Decay-, and metabolite-corrected parent plasma input functions 
Continuous decay and metabolite-corrected parent plasma input functions were generated for 
all subjects using CLICKFIT, as described previously (Jones et al., 1994, Hammers et al., 
2007b). Briefly, the continuous on-line time course of radioactivity concentration in whole 
blood was first interpolated over intervals where data was missing due to regular flushing 
with saline. Subsequently the continuous time course was calibrated against the radioactivity 
concentration measured in the four corresponding discrete blood samples. The plasma:whole 
blood ratio was calculated from the discrete blood samples and fitted to a sigmoid function. 
The final input functions were generated by multiplication of the calibrated time course of 
radioactivity in the blood with the fits to the plasma:blood ratios and metabolite fractions.  
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The mean of the decay and metabolite-corrected parent plasma input functions were 
computed for illustrative purposes. The areas under the decay-, and metabolite-corrected 
parent plasma input function curves (AUCIF) were calculated for each subject by summation 
of the counts in the parent plasma input function file, after correction for 18F radiodecay. 
 Correlations between the AUCIF and age, weight, body-mass index (BMI), and 
injected dose were examined by Spearman’s rank (ρ) correlation coefficient using SPSS. The 
author hypothesised a priori that the AUCIF would be negatively correlated with weight 
and/or BMI and positively correlated with injected dose; therefore, these correlations were not 
corrected for multiple comparisons. The AUCIF was compared across genders and smoking 
status by univariate GLM in SPSS.  
 
3.3.8 PET image pre-processing 
Attenuation and scatter-corrected dynamic PET images were corrected for head motion using 
a post hoc frame-to-frame realignment method (Hammers et al., 2007a, Turkheimer et al., 
2000, Turkheimer et al., 2008, Turkheimer et al., 1999, Studholme et al., 1997)) as previously 
described (see Section 2.9). Summation images (KBq/ml) that were weighted relative to 
frame duration were created for t = 5 - 30, t = 30 - 60, and t = 60 - 90 minutes, also as 
described previously (Gunn et al., 1997, Aston et al., 2001)).  
 The analyses did not account for potential penetration of radiolabelled metabolites 
across the blood-brain barrier.  
 
3.3.9 Global, grey- and white matter uptake  
Global (whole-brain) radioactivity concentration (i.e. uptake; kilobequerels per ml; KBq/ml) 
in the summation images was computed using a whole-brain mask which was created for each 
of the nine participants from their t = 5 – 30 minutes using Analyze 8.1 software  
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TABLE 2: Healthy participant demographics, MRI findings and [18F]GE-179 injection data. µg – micrograms; µmol – micromoles; CV – Between-subjects coefficient 
of variation; GBq – Gigabequerels; ID – Identification; yrs – years; Inj – Injected; IQR – Interquartile range; kg – kilograms; ; L – Left; M – male; MBq – Megabequerels; 
Medic – regular and recent medicine intake; MRI – Magnetic resonance imaging; n/a – non-applicable; R – Right; Spec act – Specific activity of the radioligand at the time of 
injection; sm – smoker; Un - Report unavailable; WM – White matter; yrs – years. (#Participant 8 was a regular user of ibuprofen. Analysis by univariate general linear model 
(GLM) failed to demonstrate any significant influence of this variable on the area-under the parent plasma input function or metabolite model curves; AUCmetabs and AUCIF).  
 
Control 
group ID 
Age 
(yrs) 
Sex 
Weight 
(kg) 
Handedness Smoker MRI 
Inj dose 
(MBq) 
Spec act 
(GBq/µmol) 
Purity 
(%) 
Co-injected 
mass (µg) 
1 26 M 80 L No Normal 187.6 450.1 98 0.16 
2 31 M 67 R No Normal 173.2 73.1 97 0.91 
3 55 M 83 R Yes WM foci 186.0 1428.0 97 0.05 
4 37 F 58 R No Tiny foci 180.4 769.5 96 0.09 
5 61 M 65 R No Normal 183.7 881.5 95 0.08 
6 62 F 53 R No WM foci 185.3 229.5 96 0.31 
7 25 F 81 R No Normal 192.4 263.8 96 0.28 
8# 26 M 91 L No Normal 189.2 726.6 96 0.10 
9 57 M 84 R No RF WM 
foci 
186.9 311.9 96 0.23 
           
Median/Total: 37 6 M (67%) 80.0 7R (78%) 1 sm (11%) n/a 186.0 450.1 96 0.16 
CV (%) 36 
 
 16.9 
 
   2.8 70.0 0.8 102.1 
IQR (25 – 57)  (65.0 -83.0)    (183.7 – 187.6) (263.8 – 769. 5) (96 -97) (0.09 – 0.28) 
Maximum 62  91    192.4 1428.0 98 0.91 
0.10 Minimum 25  53    173.2 
2 
73.1 95 0.05 
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(AnalyzeDirect, Inc., KS, USA) as described previously (Hammers et al., 2007a); the mean 
over the entire matrix within this mask was then computed.  
Radioactivity concentration in the grey matter of the summation images was 
computed as follows. First, an individualised grey matter mask was created for each of the 
participants by segmentation of their T1-weighted MR image using the ‘Segment’ tool in 
SPM8 (Ashburner and Friston, 2005) (Statistical Parametric Mapping 8; Wellcome Trust 
Centre for Neuroimaging, UCL, London), and thresholding of the resulting grey matter 
probability map at 0.5 using Analyze 8.1, both as described previously (see Chapter 2). 
The individual participants’ MR images and grey matter masks were co-registered to their t 
= 5 -30 minutes summation images as described previously (see Chapter 2), prior to 
calculation of the mean radioactivity concentration. White matter radioactivity 
concentrations were computed with white matter masks that had been created 
simultaneously during segmentation, and thresholded at 0.5. 
 
3.3.10 Regional distribution of radioactivity concentration 
An 83-region grey-matter-only ROI map was produced for each of the participants by 
transformation of thirty manually created atlases (Hammers et al., 2003b, Gousias et al., 
2008) to the participant’s native MRI space using MAPER (Heckemann et al., 2010a, 
Heckemann et al., 2011)), as previously described (see Section 2.13). The resulting atlas 
was then multiplied by the thresholded grey matter component of the MR image using 
Analyze 8.1 and used to extract the radioactivity concentration (KBq/ml) in each of the 83 
regions.  
The median radioactivity concentrations were calculated for the participants, 
surveying all 83 regions and combining left and right homologues for paired regions. 
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3.3.11 Left – right asymmetry of radioactivity concentration 
The median asymmetry indices (AIs) were calculated to compare radioactivity 
concentration (RC) in the ROIs highlighted by the survey (as regions of high, medium, and 
low radioligand uptake) according to the following formula.  
 
 
(4) 
 
A positive AI indicates greater radioactivity concentration in the left homologue 
than the right, and vice versa. 
 
3.3.12 Generation of time-activity curves 
Six grey-matter-only regions of interest (ROIs) were defined a priori for modelling 
purposes according to the known distribution of the NMDA receptor (Paoletti et al., 2007) 
and sampled with left and right sides combined. In order of decreasing approximate 
receptor density, the ROIs were: the putamina, the thalami, the superior frontal gyri, the 
parahippocampal gyri, the occipital lobes, and the cerebelli. Entire brain grey matter and 
white matter ROIs were also sampled. Each participant’s attenuation- and motion-
corrected dynamic PET image was sampled over all 34 time frames, using Analyze 8.1 as 
previously described (see Section 2.14). Time-activity curves (TACs) for each ROI were 
produced using CLICKFIT from the scanner information file and a weights file that had 
been generated for each ROI from the sampled dynamic PET data.  
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3.3.13 Compartmental modelling of [18F]GE-179 cerebral tissue kinetics 
3.3.13.1 Compartmental models 
Analyses of [18F]GE-179 cerebral tissue kinetics were performed using the following 
standard compartmental models  (for review see: (Gunn et al., 2001, Watabe et al., 2006):  
 One brain compartment, two rate constants (1c2kbv, reversible binding; Figure 7);   
 Two brain compartments, three rate constants (2c3kbv, irreversible binding);  
 Two brain compartments, four rate constants (2c4kbv; reversible binding, Figure 
6), and  
 Three brain compartments, six rate constants (3c6kbv, reversible binding; Figure 
5).  
The data acquired from the PET camera can be described by the following equation: 
 
 
(5) 
 
Where CPET(t) is the total radioactivity concentration measured at time t; Cf(t) is the 
radioactivity concentration attributed to free (unbound) radioligand  in brain tissue; Cs(t) is 
the radioactivity concentration attributed to specific binding of the radioligand in brain 
tissue; and Cn(t) is the radioactivity concentration attributed to non-specific binding of the 
radioligand in brain tissue.  
 In the two- and one brain compartment(s) models (Figures 6-7), the three brain 
compartments are collapsed into one- or two compartments rather than individually 
modelled.  
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 All models used here incorporated a variable blood volume component, and were 
used to calculate the delay between plasma and tissue TACs (range 5 – 25 seconds; 
(Turkheimer et al., 2006)).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 5: Three brain compartments, six rate constants (reversible binding; 3c6kbv) model.  
Cf - radioactivity concentration attributed to free (unbound) radioligand  in brain tissue;  Cn – the 
radioactivity concentration attributed to non-specific binding of the radioligand in brain tissue;  CS – the 
radioactivity concentration attributed to specific binding of the radioligand in brain tissue. (Adapted from 
(Watabe et al., 2006)). 
 
 
 
 
 
 
 
 
 
FIGURE 6: Two brain compartments, four rate constants (reversible binding; 2c4kbv) model.  
Cf - radioactivity concentration attributed to free (unbound) radioligand  in brain tissue;  Ct – the radioactivity 
concentration attributed to non-specific- and specific binding of the radioligand in brain tissue. (Adapted 
from (Watabe et al., 2006)). 
 
Models were assessed using mean grey-matter TACs for the ROIs listed above. 
Model fit was assessed using the Akaike information criterion (AICw; (Akaike, 1974)) and 
Cp 
 
 
Cf k2 
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Ct k2 
K1 
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k3 
 
Cn 
k6 k5 
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the intra-region and between-subjects coefficient of variation (CV) of the model estimates: 
the VT for all reversible binding models; and the influx trapping constant (KI) for the 
2c3kbv irreversible binding model.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 7: One brain compartment, two rate constants (reversible binding; 1c2kbv) model.  
(Taken from (Watabe et al., 2006)). 
 
3.3.13.2 Influx trapping constant and volume-of-distribution 
The volume-of-distribution (VT) is defined as the ratio at equilibrium of the concentration 
of the parent radioligand in a tissue/an organ of interest (e.g. the brain) to that of the parent 
radioligand in plasma, separated from metabolites (Innis et al., 2007): 
 
 
(6) 
 
[Where CT denotes the concentration of the parent radioligand in the tissue/organ of 
interest; CP denotes the concentration of the parent radioligand in the plasma]. 
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Cp 
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 Thus, VT represents the summed volumes of distribution of free, non – specifically 
bound, and specifically bound radioligand components: 
 
 
(7) 
 
[Where CT denotes the concentration of the parent radioligand in the tissue/organ of 
interest; CP denotes the concentration of the parent radioligand in the plasma; VF denotes 
the ratio of concentration of the free parent radioligand in the tissue/organ of interest to 
that of the parent radioligand in plasma; VNs denotes the ratio of concentration of the non-
specifically bound radioligand in the tissue/organ of interest to that of the parent 
radioligand in plasma; VS denotes the ratio of concentration of the specifically bound 
radioligand in the tissue/organ of interest to that of the parent radioligand in plasma]. 
 VT is strictly unitless, as 1cm
3 = 1ml (Innis et al., 2007), however, the VTs 
presented in this thesis can also be considered as expressed in terms of ml•cm-3. This 
(macro-) parameter is often that of most interest in PET studies, as it is a linear function of 
free receptor concentration and moreover is less sensitive to noise than parameters such as 
individual rate constants of compartmental models (see below). This is particularly 
important when quantifying at the voxel level, rather than within a region-of-interest.  
For the one brain compartment, two rate constants (1c2kbv) model, the VT is 
calculated according to: 
 
 
(8) 
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 For the two brain compartments, three rate constants (irreversible binding; 2c3kbv) 
model, the influx trapping constant KI is calculated according to: 
 
 
(9) 
  
For the two brain compartment, four rate constants (2c4kbv) model, the VT is calculated 
according to: 
 
 
(10) 
  
For the three brain compartments, six rate constants (3c6kbv) model, the VT is calculated 
according to: 
 
 
(11) 
 
Strengths of regional VT and K1 correlations, indicative of the flow dependency of 
the radioligand binding (Slifstein and Laruelle, 2001), were assessed by Spearman’s rank 
(ρ) correlation coefficients, pooling all ROI data together for the participants.  
Correlations between grey matter VT and age, weight, BMI, injected dose, specific 
radioactivity at the time of injection, and AUCIF were similarly interrogated with the 
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Spearman’s rank (ρ) statistic, with correction for multiple comparisons using Bonferroni’s 
method (Dunn, 1961, Tukey, 1977).   
 
3.3.14 Generation of parametric volume-of-distribution (VT) images 
Parametric VT images were generated by voxelwise rank-shaping regularisation of 
exponential spectral analysis (RS-ESA) (Turkheimer et al., 2003), as implemented in 
Piwave 8.0 (Turkheimer et al., 2000, Turkheimer et al., 2008).  
 (Exponential) spectral analysis (ESA; (Cunningham and Jones, 1993)) is a versatile 
method of calculating the VT of reversibly-bound radioligands. The TAC is described by 
the sum of decaying real exponentials convolved with an input function. Non-linear 
estimation of the exponential functions (as in compartmental modelling) is replaced by 
linear estimation of the coefficients of biologically plausible exponential basis functions. 
The basis functions fj(T) are defined as (Turkheimer et al., 1998): 
 
 
(12) 
 
[Where bj denotes a fixed (range pre-defined  a priori) set of values describing the 
exchange of radioligand among compartments; Cp(t) denotes the arterial input function t 
minutes after injection of the radioligand; T is the time at which the tissue activity is 
measured; N is the number of basis functions].  
 The number of bases generated (N) is large, for example, over 1000. The fastest 
bases describe the passage of radioligand in and out of the (brain) tissue within the time of 
the shortest dynamic frame. The slowest bases describe the half-life of the radioisotope and 
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thus relate to irreversible binding. The total radioactivity concentration in the field-of-view 
of the PET camera CT(T) is thus described by: 
 
 
(13) 
 
[Where aj denotes the linear coefficients of bj, defined above; fj(T) denotes the basis 
functions, defined above].  
 In practice, the continuous time parameter is replaced by discrete counterparts (t1, 
t2, ..., tM), as continuous measures of (brain) tissue radioactivity concentration are 
unavailable. Moreover, an error term εk is added to account for measurement error: 
 
 
(14) 
 
 [Where X(tk) denotes the total measured radioactivity concentration in the field-of-view of 
the PET camera at time tk].  
 Estimation of the linear coefficients aj, the non-linear bj, and the number of basis 
functions N is performed simultaneously using the non-negative least squares (NNLS) 
algorithms (Turkheimer et al., 1992, Lawson and Hanson, 1974) or the simplex algorithms 
(Cunningham and Jones, 1993) to select the subset of basis functions that provides the 
optimum solution. An advantage of ESA is that the model structure, i.e. number of 
compartments, does not need to be specified a priori. A limitation of the method is that 
 100 
noise in the data can result in the generation of spurious and erroneous estimates of the 
coefficients (Turkheimer et al., 1998).  
 RS-ESA is a development of the exponential spectral analysis estimation method 
that has been optimised for noisy datasets by incorporating a singular value decomposition 
(Golub and Reinsch, 1970) of the exponential bases. ESA is performed as above, with the 
exception that the estimation is obtained using linear least-squares rather than NNLS or the 
simplex algorithms. The matrix B which describes 100 weighted, basis functions is 
factorised according to: 
 
 
(15) 
 
 [Where P denotes an m x m orthogonal matrix; QT denotes an m x n orthogonal matrix; 
and S denotes a diagonal matrix containing singular values of B listed in decreasing order].   
 After singular value decomposition, negligible singular values of B are eliminated 
(producing a rank-reduced version of the matrix, Br). The solution is then regularised using 
a rank-shaping estimator, i.e. weighting each singular vector according to its contribution 
to Br. Estimation of the shaping coefficients is condition by the expected signal-to-noise 
ratio (SNR).  
 RS-ESA outperformed traditional ESA and Logan’s graphical analysis method 
(Logan et al., 1990) at noise levels of 10% to 20%, in terms of bias, standard deviation of 
VT, and mean squared error. This method has been successfully applied on a regional basis 
to PET data acquired using the structurally similar radioligand, [11C]CNS 5161 (Ahmed et 
al., 2008).  
 Time constants were specified as 5 seconds, equivalent to half the duration of the 
shortest frame, and 5100 seconds (85 minutes), just below the duration of the entire 
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dynamic scan. The noise fraction was specified as 0.15; a conservative estimate of signal-
to-noise based on the original guidance (Turkheimer et al., 2003) and early exploratory 
analyses.  
The parametric images were assessed visually (contrast and presence of voxels with 
outlier values). The median VT was computed within the ROIs and compared with the VTs 
derived via compartmental modelling. Correlation between regional VTs derived using 
each method was assessed by Spearman’s rank (ρ) correlation coefficient, pooling all ROI 
data together for the participants. The methods were also compared by a Tukey  mean – 
difference plot. 
 
3.4 Results 
3.4.1 Adverse or serious events 
[18F]GE-179 was well-tolerated by all participants. One participant reported self-limiting 
abdominal discomfort approximately 24 hours after injection. No serious events were 
reported. 
 
3.4.2 Plasma-over-blood model and metabolism 
An example of the plasma-over-blood model is provided in Figure 8.  
 Unmetabolised [18F]GE-179 accounted for a mean of 50% of the plasma 
radioactivity at approximately t = 16 minutes (960 seconds), 37% at t = 30 minutes (1800 
seconds), and 25% at t = 44 minutes (2640 seconds; Figure 9). The median sum of squares 
for the metabolite model was 1.24 x 10-3; IQR was 0.51 x 10-3 – 1.53 x 10-3 (see Figure 
10).  
 102 
  
FIGURE 8: Plasma-over-blood model for a representative healthy control participant (participant 5).  
Y axis denotes the ratio of concentration of [18F]GE-179 in the participant’s plasma to that in the participants’ whole blood.
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FIGURE 9: Mean fraction of parent [18F]GE-179 remaining in the plasma (t = 3.0 – 90.5 minutes).  
Error bars represent the 95% confidence interval for the mean at each timepoint. 
 
There was a significant negative correlation between the AUCmetabs and BMI (r = -
0.86, p = 0.002) that survived correction for multiple comparisons. There were no significant 
correlations with other variables or differences between sub-groups.  
 
3.4.3 Decay- and metabolite-corrected parent plasma input functions 
The parent plasma input functions peaked at a median of t = 71.5 seconds (IQR  = 65.6 - 81.7 
seconds) and decreased to less than 10% of the peak activity concentration within 5 minutes 
(Figure 11). The radioactivity concentrations in plasma at the peak of the parent plasma input 
functions had a median of 47.3 KBq per cubic centimetre (KBq/cm3; IQR = 43.4 - 65.1 
KBq/cm3), equivalent to 0.02% of the injected dose/cm3. The median AUCIF was 4782.0  
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FIGURE 10: Metabolite model for a representative healthy control participant (participant 1).  
Y axis denotes fraction of parent [18F]GE-179 remaining in the plasma.  
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FIGURE 11: Mean decay- and metabolite-corrected parent plasma input function (t = 0 – 90.5 minutes).  
Red diamonds indicate the mean radioactivity concentration attributed to parent [18F]GE-179 in the plasma of 
each participant at each timepoint. Grey squares represent 95% confidence intervals for the mean at each 
timepoint. KBq – Kilobequerels; ml – millilitre.  
 
KBq/cm3 (IQR 4165.4 - 5754.8 KBq/cm3). There was a significant negative correlation 
between the AUCIF and weight and AUCIF and BMI (both r = -0.721, p = 0.019). There were 
no significant correlations with other variables.  
 
3.4.4 Regional distribution of radioactivity 
The grey matter radioactivity concentration was 7.3 KBq/ml (IQR 5.9 - 9.2 KBq/ml) in the t = 
5 - 30 minute summation images. The highest median radioactivity concentration was 
identified in the putamina, followed by (in descending order) the cunei, the lingual gyri, 
thalami, and the cerebelli (Table 3). Radioactivity concentration in the putamina was a 
median 148% of that seen in the white matter for t = 5 - 30 minutes. 
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 The lowest median radioactivity concentration in grey matter was observed in the 
anterior medial temporal lobes, followed by (in ascending order) the parahippocampal gyri, 
the hippocampi, and the superior frontal gyri (Table 3). Radioactivity concentration in the 
parahippocampal gyri was a median 99% of that seen in the white matter for t = 5 - 30 
minutes. 
 
3.4.5 Left – right asymmetry of [18F]GE-179 radioactivity concentration 
The range of median asymmetries indices in the regions reported above was from – 0.03 (IQR 
– 0.05 – 0.01) in the thalami to (+) 0.03 (IQR 0.00 – 0.05) in the lingual gyri (Table 3).   
 
3.4.6 Time-activity curves 
The mean grey-matter radioactivity concentration peaked at 8.9 KBq/ml, equivalent to a mean 
of 0.0048 ID%, at t = 7.5 minutes. The mean white-matter radioactivity peaked at 5.1 KBq/ml 
(0.0028 ID%), at t = 13 minutes. The radioactivity declined more quickly in grey than in the 
white matter. 
 The highest mean grey-matter radioactivity concentration was seen in the putamina, 
which peaked at 10.4 KBq/ml (0.0056% ID), at t = 7.5 minutes (Figure 12). This was 
followed in descending order by the thalami, the occipital lobes, the cerebelli, the superior 
frontal gyri and the parahippocampal gyri. Radioactivity concentration in the putamina 
decreased to approximately 58% of the peak at approximately t = 91.5 minutes, similarly to 
63% in the thalami, 53% in the occipital lobes, 51% in the cerebelli, and 64% in the superior 
frontal gyri. The radioactivity concentration peaked at t = 13 minutes in the parahippocampal 
gyri, later than in other ROIs, but also declined more slowly than in the other grey matter 
regions (68% of the peak at t = 91.5 minutes). 
 
 107 
TABLE 3: Median regional radioactivity concentration and asymmetry indices. Data is derived from t = 5 – 
30 minutes summation images.  Ant. – Anterior aspect; CV – Between-subjects coefficient of variation; IQR – 
Interquartile range; KBq – Kilobequerels; ml – millilitres; n/a – non-applicable. 
 
Region 
Radioactivity concentration 
Median (IQR; KBq/ml) 
CV (%) 
Asymmetry index 
Median (IQR) 
Putamina 8.7 (6.8 – 111.6) 27.7 0.00 (-0.02 – 0.02) 
Cunei 8.4 (7.0 – 11.3) 29.2 0.00 (-0.02 – 0.02) 
Lingual gyri 8.3 (6.9 – 10.9) 27.4 0.03 (0.00 – 0.05) 
Thalami 8.3 (6.6 – 11.2) 26.9 -0.03 (-0.05 – 0.01) 
Cerebelli 7.6 (6.2 – 9.7) 26.7 0.00 (-0.02 – 0.01) 
Superior frontal gyri 7.5 (6.0 – 9.4) 26.1 0.01 (-0.02 – 0.01) 
Hippocampi 6.7 (5.5 – 8.6) 28.2 -0.01 (-0.04 – 0.02) 
Parahippocampal gyri 6.1 (4.9 – 7.6) 26.5 -0.03 (-0.06 – 0.00) 
Ant. medial temporal lobes 6.0 (4.8–7.5) 25.4 -0.00 (0.00 – 0.06) 
    
White matter 6.0 (4.5 – 7.8) 28.1 n/a 
 
3.4.7 Compartmental modelling of [18F]GE-179 cerebral tissue kinetics 
The two brain compartments, four rate constant (2c4kbv) model best described the 
radioligand’s kinetics in grey matter (AICw = -207; Table 4), with a slight bias towards 
overestimation of peak radioactivity concentration. This model performed similarly in the 
putamina (Figure 13) and in the other ROIs (Table 4). In contrast, the one-compartment, two 
rate constant (1c2kbv) and two-compartment, three rate constant (2c3kbv) models (see Table 
5) were characterised by consistently higher AICw, e.g. -114 in grey matter, and the three- 
compartment, six rate constant (3c6kbv) model was characterised by a large number of outlier 
values within each ROI.  
Median estimates of VT in each ROI, derived by application of the 2c4kbv models to 
individual TACs, are shown in Table 4.  
A significant positive correlation was detected between VT and k1 (Spearman’s rho = 
0.313; p =0.021; Figure 14). 
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FIGURE 12: Time-activity curves:  percentage of injected dose of [18F]GE-179 per ml (in ROIs) versus time.  
Data has been decay – corrected; y axis – x 10-3 %. ml – millilitres; ROI – Region-of-interest. 
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FIGURE 13: Compartmental modelling of [18F]GE-179 putamina tissue kinetics over 90 minutes for a representative healthy participant.  
Black Xs denote the observed total radioactivity concentration (KBq/ml) measured from the putamina (left and right combined) over each of 34 frames. The coloured lines 
illustrate the time-activity curve (TAC) that would be expected given each of four different compartmental models. The red line represents one brain compartment, two 
rate-constants model [1c2kbv]; the green line represents two brain compartments, three rate-constants (irreversible binding) model [2c3kbv]; the blue line represents two 
brain compartments, four rate-constants model [2c4kbv]; the magenta line represents three brain compartments, six rate-constants model [3c6kbv]. The proximity of the 
Xs to each line indicates the fit of each model to the observed data. The insets illustrate the fit at the peak and tail of the TAC; the 2c4kbv (blue line) and 3c6kbv models 
(magenta line) closely approximate the observed data from the putamina for this participant.   
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FIGURE 14: [18F]GE-179 VT  as calculated by regional 2c4kbv versus K1 as calculated by the same 
method.  
Data is pooled; six ROIs are presented for each participant, with the whole-brain grey matter region 
excluded. 2c4kbv – 2 brain compartments, 4 rate-constants (reversible binding) model; VT – Volume-of-
distribution. 
 
There was a positive correlation between grey matter VT and age (Spearman’s rho 
= 0.803; p =0.009). There were no significant correlations with other variables. 
 
3.4.8 Voxelwise rank-shaping regularisation of exponential spectral analysis  
Voxelwise rank-shaping regularisation of exponential spectral analysis (RS-ESA) yielded 
VTs that correlated with those derived from regional compartmental modelling 
(Spearman’s rho = 0.901; p <0.001; Table 6, Figures 15-6). A bias towards  
 
 111 
TABLE 4: [18F]GE-179 VT  and K1 as calculated by regional 2c4kbv model. “Grey matter” refers to the grey matter of the entire brain. 2c4kbv – two brain compartments, 
four rate-constants (reversible binding) compartmental model; AICw – Akaike information criterion; CV – Between-subjects coefficient of variation; IQR - Interquartile 
range; VT – volume-of-distribution.  
 
Region AICw Median (IQR) K1 (x 10-3; median) VT Median (IQR) CV in VT (%) 
Grey matter -207.4 (-202.0 – -218.0) 3.6 9.0 (8.7 – 10.7) 24.9 
Thalami -146.6 (145.1 – -147.4) 4.5 11.8 (10.4 – 13.0) 15.7 
Putamina -149.1 (-115.3 – -159.3) 4.5 11.7 (9.9 – 12.7) 15.9 
Occipital lobes -207.1 (-198.6 – -212.4) 4.1 9.5 (8.8 – 10.7) 13.7 
Parahippocampal gyri -160.9 (-149.7 – -179.2) 3.1 9.3 (8.1 – 9.7) 16.0 
Cerebelli -191.6 (-186.6 – -209.6) 4.0 8.9 (8.0 – 10.2) 13.4 
Superior frontal gyri -182.4 (-142.9 – -186.7) 3.9 8.6 (8.4 – 9.2) 12.9 
     
Median -182.4 4.1 9.3 15.8 
IQR (-155.0 – -199.3) (3.8 – 4.3) (9.0 – 10.6) (13.6 – 16.0) 
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TABLE 5: [18F]GE-179 KI  and K1 as calculated by regional 2c3kbv model. “Grey matter” refers to the grey matter of the entire brain. 2c3kbv – two brain compartments, 
three rate-constants (irreversible binding) compartmental model; AICw – Akaike information criterion; CV – Between-subjects coefficient of variation; IQR - Interquartile 
range; KI – influx trapping constant.  
 
Region AICw median (IQR) K1 (x 10-3; median) KI median, (x 10
-4; IQR) CV in KI (%) 
Grey matter -154.0 (-146.6 – -169.7) 3.5 4.0 (3.6 – 4.8) 17.1 
Thalami -124.0 (-102.3 – -133.1) 3.8 5.3 (5.0 – 6.3) 18.1 
Occipital lobes -150.8 (-141.0 – -180.1) 3.9 4.9 (4.3 – 5.1) 13.1 
Superior frontal gyri -157.0 (-131.5 – -173.2) 3.4 4.6 (3.2 – 4.7) 27.9 
Cerebelli -149.0 (-139.8 – -161.3) 3.8 4.0 (3.4 – 4.2) 17.8 
Putamina -117.2 (-112.0 – -136.2) 3.9 3.5 (3.5 – 5.3) 35.9 
Parahippocampal gyri -131.9 (-127.2 – -151.3) 2.8 3.1 (2.6 – 5.0) 50.2 
     
Median -149.0 3.8 4.0 18.1 
IQR (-128.0 – -152.4) (3.5 – 3.9) (3.8 – 4.8) (17.5 - 31.9) 
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TABLE 6: [18F]GE-179 VT as calculated by voxel-wise RS-ESA. “Grey matter” refers to the grey matter of 
the entire brain. CV – Between-subjects coefficient of variation; IQR – Interquartile range; RS-ESA – Rank-
shaping regularisation of exponential spectral analysis; VT – volume-of-distribution.  
 
Region VT Median (IQR) CV in VT (%) 
Grey matter 8.4 (7.7–9.9) 12.3 
Thalami 11.1 (9.4–11.6) 13.6 
Putamina 10.9 (9.5–12.5) 14.8 
Cerebelli 8.3 (7.4–9.5) 13.7 
Occipital lobes 8.2 (8.2–8.8) 12.6 
Superior frontal gyri 8.2 (7.8-9.3) 11.6 
Parahippocampal gyri 7.8 (7.2-8.1) 13.2 
   
Median 8.3 13.2 
 IQR (8.2 – 9.7) (12.4 – 13.7) 
 
of VT, relative to that derived from the 2c4kbv model, was observed (Figure 17). 
 
3.5 Discussion 
The author described the first use of [18F]GE-179 as a PET radioligand in humans. The major 
findings are that the radioligand has high brain extraction with a relatively homogeneous 
distribution, rapid uptake by grey matter, and rapid peripheral metabolism. Quantification of 
volumes-of-distribution was feasible within ROIs using a two brain-tissue compartments, four 
rate-constants model, and at the voxel level using rank-shaping regularisation of exponential 
spectral analysis. 
 Properties of PET radioligands that are considered desirable were summarised at the 
beginning of the chapter. [18F]GE-179 has KI = 2.4 nM and a KD = 2.35 +/- 0.2 nM (Robins 
et al., 2010), which are indicative of low – moderate affinity for the intra-channel site of the 
rat NMDA receptor, and less than seen with other radioligands such as raclopride for its 
target (Kohler et al., 1985, Farde et al., 1989). However, this disadvantage is offset in part by  
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FIGURE 15: Volume-of-distribution (VT) of 
[18F]GE-179 for a representative participant (1), as calculated by rank-shaping regularisation of exponential spectral 
analysis (RS-ESA).  
Image has been smoothed by an isotropic Gaussian filter of 6 mm at FWHM.
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FIGURE 16: [18F]GE-179 VT as calculated by voxelwise RS-ESA versus [
18F]GE-179 VT  as calculated by  
regional 2c4kbv.  
Data is pooled; six ROIs are presented for each participant, with the whole-brain grey matter region excluded. 
2c4kbv – 2 brain compartments, 4 rate-constants (reversible binding) model; RS-ESA – Rank-shaping 
regularisation of exponential spectral analysis; VT – Volume-of-distribution. 
 
moderately-paced kinetics in grey matter, which allowed capture of the initial part of the 
washout phase within 90 minutes. The plasma-over-blood ratio did not reach equilibrium 
within 90 minutes; however, the plasma free fraction appeared to be high. 
 The rate of metabolism of [18F]GE-179 is less rapid than that of [11C]CNS-
5161(Asselin et al., 2004), [123I]CNS 1261 (Erlandsson et al., 2003), but not [18F] memantine 
(Ametamey et al., 2002) (data not reported for other NMDA-receptor radioligands). The 
analyses have assumed radiolabelled metabolites did not penetrate the brain, although one 
compound (more polar than GE-179) was identified in rodent brains at  
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FIGURE 17: Tukey mean-difference plot (also known as Bland-Altman plot) for comparison of [18F]GE-
179 VT as calculated by voxelwise RS-ESA and regional 2c4kbv.  
Data is pooled; six ROIs are presented for each participant, with the whole-brain grey matter region excluded. 
Underestimation is seen with RS-ESA, relative to quantification by 2c4kbv. 2c4kbv – 2 brain compartments, 4 
rate-constants (reversible binding) model; RS-ESA – Rank-shaping regularisation of exponential spectral 
analysis; VT – Volume-of-distribution.  
 
30 minutes (GE Healthcare, unpublished data, on file). Hence, this is a limitation of the study. 
Parent [18F]GE-179 accounted for 84% of the cerebral radioactivity at 30 minutes post-
injection; in humans, the slower plasma metabolism of the radioligand suggests it is should 
account for an even greater proportion at this timepoint. 
Brain penetration of [18F]GE-179 was very good with a highest grey matter mean peak 
radioactivity concentration  of 8.9KBq/ml (in the putamina), which is greater than that 
achieved using the putative NMDA radioligands [18F]memantine (Ametamey et al., 2002), 
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[11C]CNS-5161 (Asselin et al., 2004), and [11C]AcL703 (Matsumoto et al., 2007) (normalised 
to injected volume). Comparison with other radioligands targeted at the NMDA receptor is 
limited as mean global and grey matter radioactivity concentrations have not been reported 
(Hartvig et al., 1995, Kumlien, 1999, Brown et al., 1997, Erlandsson et al., 2003). 
High non-specific binding is a frequent cause of radioligand failure. The distribution 
of radioactivity in grey matter following injection of [18F]GE-179 injection was relatively 
homogeneous, with highest concentration in the putamina.  High radioactivity concentration 
was observed in the cerebelli, as would be expected given the known expression of NMDA 
receptors in this region (Jansen et al., 1990, Scherzer et al., 1997).  
 The channel maximal open probability of the NMDA receptor (NR) subunit NR2A is 
approximately two to five  times higher than that  of the NR2B subunit (Chen et al., 1999) 
(Erreger et al., 2005) fifty times higher than that  of the NR2C (Dravid et al., 2008) and nine 
times higher than that  of NR2D subunits (Wyllie et al., 1998). As access to the PCP-binding 
site occurs on channel pore opening, it is reasonable to expect radioactivity concentration to 
mainly reflect the distribution of the NR2A NMDA receptor subunit. As access to the PCP-
binding site occurs on channel pore opening, and given that NR2A subunits are not expressed 
in the human putamen, the findings might be explained by the high expression NR2B subunits 
in this region (Rigby et al., 1996). 
 NMDA receptors are relatively concentrated in the hippocampi, with NR2B subunits 
present in higher concentrations than NR2A receptors (Rigby et al., 1996); the lower channel 
opening probabilities of this subunit might underlie the modest radioactivity concentration 
observed in medial temporal regions. Radioactivity concentration was low in the brainstem, 
which is consistent with the lack of NR2A and NR2B expression in this region (Rigby et al., 
1996), and suggests specificity of grey matter binding. However, the weak-to-moderate 
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positive correlation between K1 and volume-of-distribution suggests partial cerebral blood 
flow-dependency, and questions the specificity of [18F]GE-179 uptake in vivo. 
 Whilst the specificity [18F]GE-179 has been confirmed in vitro (GE Healthcare, 
unpublished data, on file), ideally binding would be quantified in vivo by co-administration of 
another unlabelled agent with high affinity and selectivity for the PCP- binding site. However, 
this is not feasible in humans because of poor tolerability of the necessary of blocking doses 
of unlabelled NMDA antagonists. A dose-escalation safety study with  CNS-5161 was 
abandoned after a sustained systolic blood pressure increase in one of two patients 
administered 750 µg of CNS-5161 (Forst et al., 2007); another group additionally found 
tolerability  limited in [11C]CNS-5161 blocking studies (Hammers et al., 2004, unpublished 
data, on file). Further evidence could also be provided from in vitro studies, for example by 
co-administration with NMDA receptor antagonists other than MK-801. 
 [18F]GE-179 exhibits faster grey matter tissue uptake and washout than [11C]CNS-
5161 (Asselin et al., 2004) (and also [123I]MK-801 (Brown et al., 1997, Owens et al., 1997), 
[18F]memantine (Ametamey et al., 2002), and [11C]AcL703 (Matsumoto et al., 2007)) which 
argues against irreversible binding; this was corroborated by high AICw with the 2c3kbv 
model - a better fit was observed for the reversible model. Radioactivity concentration in grey 
matter peaked more rapidly than seen with its predecessor (Asselin et al., 2004), eliminating 
the need for prolonged dynamic scanning sessions, e.g. of 120 minutes or more. The data 
indicate that quantification of [18F]GE-179 volume-of-distribution at the regional level  is 
achievable with a two brain compartments, four rate-constants model with variable blood 
component. Voxelwise quantification of [18F]GE-179 VT with RS-ESA yielded comparable 
estimates that were strongly correlated with those derived by the 2c4kbv model; this 
quantification  method  is suggested for comparison of VT between populations when a priori 
delineation of regions-of-interest is not appropriate. Alternative quantification strategies, such 
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as graphical analyses methods (Logan et al., 1990, Ito et al., 2010) could explored in an 
attempt to maximise the concordance between regional and voxelwise estimates. 
 [18F]GE-179 uptake and VT have moderate-to-low between-subjects variability in 
healthy participants, with between-subjects regional CVs of 16% or less. In the current study, 
[18F]GE-179 was prepared with a higher specific activity than that achieved in previous PET 
and SPECT studies of related compounds (Brown et al., 1997, Waterhouse and Waterhouse, 
2003b, Matsumoto et al., 2007, Knol et al., 2009); hence this should not be an obstacle to 
further applications. 
 Interestingly, a correlation between grey matter VT and age was observed, which was 
unexpected given reports of impaired NMDA receptor binding and function with advancing 
age in preclinical models (for review see: (Foster, 2012, Magnusson et al., 2010)). The limited 
human data available suggest a regionally-variant relationship between NMDA receptor 
binding in the normal brain and aging, with reductions in the frontal lobes, and basal ganglia, 
but not the hippocampi, (Villares and Stavale, 2001, Piggott et al., 1992, Perry et al., 1993). 
The correlation is also difficult to reconcile with the widely-reported decrease in rCBF with 
aging ((Buijs et al., 1998, Leenders et al., 1990, Gur et al., 1987); for review see: (Goldstein 
and Reivich, 1991)). Considering this literature and the sample size, confirmation of this 
correlation in a larger study is required.  
 As expected, participants of higher weight and/or BMI had a lower parent plasma 
input, lower whole-brain uptake and lower grey-matter uptake than the remaining controls; 
therefore global uptake is an essential covariate when comparing summation images (i.e. 
when no metabolite-corrected parent plasma input function is available) and ideally, 
subgroups should be BMI-matched. 
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3.5.1 Limitations 
Limitations of this first-in-man study include lack of test - re-test data, and the small sample 
size (which was, however, larger than all healthy control populations used in similar studies to 
date; see Table 1). [It was not possible to acquire test – re-test data from this population as 
Hammersmith Imanet Limited ceased all operations prior to completion of the study]. The 
quantification of binding in small ROIs such as the hippocampi and parahippocampal gyri 
requires partial-volume effect correction techniques, as previously demonstrated ((Meltzer et 
al., 1996, Koepp et al., 1997, Hoffman et al., 1979); a novel method is described subsequently 
in this thesis).  
 The most significant limitation of RS-ESA is the need to specify the expected noise a 
priori. However, when the noise level was erroneously specified as 10%, under- and over-
estimations of the true noise of up to 5% (in absolute terms) reduced or increased the bias and 
the standard deviation by only 1% of the VT, respectively (Turkheimer et al., 2003). Thus, 
despite an estimation error of 5%, the RS-ESA still outperformed traditional ESA and 
Logan’s graphical analysis method.  
   
3.6 Conclusion 
This first-in-man evaluation of [18F]GE-179 has demonstrated several properties that are 
desirable in PET radioligands, such as high brain uptake and acceptable between-subject 
variability. Quantification of VT appears feasible within regions-of-interest and at the voxel 
level. The specificity of [18F]GE-179 binding requires further characterisation and could 
potentially limit its application. Further in vivo evaluation of [18F]GE-179 is warranted.  
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CHAPTER 4 
ACTIVATED NMDA RECEPTOR AVAILABILITY IN 
PARTICIPANTS WITH FREQUENT INTERICTAL 
EPILEPTIFORM DISCHARGES 
__________________________________ 
4 ACTIVATED NMDA RECEPTOR AVAILABILITY AND 
FREQUENT IEDs 
Excessive NMDA receptor activation has been proposed to contribute to epileptogenesis, 
and blockade of NMDA receptors has anticonvulsant and neuroprotective effects (see 
Chapter 1 for further details). However, increased availability of activated NMDA 
receptors has not yet been demonstrated in humans with epilepsy, in vivo (Kumlien, 1999). 
In this Chapter, the author quantifies activated NMDA receptor availability in participants 
with frequent IEDs using [18F]GE-179 PET.   
 
4.1 Objective 
The objective of the study was as follows: 
1. Demonstrate increased [18F]GE-179 VT in participants with frequent IEDs, in vivo, 
relative to healthy control participants [rather than to evaluate [18F]GE-179 PET as 
a tool for  pre-surgical evaluation in refractory epilepsy].   
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4.2 Hypotheses 
The primary hypothesis was:  
1. Focal increases in [18F]GE-179 VT would be identified for participants with frequent 
IEDs, in vivo , relative to healthy control participants. 
The secondary hypothesis was:  
2. The focal increases in [18F]GE-179 VT identified for participants with frequent IEDs 
would be localised to the presumed epileptogenic lobe in each participant.  
 
4.3 Materials and methods 
The study was approved by the Research Ethics Committee of the Royal Marsden 
Hospital, and the previously described regulatory authorities (see Section 2.1).  
 
4.3.1 Epilepsy and control populations 
The inclusion criteria for the epilepsy (IEDs) group were as follows: 
 Age between 18 and 80 years on the day of the PET scan 
 Very frequent (≥10/hour) IEDs on scalp electroencephalography. 
 History of focal epilepsy 
The exclusion criteria were as follows: 
 Claustrophobia 
 Standard MRI exclusion criteria (e.g. ferromagnetic implants) 
 Advice from the participant’s GP against participation 
 Inability to provide informed consent 
 Regular (i.e. on five or more occasions) or recent (within the preceding three 
months) recreational drugs use, other than cannabis-containing substances 
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 Positive urinary drugs-of-abuse screen (other than cannabis-containing substances; 
Monitect©; BMC, California, USA.) on the day of the PET scan 
 Pregnancy; a positive (urinary) pregnancy test on the day of the PET scan 
 Unsatisfactory modified Allen’s test (Cable et al., 1999, Allen, 1929) on the day of 
the PET scan 
 The primary inclusion criterion for the patient group was evidence of very frequent 
(≥10/hour) IEDs on scalp electroencephalography. This criterion was employed to exclude 
the possibility that any subsequent negative findings were attributable to insufficient 
cortical excitability in the participants. [The underpinning hypothesis was that these 
individuals with very frequent IEDs have highly excitable cerebral cortices, and thus 
would be likely to have an identifiable increase in the availability of activated NMDA 
receptors]. Twelve such participants were enrolled into the study; one participant withdrew 
from the study prior to scanning. Thus, 11 participants (median age 33 years; IQR 23 – 41 
years; six males) were scanned (demographics and clinical details are listed in Table 7). 
 Their diagnoses were based on history, seizure semiology, prolonged and repeated 
interictal and ictal video-EEG recordings, and MRI data. Interictal [18F]FDG PET data was 
available for nine of the 11 participants. As this study did not seek to evaluate the capacity 
of [18F]GE-179 to localise epileptogenic foci in participants with refractory epilepsy, 
discordance between clinical, EEG, and imaging data was not an exclusion criterion.   
The control group consisted of ten healthy volunteers without history of 
neurological or psychiatric illness (median age 47 years; IQR 27 – 58 years; seven males; 
as previously described – see Section 3.3.1). The inclusion criterion, exclusion criteria, and 
demographic data were previously presented for nine of the ten control group participants 
(Table 2); here, [18F]GE-179 PET data that was acquired from an additional 58-year-old 
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male was additionally used for comparison. Demographic data for the participants with 
very frequent IEDs is presented in Table 7. 
 
4.3.2 Radiochemistry  
[18F]GE-179 was synthesised by Hammersmith Imanet Limited as previously described 
(Robins et al., 2010, Brown J et al., 2011) and administered also as previously described 
(see Section 2.3). Injectate data was previously presented for nine of the control group 
participants (Table 2); injectate data for the participants with very frequent IEDs is 
presented in Table 8. 
 
4.3.3 Analysis of demographic and injectate data  
Age, weight, BMI, injected dose, specific activity, radiochemical purity, and co-injected 
mass were compared between groups using the non-parametric Wilcoxon signed-rank test 
(Wilcoxon, 1945). Gender balance, handedness, and prevalence of smokers were compared 
between groups using the Pearson’s chi-squared test (Pearson, 1900).   
 
4.3.4 PET image acquisition 
Images were acquired using a Siemens/CTI ECAT EXACT3D HR+ (962) PET camera 
(Siemens, Erlangen, Germany) as previously described (see Section 3.3.3).  
 Continuous and discrete arterial blood sampling was performed as previously 
described (see Section 3.3.3). Sample radioactivity concentration for whole blood and 
plasma and the fraction of unchanged (parent) [18F]GE-179 in the plasma were quantified 
as previously described (see Section 3.3.3). The participants were closely observed for 
evidence of seizures throughout the scan. 
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TABLE 7: Patients with refractory focal epilepsy and frequent IED - clinical details (overleaf). bil/Bil – bilateral; C – Central region; calc – calcified lesions; CBZ – 
Carbamazepine; CLB – Clobazam; CLN – Clonazepam; CPS – Complex partial (focal) seizures; EEG – Electroencephalography; F – frontal lobe; Fe – Female; [18F]FDG 
PET – [18F]fluoro-deoxyglucose positron emission tomography; gen – generalised; h – hours; HS – Hippocampal sclerosis; ID – Identification; IFG – Inferior frontal gyrus; 
IED – Interictal epileptiform discharge; ins  – insula; L – Left; LAC – Lacosamide; LEV – Levetiracetam; LTG – Lamotrigine; M – Male; MEG – Magnetoencephalography; 
MDZ – Midazolam; mins – minutes; MRI – Magnetic resonance imaging; n/a – unavailable; Neg./neg. – Negative i.e. no significant findings; O – Occipital lobe; OXC – 
Oxcarbazepine; P – Parietal lobe; PHT – Phenytoin; post – posterior aspect; prn – pro re nata i.e. as required; R – Right; RUF – Rufinamide; SGS – Secondary generalised 
seizures; SPS – Simple Partial Seizures; T – Temporal lobe; TPM – Topiramate; Un – Unknown; VAL – Valproate; wk – week; ZNS – Zonisamide. 
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IEDs 
ID 
Age/sex/ 
handedness 
Probable 
lateralisation 
& localisation 
Onset/ 
duration 
(years) 
Post- 
ictal 
interval 
Treatment 
Seizur
es 
EEG 
(inter-/ 
ictal) 
EEG  
(ictal) 
MRI 
[18F]FDG
PET 
1 33/M/L L ?F-T 19/14 Un CLN, RUF, fluoxetine CPS, L T/L L F-T Neg. Neg. 
2 23/M/L R F 16/7 3 days CBZ, VAL SPS, SGS R F-C/R N/a Neg. Neg. 
3 28/Fe/R R P-O 10/18 20.5h 
LEV, sertraline, 
amlodipine 
SPS, 
CPS 
R post./ 
R T-P-O 
R P-O> 
R T>L O 
Tubers L F, R F, L T, 
R P-O, L O 
N/a 
4 41/M/R L F-T 14.5/26.5 16.0h 
CBZ, LEV, LTG, MDZ 
prn, ZNS 
SPS, CPS, 
SGS 
L F-T/ L ?F-T N/a R IFG lesion L T 
5 50/Fe/R L T/?bi-T 11/39 39 days 
LEV, PHT, 
lofepramine 
CPS 
SGS 
L & R T/ 
L & R T 
L & R T Neg. L T 
6 24/M/R ?multifocal 7/17 6.5h 
LAC, LEV, LTG, 
OXC, CLB 
CPS, 
SGS 
R F-C/ 
R and gen 
L F>L ins 
>L F-T 
Neg. Neg. 
7 22/M/R L F-T 4/18 7.5h 
CBZ, LEV, LAC, 
MDZ prn 
CPS, 
SGS 
L F-T & RT/ 
L F-C-T 
N/a L HS L T-P-O 
8 38/M/L R F-T 2.5/36.5 45 mins 
PHY, CBZ, TPM, CLB, 
MDZ, fexofenadine 
SPS, CPS, 
SGS 
R F-T/RT 
R F, 
L & R T 
Bil. tubers: F, P,L-O, 
periventricular calc 
R T 
9 50/Fe/R ?bi-T 13/37 10+ years LEV, LAC, LTG, Nil L & R T/Un. L & R T Neg. N/a 
10 20/Fe/R Un. 14/6 39.5h OXC, CLB, MDZ 
CPS, 
SGS 
T-F/ 
R T & bil 
N/a Neg. Neg. 
11 40/Fe/L L F 12.5/28 11 days OXC, LAC, CLB SGS L & R F/L F L F Neg L F 
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TABLE 8: Participant demographics and [18F]GE-179 injection data (overleaf).  µg – micrograms; µmol – micromoles; CV – Between-subjects coefficient of variation; 
Fe – Female; GBq – Gigabequerels; ID – Identification; yrs - years; IED – Interictal epileptiform discharge; Inj – Injected; IQR – Interquartile range; kg – kilograms; L – left; 
M – Male; MBq – Megabequerels; n/a – non-applicable; sm – smoker; Spec. act. – Specific activity of the radioligand at the time of injection.  
ID 
Age 
(years) 
Gender Weight (kg) Handedness Smoker 
Inj Dose 
(MBq) 
Spec. act. 
(GBq/µmol) 
Purity (%) 
Co-injected 
mass (µg) 
IEDs-1 33 M 84.0 L No 187.1 24.8 100 0.29 
IEDs-2 23 M 76.7 L No 188.7 27.0 100 2.71 
IEDs-3 28 Fe 95.3 R No 194 1862.0 100 0.04 
IEDs-4 41 M 55.8 R Yes 187.7 232.0 100 0.31 
IEDs-5 50 Fe 80.6 R No 186.8 597.8 98 0.12 
IEDs-6 24 M 81.0 R No 184.3 336.8 97 0.21 
IEDs-7 22 M 62.8 R No 190.2 608.0 95 0.12 
IEDs-8 38 M 82.6 L No 190.9 215.6 96 0.34 
IEDs-9 50 Fe 62.0 R No 188.8 725.0 96 0.10 
IEDs-10 20 Fe 64.0 R No 187.7 721.0 96 0.10 
IEDs-11 40 Fe 77.6 L No 191.9 1053.0 97 0.07 
IEDs median/total: 33 6 M (54%) 77.6 7 R (64%) 1 sm (9%) 188.7 597.8 97.2 0.12 
IEDs CV (%) 31 n/a 16.0 n/a n/a 1.4 87.2 1.9 183.8 
IEDs IQR (24 – 41) n/a (63.4 – 81.8) n/a n/a (187.4 –90.5) (223.4 – 723.0) (96.0 – 
100.0) 
(0.10 – 0.30) 
IEDs maximum 50 n/a 55.8 n/a n/a 194.0 1862.0 1 0 2.71 
IEDs minimum 20 n/a 95.3 n/a n/a 184.3 24.7 95 0.04 
Controls median/total: 46 7 M (70%) 80.5 8 R (80%) 1 sm (10%) 186.5 381.0 96.0 0.20 
Controls IQR (27 – 58) (65.5 – 83.8) (65.5 – 83.8) n/a n/a (184.1 – 188.2) (238.1 – 758.7) (96.0 – 97.0) (0.09 – 0.30) 
 
 128 
4.3.5 MRI data acquisition 
3D volumetric T1-weighted coronal SPGR MRI sequences were acquired for each participant 
to identify/exclude relevant intracranial structural abnormality, and for co-registration with 
the PET images, as previously described (see Section 2.11). MR images were reviewed by an  
experienced neuroradiologist. 
 
4.3.6 Electroencephalography  
All patients had an EEG during the PET scan using a TrackitTM 18/8 (Lifelines Limited, 
Hants., U.K.) ambulatory EEG recorder and an ECI E1 Cap (Electro-Cap International, Eaton, 
Ohio, U.S.A.) with 19 electrodes placed according to the “10-20” system of the International 
Federation of Societies for Electroencephalography and Clinical Neurophysiology (Jasper, 
1958). An additional reference electrode (Fpz) was sited just anterior to Fz. The O1 and O2 
electrodes were removed from the cap for several patients who complained of discomfort 
whilst in the scanner. The EEGs were reviewed by an experienced neurophysiologist. 
 Correlation between global [18F]GE-179 VT and the approximate number of IEDs 
observed in the first 30 minutes following injection was examined by Spearman’s rank (ρ) 
correlation coefficient in SPSS.  
 
4.3.7 Metabolism of [18F]GE-179 
For each participant, the plasma-over-blood ratio of [18F]GE-179 was fitted to a function with 
four free parameters, as previously described (see Section 3.3.5). 
 For each participant, the fraction of plasma radioactivity attributable to the parent 
[18F]GE-179 was fitted to a sigmoidal function, as previously described (see Section 3.3.5). 
The area under the metabolite model curve (AUCmetabs) was used as a measure of the 
rate of metabolism for each individual. The AUCmetabs was compared between epilepsy and 
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control groups by univariate ANCOVA in SPSS, with age as a covariate to control for the 
slight difference in distribution between groups. The threshold of statistical significance for 
this test was p = 0.05. 
 
4.3.8 Decay-, and metabolite-corrected parent plasma input functions 
Continuous decay-, and metabolite-corrected parent plasma input functions were generated 
using CLICKFIT, as described previously ((Jones et al., 1994, Hammers et al., 2007b); see 
Section 3.3.6).  
The AUCIF, indicative of total [
18F]GE-179 delivered to the brain, was compared 
between groups by univariate ANCOVA, as for the AUCmetabs. 
 
4.3.9 PET image pre-processing 
Scatter- and attenuation-correction was performed as previously described (see Section 3.3.3). 
Attenuation- and scatter-corrected dynamic PET images were corrected for head motion using 
a post hoc frame-to-frame realignment method (Hammers et al., 2007a, Turkheimer et al., 
2000, Turkheimer et al., 2008, Turkheimer et al., 1999, Studholme et al., 1997)) as previously 
described (see Section 2.9). Weighted summation images (KBq/ml) were created for t = 5 - 30 
minutes, as previously described (Gunn et al., 1997, Aston et al., 2001); see Section 2.10). 
This early timeframe was selected to minimise the influence of blood flow and any 
radiolabelled metabolites.  
 Each participant’s summation image and volume-of-distribution (VT) image was co-
registered to their T1-weighted MR image using SPM8 (Statistical Parametric Mapping, 
Wellcome Trust Centre for Neuroimaging, UCL, London, www.fil.ion.ucl.ac.uk/spm) as 
previously described ((Collignon et al., 1995, Maes et al., 1997); see Section 2.11). Co-
registered summation images and VT images were transformed to standard space (i.e. the 
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MNI152/ICBM template image) by applying the warp matrix that was calculated by (tissue-
class) segmentation of the MRI, as previously described  ((Ashburner and Friston, 2005); see 
Section 2.12). 
 The normalised (i.e. in standard space) summation and VT images were smoothed by a 
10mm FWHM (full-width at half-maximum) isotropic Gaussian kernel for an approximate 
final smoothness of 14 mm x 16.5 mm x 16.5 mm (summation images) and 15.5 mm x 18.5 
mm x 18 mm (VT images) FWHM. The extent of smoothing employed in PET pre-processing 
(and that of other functional neuroimaging data) is variable and subject to debate. 
Traditionally, a minimum smoothness of at least twice the voxel size has been recommended, 
in order to meet the requirement that the data constitute a smooth Gaussian field (Worsley and 
Friston, 1995). Smoothing also minimises the influence of inaccuracies in spatial 
transformation, and can improve signal-to-noise ratio, at the cost of effective spatial 
transformation (for review see: (Mikl et al., 2008)). Here, the 10mm isotropic Gaussian 
FWHM kernel, which constitutes a modest degree of smoothing in PET pre-processing, was 
selected as a compromise between these competing requirements and the desire to evidence 
small, but clinically-relevant foci of increased radioactivity concentration and/or VT.  
MR images were not available for one control subject (control participant 5), in whom 
3.0 Tesla MRI was unexpectedly contra-indicated. This subject’s summation image and VT 
image was spatially normalised using SPM8 to a summation image template that had been 
created by calculation of the mean of the nine other controls’ transformed summation images. 
The resultant normalised summation and VT images image were visually inspected to ensure 
it was in register with those of all other subjects. Excluding this subject did not significantly 
alter the results.  
 
 
 131 
4.3.10 Voxel-wise quantification of [18F]GE-179 VT 
The VT of [
18F]GE-179was computed at the voxel level for each participant by rank-shaping 
regularisation of exponential spectral analysis (RS-ESA), as previously described 
((Turkheimer et al., 2000, Turkheimer et al., 2008, Turkheimer et al., 2003); see Section 
3.3.13). 
 
4.3.11 Global increases and decreases in radioactivity concentration 
Global radioactivity was compared between groups using the non-parametric Wilcoxon 
signed-rank test (Wilcoxon, 1945).  
 
4.3.12 Focal increases and decreases in radioactivity concentration 
Due to the difficulty in localising the epileptogenic zone for several participants of the IEDs 
group, radioactivity concentration was compared between participants with very frequent 
IEDs and controls across the whole brain on a voxel-by-voxel basis, rather than in predefined 
regions-of-interest. Individual SPM8 analyses based initially on the transformed, smoothed 
summation images, (subsequently and separately on the parametric VT images) were 
performed for each of the participants with frequent IEDs against the ten control subjects. The 
images were compared using a two-sample t-test, assuming equal variances, with age (in 
years) included as a covariate, grand mean scaling, and global activity taken into account via 
an ANCOVA by group.  
The contrasts (1 -1) and (-1 1) were used to identify focal increases and decreases, 
respectively, in radioactivity concentration (i.e. [18F]GE-179 uptake) within the summation 
images. Voxels were assessed at p < 0.001 (uncorrected). The resultant statistical parametric 
maps were thresholded at the cluster level at p < 0.05 (uncorrected). All findings were 
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inspected in conjunction with the normalised summation images and the T1-weighted MRI 
image, in order to exclude spurious results due to transformation error. 
For reference, each of the control subjects’ summation image was compared to those 
of the remaining nine controls by the same procedure. 
 Data (mean, standard deviation) was extracted (‘sampled’) from the statistically 
significant clusters of difference in radioactivity concentration using the MarsBar toolbox 
(Brett M et al., 2002).  
 
4.3.13 Global increases and decreases in VT 
Global VT was compared between groups using the non-parametric Mann Whitney U (Mann 
and Whitney, 1947). Correlations between global VT and seizure frequency, and global VT 
and post-ictal interval were examined by Spearman’s rank (ρ) correlation coefficient in SPSS.  
 
4.3.14 Focal increases and decreases in VT 
VT was compared between participants with as previously described for the summation 
images (see Section 4.3.11). Global VT was taken into account via an ANCOVA by group.  
 Data was extracted from the statistically significant clusters of difference in VT and 
scaled as previously described ((Brett M et al., 2002); see Section 2.14).  
 
4.4 Results 
4.4.1 Demographic and injectate data  
There were no differences between the IEDs- and control groups in terms of age (p > 0.11), 
weight, BMI (p > 0.76), injected dose, specific activity, radiochemical purity, co-injected 
mass; nor in terms of gender mix (p > 0.36), handedness, or prevalence of smokers.  
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4.4.2 EEG 
Frequent habitual IED were noted in the EEG of nine participants throughout the scan 
acquisition (Figure 18; Table 9). IEDs were not captured for participant 8, and the EEG of 
participant 3 could not be interpreted due to data corruption. Excluding participant 9, who had 
near-continuous IEDs, the median number of IEDs in the first 30 minutes following injection 
was 42 (I.Q.R. 9 – 62). 
 A borderline-significant negative correlation was observed between global VT and the 
approximate number of IEDs observed in the first 30 minutes following injection (Spearman’s 
rho -0.667, p = 0.05). [The participant with near-continuous IEDs was excluded from this 
analysis].   
 
4.4.3 Metabolism of [18F]GE-179 
The mean parent fraction of [18F]GE-179 remaining in the plasma was non-significantly 
greater for the IEDs group than for the control group at each time-point (Figure 19).  
There were no significant differences in the area under the metabolite model curves 
(AUCmetabs) between the epilepsy and control groups, over t = 0 – 30 or t = 0 – 90.5 minutes 
(p > 0.27 and 0.45, respectively). 
 
4.4.4 Decay-, and metabolite-corrected parent plasma input functions 
The parent plasma input function of [18F]GE-179 peaked within t = 110 seconds and 
decreased to less than 10% of the peak radioactivity concentration within 5 minutes. The time 
to peak radioactivity concentration did not differ significantly between the epilepsy and 
control groups (p = 0.567). 
There were no significant differences in the area under parent plasma input function 
curves AUCIF between the IEDs and control groups, over t = 0 – 90 minutes (IEDs median 
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FIGURE 18: EEG data from patient 4. Bipolar (‘double-banana’) montage, 1 cm/s) 10 mm/µV, t = 8.0 – 8.5 minutes post-injection approximately.  
Interictal epileptiform discharges are visible in left infra-sylvian channels, particularly F7-T3. µV – microvolt; cm – centimetres; s – second; mm – millimetres.  
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TABLE 9: Participants with refractory focal epilepsy and frequent IEDs – ictal and intra-scan EEG data.  
Approx – Approximate; Bilat – Bilateral; Cont/cont – Continuous; F – Frontal; freq – frequent; h – hours; hemi – hemisphere; ID – Identification; IED – Interictal 
epileptiform discharge; independ – independent; infreq – infrequent; L – Left; mins – minutes; O – occipital; P – Parietal; s – seconds; T – Temporal; Un – Unavailable; VT – 
[18F]GE-179 volume of distribution; yrs – years. 
 
ID Probable 
localisation 
(Approx) seizure 
frequency (/day) 
Post- ictal 
interval 
Mean 
global VT 
(Approx) observed 
IEDs (t = 0 – 30 
minutes) 
Observed IEDs location Comments 
1 L ?F-T 2.0 Un 3.04 168 L T Sharp; single and in runs of 1-5 s. 
2 R F 0.5 3 days 6.08 86 Bi-F More freq mid-scan 
3 R P-O 9.0 20.5h 3.57 Un Un Unreadable 
4 L F-T 15.0 16.0h 4.44 62 L T; T3 Sharp and slow 
5 L T/?bi-T 1.0 39 days 4.27 26 L T; rare independ R T More freq mid-scan 
6 ?Multifocal 2.0 6.5h 6.26 9 Bi-F; R>L Runs 1-10 s, very freq mid-late scan 
7 L F-T 2.5 7.5h 5.69 43 R ant. T; bilat Very freq mid-scan 
8 R F-T 2.0 45 mins 6.29 0 R F Very infreq 
9 ?Bi-T 0.0 10+ years 6.30 Cont/seizure Bi-T; later L hemi, R T Approximately cont 
10 Un. 0.5 39.5h 6.89 3 Bi-F; (L>R, but inconsistent) Scattered 
11 L F 3.0 11 days 6.54 42 Bilat & bi-F Nil mid/end-scan 
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FIGURE 19: Metabolism of [18F]GE-179: mean fraction of parent [18F]GE-179 remaining in plasma (t = 0 – 90.5 minutes).  
Dotted lines represent the 95% confidence intervals for the mean at each time-point). 
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4861.2, IQR 4451.6 – 5556.8; controls 4782.0, 4056.2 – 5922.6; p > 0.94 and 0.84, 
respectively).  
 
4.4.5 Increases and decreases in radioactivity concentration 
Global radioactivity concentration did not differ between the groups (median, IQR; patients: 
4.42, 3.90 – 5.14; controls: 4.09, 3.23 – 5.26; [KBq/ml]).  
At least one focal increase in radioactivity concentration uptake was identified in three 
of the ten control subjects’ summation images, with a maximal Z score of 4.54 (Table 10).  
At least one focal decrease in radioactivity concentration was identified in three of the 
ten control subjects’ summation images. 
At least one focal increase in radioactivity concentration was identified in seven of the 
11 IEDs group participants’ summation images, with a maximal Z score of 4.98, and a median 
increase of 18.1% (IQR: 15.5 – 20.5%; maximum 34.8%; Table 11). Of these seven 
participants, five had unremarkable/non-contributory MRI scans, and three had unremarkable 
[18F]FDG PET scans. 
Focal decreases were seen for three of the 11 patients. 
 
4.4.6 Global increases and decreases in VT 
Global VT did not differ significantly between the groups (median, IQR; patients: 6.08, 4.35 – 
6.30; controls:  4.74, 4.55 – 5.14; p = 0.29). The [18F]GE-179 global VT was lower than two 
times the standard deviation of the mean of the controls for two of the IEDs group participants 
(1 and 3), and higher for five participants (2, 6, 8 – 11; Figure 20).  
 There was no significant correlation between global VT and seizure frequency, or 
between global VT and post-ictal interval, even with the exclusion of those participants with a 
post-ictal interval of greater than 10 days.  
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FIGURE 20: [18F]GE-179 global VT.  
The [18F]GE-179 global VT for six participants was greater than two times the standard deviation of the mean of the healthy controls participants. s.d. – standard deviation; 
IEDs – (participants with frequent) interictal epileptiform discharges; VT – volume-of-distribution. 
 139 
TABLE 10: Focal increases in radioactivity concentration - 1 control versus 9 controls (t = 5 – 30 minutes) – 10mm FWHM.  conc – concentration; F– Frontal lobe; 
FWHM – Full width at half-maximum; ID – Identification; IQR – Interquartile range; KBq – Kilobequerels; L – left; ml – millilitre; mm – millimetres; O – Occipital lobe; 
P – Parietal lobe; R – right; sd – standard deviation; T – Temporal lobe; * – p < 0.001 voxelwise AND p < 0.05 (uncorrected) at cluster; ** – p < 0.001 voxelwise AND p 
< 0.05 (FWE-corrected) at cluster. 
 
Controls 
ID 
t-test 
increases 
Cluster 
size 
(voxels) 
Peak voxel 
coordinates 
 (x, y, z; mm) 
Zmax 
peak 
Radioactivity 
conc (KBq/ml) 
Radioactivity conc 
– 9 controls 
Mean (sd; KBq/ml) 
% 
increase 
3 L F 184** -24 -46 14 3.89 4.7 3.7 (0.1) 26.0 
 R F 67* 12 54 -16 4.08 5.0 4.2 (0.1) 20.7 
5 Corpus callosum 113* 00 10 24 4.18 3.9 3.2 (0.2) 22.7 
 R F 73* 22 26 54 4.28 5.7 5.0 (0.2) 13.9 
 L & R medial P 60* 02 -40 46 3.69 6.7 6.2 (0.4) 7.8 
6 L O 158** -12 -92 10 3.79 12.5 10.2 (0.4) 22.9 
 R P 102* 10 -60 30 3.93 11.5 9.7 (0.2) 17.8 
 R cerebelli 87* 06 -76 -36 4.40 10.9 9.1 (0.3) 20.1 
 R P-O 82* 22 -78 30 4.54 11.3 9.4 (0.3) 20.5 
 R T 77* 46 -32 10 4.54 11.1 9.4 (0.3) 17.6 
 Pons 51* 00 -38 -38 4.33 10.0 8.2 (0.3) 21.0 
 L insula 45* -30 -02 -04 4.13 11.9 10.5 (0.4) 13.5 
 Median: 80  4.16 10.5 8.7 20.3 
 IQR: (65 – 105)  (3.92 – 4.35) (5.5 – 11.4) (4.8 – 9.5) (16.7 – 21.4) 
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TABLE 11: Focal increases in radioactivity concentration - 1 patient versus 10 controls (t = 5 - 30 minutes) – 10mm FWHM (overleaf). conc – concentration; F– 
Frontal lobe; FWHM – Full width at half-maximum; ID – Identification; IED -  Interictal epileptiform discharge; IQR – Interquartile range; KBq – Kilobequerels; L – left; 
ml – millilitre; mm – millimetres; O – Occipital lobe; P – Parietal lobe; R – right; sd – standard deviation; T – temporal lobe; * – p < 0.001 voxelwise AND p < 0.05 
(uncorrected) at cluster; ** – p < 0.001 voxelwise AND p < 0.05 (FWE-corrected) at cluster. 
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IEDs 
ID 
Probable 
localisation t-test increases 
Cluster size 
(voxels) 
Peak voxel coordinates 
(x, y, z; mm) 
Zmax 
peak 
Radioactivity 
conc 
(KBq/ml) 
Radioactivity conc – 
controls 
Mean (sd; KBq/ml) 
% increase 
2 R F R F-P 262** 18 -26 66 4.78 9.2 7.8 (0.2) 17.6 
  L F 162* -30 30 38 4.59 10.3 8.5 (0.3) 21.1 
  R F 140* 28 04 46 3.93 10.3 8.6 (0.2) 20.0 
  L F 100* -18 20 56 3.95 9.3 8.2 (0.3) 13.6 
  L F-P 94* -18 -24 68 3.77 10.0 8.2 (0.3) 21.2 
  R F 83* 46 22 06 4.04 10.1 8.7 (0.2) 17.1 
4 L F-T L post. T 334** -24 -58 -16 3.96 6.9 6.0 (0.2) 15.8 
  L T 212** -32 06 -36 4.34 5.6 4.6 (0.1) 20.2 
  L and R medial F 155* 06 20 36 3.85 6.3 5.2 (0.2) 21.1 
  L F 107* -46 -16 40 3.84 6.8 5.9 (0.1) 14.2 
  L F 102* -20 14 -02 3.75 6.5 5.5 (0.2) 18.3 
  R T-P 95* 48 -44 26 4.22 6.9 5.5 (0.2) 26.3 
  R F-P 90* 18 -24 66 4.17 5.7 4.9 (0.2) 16.8 
  R F 73* 46 22 06 3.90 6.4 5.6 (0.1) 13.3 
5 L T/?bi-T R P 78* 32 -58 32 3.98 7.2 5.3 (0.3) 34.8 
6 ?multifocal L post. T 251** -22 -52 -12 3.82 9.5 8.4 (0.2) 13.6 
  R O 66* 14 -86 18 3.95 9.6 8.1 (0.3) 18.1 
  R post. T 66* 40 -36 -20 3.70 7.9 6.9 (0.5) 14.7 
7 L F-T R F 136* 48 24 08 4.46 11.8 10.0 (0.2) 18.0 
  R F-P 74* 18 -24 66 4.16 9.7 8.6 (0.2) 13.5 
8 R F-T R O-cerebellum 174** 14 -74 -12 4.06 8.6 7.1 (0.2) 20.1 
  R F 162* 16 -04 56 4.65 7.2 5.9 (0.3) 21.9 
  L F 115* -46 -16 40 3.83 8.3 7.1 (0.2) 16.2 
10 Un. R F 239** 18 -24 66 4.98 9.4 7.8 (0.2) 20.3 
  Median: 111  3.97 8.5 7.1 18.1 
  IQR: (88.3 – 165)  (3.85 – 4.25) (6.9 – 9.6) (5.6 – 8.3) (15.5 – 20.5) 
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The IEDs group could be subdivided into those with significantly lower global VT than 
controls (IEDs group participants 1, 3 – 5; 3.92, 3.17 – 4.39; maximum 4.44; p = 0.011) 
and those with significantly higher global VT than controls (IEDs group participants 2, 6-
11; 6.20, 6.08 – 6.54; maximum 5.69; p = 0.001). These groupwise differences were also 
statistically significant in a univariate GLM with age and AUCIF as covariates (p = 0.009 
and p <0.000, respectively).    
 
4.4.7 Focal increases and decreases in VT 
At least one focal increase in VT was identified in three of the ten control subjects’ VT 
images, with a maximal Z score of 4.47, and a median increase of 20.1% (IQR: 16.3 – 
35.4%; maximum 14.9% (Table 12). A focal increase survived correction for family-wise 
error for one control participant only.  
Focal decreases in radioactivity concentration were not identified in any (of the ten 
control subjects’ VT images.  
At least one focal increase in VT was identified in three of the 11 IEDs group 
participants’ VT images, with a maximal Z score of 4.83, and a median increase of 20.0% 
(IQR: 17.8 – 22.9%; maximum 13.2%; Table 13, Figures 21-23). Of these three patients, 
all three had unremarkable/non-contributory MRI scans, and two had unremarkable 
[18F]FDG PET scans (Table 7). Focal increases survived correction for family-wise error 
for two of IEDs group only (with two clusters for each).  
Focal decreases in VT were not identified seen for any of the 11 IEDs group 
participants. 
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TABLE 12: Focal increases in [18F]GE-179 VT – 1 control participant versus 9 control  participants – 10 mm FWHM Gaussian filter smoothing. F – Frontal lobe; 
FWHM – Full width at half-maximum; ID – Identification; IQR – Interquartile range; L – left; mm – millimetres; O – Occipital lobe; P – Parietal lobe; R – right; sd – 
standard deviation; VT – Volume-of-distribution; * – p < 0.001 voxelwise AND p < 0.05 (uncorrected) at cluster; ** – p < 0.001 voxelwise AND p < 0.05 (FWE-corrected) at 
cluster. 
 
Controls 
ID 
t-test 
increases 
Cluster 
size 
(voxels) 
Peak voxel 
coordinates 
(x, y, z; mm) 
Zmax 
peak 
VT 
Scaled VT – 9 controls 
mean (sd) 
% increase 
3 L F 74* -28 20 04 4.47 10.7 9.3 (0.4) 14.9 
4 L P-O 187** -14 -82 28 3.59 12.4 9.7 (0.3) 28.7 
 L O (?artifact) 70* -14 -86 -12 3.88 13.2 10.5 (0.2) 25.4 
6 L F 88* -38 06 22 4.27 10.2 8.8 (0.3) 16.3 
 R P 69* 12 -56 28 3.86 10.9 9.0 (0.4) 20.1 
 Median: 74  3.88 10.9 9.3 20.1 
 IQR: (70 – 88)  (3.86 – 4.27) (10.7 – 12.4) (9.0 – 9.7) (16.3 – 25.4) 
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TABLE 13: Focal increases in [18F]GE-179 VT – 1 participant with IEDs versus 10 control participants – 10mm FWHM Gaussian filter smoothing. F – Frontal lobe; 
FWHM – Full width at half-maximum; ID – Identification; IED – Interictal epileptiform discharge; IQR – Interquartile range; mm – millimetres; P – Parietal lobe; R – right; 
sd – standard deviation; VT – volume-of-distribution. T – Temporal lobe; * - p<0.001 voxelwise AND p<0.05 (uncorrected) at cluster; ** - p<0.001 voxelwise AND p<0.05 
(FWE-corrected) at cluster. 
 
IEDs ID 
Probable lateralisation 
& localisation 
t-test 
increases 
Cluster size 
(voxels) 
Peak voxel 
coordinates 
(x, y, z; mm) 
Zmax 
peak 
VT mean 
Scaled VT – controls 
Mean (sd) 
% increase 
2 R F R F 342** 22 14 54 4.25 12.5 10.4 (0.4) 20.0 
  L F 252** -12 10 56 4.40 11.6 10.0 (0.4) 16.1 
  L F 109* -32 30 36 3.78 12.9 11.0 (0.4) 16.9 
4 L F-T L F 1023** -34 -18 54 4.27 9.6 7.8 (0.3) 22.7 
  L F 618** -12 10 54 4.83 9.0 7.4 (0.3) 23.1 
  R F 202* 22 14 54; 4.15 9.2 7.8 (0.2) 19.0 
  L F 104* -58 -02 06 3.43 9.6 8.1 (0.2) 18.5 
  R P 103* 48 -42 28 4.46 9.8 8.0 (0.3) 23.4 
  L T 101* -34 -04 -38 3,90 9.0 7.4 (0.2) 22.4 
  R F-P 101* 40 -14 52 3.58 9.5 7.7 (0.2) 23.8 
10 Un R F 106* 22 14 54 4.32 13.4 11.8 (0.4) 13.2 
  Median: 109  4.26 9.6 8.0 20.0 
  IQR: (104 – 297)  (3.87 – 4.38) (9.4 – 12.1) (7.8 – 10.2) (17.8  - 22.9) 
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FIGURE 21: Focal increase in [18F]GE-179 VT in right frontal lobe of IEDs group participant 2.  
The increase is shown on the participant’s bias-corrected, T1-weighted MR image normalised to MNI space. 
IED – Interictal epileptiform discharge; MNI – Montreal Neurological Institute; MR – magnetic resonance; VT – 
Volume-of-distribution. 
 
4.5 Discussion 
Using [18F]GE-179 PET the author identified focal increases in VT for three of eleven 
participants with frequent IEDs. Focal increases in radioactivity concentration were also 
identified for seven of eleven participants with frequent IEDs. 
 The focal increases in VT were consistent with activated/open NMDA receptors in 
actively discharging cortex, and pre-clinical work (Savage et al., 1982, Yeh et al., 1989). In 
the only other in vivo study of the NMDA receptor in epilepsy, (Kumlien, 1999) were unable  
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FIGURE 22: Focal increase in [18F]GE-179 VT in left frontal lobe of IEDs group participant 4.  
The increase is shown on the participant’s bias-corrected, T1-weighted MRI image normalised to MNI space. 
IED – Interictal epileptiform discharge; MNI – Montreal Neurological Institute; MR – magnetic resonance; VT – 
Volume-of-distribution. 
 
to demonstrate focal increases in activated receptor availability using (S)-[N-methyl-
11C]ketamine. Interestingly, each patient of Kumlien et al.’s cohort showed temporal 
hypometabolism on [18F]FDG PET, and the authors conceded that there results could have 
been significantly influenced by (ipsilateral) cerebral hypoperfusion. Four of the IEDs group 
participants in this study were [18F]FDG PET-negative (Table 7; two of whom had focal 
increases in [18F]GE-179 VT; an additional two participants have not been investigated with 
this radioligand. The absence of regional differences in cerebral metabolism may have  
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FIGURE 23: Focal increase in [18F]GE-179 VT in right frontal lobe of IEDs group participant 10.  
The increase is shown on the participant’s bias-corrected, T1-weighted MRI image normalised to MNI space. 
IED – Interictal epileptiform discharge; MNI – Montreal Neurological Institute; MR – magnetic resonance; VT – 
Volume-of-distribution. 
 
facilitated visualisation of activated NMDA receptors in the cohort. Alternatively, the 
author’s cohort might have had more actively spiking cortex given the high frequency of IEDs 
and seizures, and thus possibly greater NMDA receptor activation.  
 The failure to identify significant focal increases in VT for eight of the 11 participants 
with frequent IEDs does not, for the most part, seem attributable to a lack of IEDs. The 
proportion of NMDA receptors that are active in healthy, resting physiological state is 
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unknown. The power to detect subtle changes in state superimposed on this (possibly large) 
background activity was limited by the small sample size and conservative thresholds.  
 A surprising, borderline-significant negative correlation was observed between global 
VT and the approximate number of IEDs observed in the first 30 minutes following injection.  
This finding should be interpreted with caution as the true extent of epileptic activity might 
not be detectable on scalp EEG. Moreover, quantification in participants with the most 
frequent IEDs could have been confounded by subtle decreases in global, cerebral blood flow, 
and hence radioligand delivery (k1). If replicated after accounting for these influences, it 
might be indicative of ‘surround’ inhibition mediated by relative NMDA receptor 
hypofunction.   
 That focal increases in VT were only demonstrated for three of the IEDs group might 
suggest that excessive fast excitatory neurotransmission via the NMDA receptor most evident 
earlier in epileptogenesis. Alternatively excessive NMDA receptor activation might be diffuse 
in people with refractory, end-stage focal epilepsy. Interestingly, a 7-participant subgroup 
with significantly higher global [18F]GE-179 VT than controls was identified; the difference 
was not explained by age or the radioligand availability (AUCIF). This finding supports the 
latter hypothesis, and could indicate that excitatory neurotransmission via the NMDA 
receptor is excessive (and presumably mechanistically-relevant) in only a proportion of 
people with focal epilepsy. A larger study is required to determine whether this is a chance 
finding or if participants with focal epilepsy can be divided into those with low- and high 
global [18F]GE-179 VT. If the latter is confirmed, [
18F]GE-179 PET would not hold promise as 
a tool for localisation of epileptogenic foci in vivo, at least not in chronic epilepsy. However, 
the PET imaging with the radioligand might instead demonstrate prognostic value in epilepsy 
or other neurological and psychiatric conditions.  
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Focal decreases in [18F]GE-179 VT were not seen for any of the participants, but focal 
decreases in radioactivity concentration were identified for three of each group. Comparison 
of [18F]GE-179 VT rather than radioactivity concentration is suggested as a more specific 
investigation, given that parent plasma input functions are used to inform the analysis.  
 Concordance of [18F]GE-179 foci with electroencephalographic, structural and 
functional imaging, and other data is difficult to assess in the cohort. Most of the patients 
have been excluded from surgery due to lack of MRI structural abnormalities or due to 
evidence for multifocal abnormalities on EEG and adjunctive investigations, including MEG 
and functional MRI (fMRI). IEDs group participant 4 constituted one of the best-localised 
cases in the cohort, having concordant scalp EEG, [18F]FDG PET, and ictal SPECT findings 
(Table 7); intracranial EEG recordings subsequently identified diffuse ictal onset over the 
entire left temporal lobe, which could be indicative of spread from a nearby (e.g. left frontal) 
source. Encouragingly, the largest focal increases in [18F]GE-179 VT that were observed for 
this participant were both localised to the left frontal lobe (Table 13).However, smaller right-
sided foci were also observed. IEDs group participant 2 was presumed to have a right frontal 
epileptogenic zone, largely on the basis of EEG findings as MRI and [18F]FDG PET were 
unrevealing. Again, the largest focal increase [18F]GE-179 VT was concordant with the 
probable localisation in this participant, but smaller contralateral focal increases were also 
observed. 
The specificity of focal increases in [18F]GE-179 VT for activated NMDA receptor 
availability is questionable, given that these were observed for three of the control 
participants. The clusters were smaller for the controls than for the participants with IEDs, 
and less survived correction for multiple comparisons; this is of uncertain significance. A 
focal change in a control image would be expected to occur by chance considering the 
number of comparisons made (two in each of 10 controls).  
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In summary, the capacity of [18F]GE-179 VT to localise the epileptogenic region is 
therefore unclear; these findings could indicate false or inaccurate localisation, or the 
presence of multiple epileptogenic foci in longstanding, refractory focal epilepsy. A larger 
study with a more homogeneous and well-defined cohort are required to assess the potential 
of [18F]GE-179 to localise epileptogenic foci in vivo. Ideally the study would be supported by 
intracranial EEG and post-surgical outcome data. 
Inter-ictal rCBF studies are usually normal in focal epilepsy (Devous et al., 1998), and 
significant increases in rCBF scans were only seen following electrostimulation and 
prolonged discharges of 8 to 105 seconds (Kahane et al., 1999). The findings of comparison 
of [18F]GE-179 VT images (Table 13) in particular are unlikely to reflect changes in cerebral 
blood flow (i.e. altered [18F]GE-179 availability) as in all IEDs group participants but one 
(participant 9; a) the maximum length of discharges was less than 8 seconds, and the 
maximum percentage of scanning time occupied by spikes was less than 10%; (b) parent 
plasma input functions were used to generate of VT images; (c) global [
18F]GE-179 VT was 
accounted for by ANCOVA [in any case, the influence of flow-dependency on VT in healthy 
controls participants was modest (see Chapter 3; Spearman’s rho = 0.313; Figure 14); (d) one 
might expect a decrease in rCBF in the epileptogenic zone, which if present would manifest 
as decreased [18F]GE-179 VT, rather than focal increases as identified in this study.  
 
4.5.1 Limitations 
The limitations of this proof-of-principle study include the small and heterogeneous study 
population. The post-ictal interval and approximate seizure frequency varied considerably 
between participants. This might be expected to influence activated NMDA receptor 
availability and hence [18F]GE-179 binding, as has been observed in other receptor PET 
studies (Hammers et al., 2007a, Goffin et al., 2011). Several of the participants with IEDs had 
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been diagnosed with depression, which itself is increasingly associated with dysfunctional 
NMDA- (and other glutamate) receptor-mediated neurotransmission (for review see: 
(Mitchell and Baker, 2010, Sanacora et al., 2012, Mathews et al., 2012)). The between-subject 
variability in drug regimen constitutes an additional confound; several anti-epileptic (review 
see: (Rogawski and Loscher, 2004)) and many anti-depressant drugs (for reviews see: 
(Musazzi et al., 2013)) show mechanistic action at the NMDA receptor, which could be 
postulated to reduce [18F]GE-179 VT. Examples of such include topiramate and fluoxetine, 
which were taken regularly by IEDs group participants 1 and 8, respectively. It was not 
possible, within time constraints of the thesis, to assemble and study a homogeneous sample 
of participants with frequent IEDs. Hence the author was unable to minimise the influence of  
confounds described above.  
 Whilst [18F]GE-179 has a low affinity for other CNS receptors in vitro, it is possible 
that non-specific binding confounded the analyses. Radiolabelled metabolites may have 
contributed to the images. [18F]GE-179 accounted for 84% of brain radioactivity at 30 
minutes post-injection in rats (GE Healthcare Ltd., unpublished, on file); both participants 
with frequent IEDs and controls, however, metabolised [18F]GE-179 more slowly, and 
therefore might be expected to have a lower radiolabelled metabolite contribution. The 
potential effect on summation images was minimized by the use of the early (t = 5 - 30 
minutes) timeframe. 
Further studies are indicated to confirm the findings, and to quantify reproducibility 
and specificity of [18F]GE-179 binding in vivo. Such studies should be designed to minimise, 
or ideally quantify, the influence of the factors described above. 
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4.6 Conclusion 
These results suggest focal increases in activated NMDA receptor availability in patients with 
focal epilepsy. A PET radioligand that reliably demonstrates focal increases in NMDA 
receptor activity in humans in vivo would hold potential as a method to investigate 
epileptogenesis in vivo after brain injury, to investigate the role of activated NMDA receptor 
availability in other conditions, and possibly in the pre-surgical investigation of participants 
with refractory focal epilepsy. Further evaluation of [18F]GE-179 is required in this regard.
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CHAPTER 5 
OPIOID RECEPTOR AVAILABILITY FOLLOWING 
SPONTANEOUS EPILEPTIC SEIZURES; CORRECTION OF 
[11C]DIPRENORPHINE PET DATA FOR THE PARTIAL 
VOLUME EFFECT 
__________________________________ 
5 OPIOID RECEPTOR AVAILABILITY FOLLOWING 
SPONTANEOUS SEIZURES 
There is growing evidence for an anticonvulsant action of endogenous peptides (Pleuvry, 
1991), and in particular for a role in post-ictal seizure inhibition (Pirker et al., 2009, Engel Jr 
et al., 1981). However, all PET studies to date have failed to demonstrate significant alteration 
of hippocampal or parahippocampal gyrus opioid peptide receptor binding in TLE. This may 
relate in part to failure to correct for the partial-volume effect. In this Chapter, the author 
applies a novel PVE correction method, SFS-RR, to post- and interictal [11C]DPN PET data 
acquired from participants with refractory TLE.   
 
5.1 Objectives 
The objectives of the study were as follows: 
1. Quantify post-ictal and interictal [11C]DPN VT binding in participants with refractory 
TLE, after correction for the PVE.  
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2. Examine the relationships between clinical variables (hippocampal sclerosis, 
spontaneous seizures) and [11C]DPN VT per unit of grey matter.  
 
5.2 Hypotheses 
The primary hypothesis was: 
1. Decreased interictal [11C]DPN VT would be evident in the sclerotic hippocampus of 
participants whose TLE is associated with HS.  
The secondary hypothesis was: 
2. Increased post-ictal [11C]DPN VT would also be evident in mesial temporal structures, 
in addition to the previous finding of post-ictal increases in [11C]DPN VT in the extra-
mesial ipsilateral temporal lobe in PVE-uncorrected data. 
 
5.3 Methods and Materials 
The datasets for this study had been previously acquired for another study, which did not use 
PVE correction. Details of participants’ demographics and clinical data, PET and other data 
acquisition have been described in detail elsewhere (Hammers et al., 2007a; Hammers et al., 
2007b). Briefly, for re-analysis eight participants with refractory TLE (four males; median 
age 45.5 years, range 32-60 years) who were scanned interictally (seizure-free for at least 5 
days; median 208 hours/8.7 days, range 152 – 1344 hours/6.3 – 56 days), and also post-ictally 
(within 24 hours; median 10.0 hours, range 1.5 – 21.3 hours) after spontaneous temporal lobe 
seizures were available. One of the original nine participants with refractory TLE (number 5) 
was excluded from re-analysis due to irretrievable loss of MRI data. Eleven healthy controls 
(eight males; median age 42.0 years, range 30-58 years) had been scanned twice under the 
same conditions.  
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5.3.1 PET data acquisition and analysis 
Images had been acquired using a Siemens/CTI ECAT EXACT3D HR ++ (966) PET camera 
over 90 minutes, subsequent to injection of a median dose of 185MBq (range 130 – 200MBq) 
of [11C]DPN. Image data were reconstructed using a reprojection algorithm (Kinahan and 
Rogers, 1989) with ramp and Colsher filters at Nyquist frequency. Attenuation- and scatter 
correction (Watson et al., 1996) was performed after segmentation of the image (Bailey et al., 
1998). The voxel size following reconstruction was 2.096 mm x 2.096 mm x 2.43 mm.  
 3D Volumetric T1-weighted MRI scans were acquired for co-registration with the 
PET dataset using a 1.0T Picker HPQ scanner (Robert Steiner MRI unit, Hammersmith 
Hospital; voxel sizes 1 mm×1 mm×1.3 mm) or a 1.5T General Electric Signa Echospeed 
scanner (National Society for Epilepsy; voxel sizes 0.9375 mm×0.9375 mm×1.5 mm). 
Dynamic images, metabolite-corrected arterial plasma input functions (COMIF; in-
house software), and spectral analysis (Cunningham and Jones, 1993) implemented in RPM 
version 6 (Turkheimer et al., 2003, Gunn et al., 1997, Aston et al., 2001) were used to create 
voxel-by-voxel parametric images of [11C]DPN VT as previously described (Hammers et al., 
2007b).  
 
5.3.2 Resolution recovery with SFS-RR 
5.3.2.1 SFS-RR 
‘Structural and Functional Synergistic – Resolution Recovery’ is a post-reconstruction, 
wavelet-based voxelwise partial volume effect correction method (Shidahara et al., 2009, 
Shidahara et al., 2012). SFS-RR uses an individualised, anatomical brain atlas to provide 
structural information, as previously described (del Campo et al., 2011, Rousset et al., 2008).  
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 Similar to other previously described methods (e.g. (Goffin et al., 2010)), SFS-RR 
assumes MRI and PET data share some mutual information. Uniform distribution of the 
radioligand is assumed for each anatomical region-of-interest (ROI).  
 The first step of SFS-RR is the decomposition of the PET image and corresponding 
anatomical (in this case, MRI) image into multiple resolutions by the WT in a process called 
multi-resolution analysis (MRA: (Mallat, 1989)). The WT is similar to the Fourier 
transformation, which decomposes a signal into constituent sinusoidal components. Wavelets, 
however, are short or small complex waveforms. They are typically asymmetric, irregular, of 
limited duration, and with an average value of zero. Wavelet analysis can be considered a 
signal decomposition technique that utilises variable time windows to yield precise low- and 
high frequency information (MathWorks, 1996). The WT provides a spatio-frequency 
decomposition of the observed signal (rather than solely frequency-based decomposition) 
with preservation of the time domain. 
 SFS-RR uses a discrete waveform transform, whereby the original signal is passed 
through a pair of high- and low-pass filters to yield two novel signals. This process is repeated 
(successive filtering) to decompose the original signal into many lower-resolution 
components. MRA proceeds according to: 
 
 
(16) 
 
[Where f(x) is the signal; Cj(k) is the scaling coefficient; dj(k) are the wavelet coefficients 
given by the scalar product of the original image with φj,k basis elements; j is the frequency 
band (i.e. the decomposition/resolution level); k is the position; φ is a high band-pass 
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function; and θ is a low-pass scaling function]. The first- and second terms of the equation 
represent decomposed high- and low frequency components of the image, respectively. A 3D 
dual-tree complex wavelet transform (Kingsbury, 2001, Selesnick and Li, 2003) was used to 
decompose the image in multiple directions, resulting in 27 quadrants for each j frequency 
band.  
 The process outlined above yields discrete wavelet coefficients, which provide an 
index of how similar each constituent wavelet is compared to a pre-defined analysing wavelet 
(MathWorks, 1996). Small discrete wavelets can be discarded without loss of significant 
information from the original. The second stage of SFS-RR involves replacement of the high-
frequency wavelet coefficients of the PET image with those of the corresponding anatomical 
image according to: 
 
 
(17) 
 
[Where αj is a scaling coefficient that compensates for the difference in intensity of wavelet 
coefficients between the PET and anatomical images; βj is the SFS-RR scaling coefficient, 
which accounts for the difference in resolution between the PET and anatomical images; 
dj
ana(k, q) is the high-frequency wavelet coefficients of the anatomical image at position k in 
quadrant q within the frequency band j; dj
corr(k, q)  is the resolution-recovered wavelet 
coefficients at position k in quadrant q within the frequency band j; dj
PET(k, q)  is the wavelet 
coefficients of the PET image at position k in quadrant q within the frequency band j; and γj is 
a statistical scaling factor that weights the anatomical versus the PET information]. 
 In the third and final stage of SFS-SS, the resolution-recovered PET image is 
generated by application of the inverse of the WT. 
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5.3.3 SFS-RR batch processing 
The author adapted and corrected existing MATLAB (.m) scripts, and additionally created 
novel scripts, to allow the application in SFS-RR in batch and use of the Hammersmith atlas 
(see below; (Gousias et al., 2008, Hammers et al., 2003a)). The existing scripts required 
modification to allow application to data generated at the Cyclotron Building site, which used 
a different nomenclature to the real PET data used for the original evaluations (Shidahara et 
al., 2009, Shidahara et al., 2012). Errors that were subsequently attributed to mishandling of 
the image orientation and origin header fields were identified, explored, and corrected, with 
the assistance of a collaborator (MS).  
 Using MATLAB 7.4 (The MathWorks Inc., Natick, MA, USA) and Statistical 
Parametric Mapping software (SPM5; Wellcome Trust Centre for Neuroimaging, UCL, 
London, UK), the SFS-RR PVE correction method was applied in batch to the eight TLE 
datasets, and all eleven control datasets. All transformations between PET and MRI spaces 
were performed using the corresponding weighted summation images (0-90 minute data) in 
SPM5.  
The Hammersmith atlas, a 3D probabilistic atlas of the human brain generated from 
manual definition of 83 anatomical structures for 30 normal subjects (Gousias et al., 2008, 
Hammers et al., 2003a), was used to inform the resolution recovery process as the anatomical 
image. First, each subject’s MR image was tissue-class segmented using SPM5 according to 
the Unified Segmentation method (Ashburner and Friston, 2005). The grey matter component 
was then thresholded at 50% probability using Analyze AVW 8.1. This was then multiplied 
(Analyze AVW 8.1) by an individualised Hammersmith atlas created by 30 high-dimensional 
registrations between the MRIs underlying the 30 individual atlases and the target MRI, 
propagation of the associated atlases, and decision fusion in the target MRI space (MAPER 
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(Heckemann et al., 2010)). The individualised atlases were smoothed by an isotropic 
Gaussian filter of 4 mm FWHM prior to calculation of βj, the ratio of the wavelet coefficients 
of the original individualised atlas image to the smoothed version of the same image. 
Despite evidence that multi-atlas propagation with decision fusion in general (Gousias 
et al., 2008) and MAPER in particular are able to label atrophic hippocampi correctly 
(Heckemann et al., 2011), the author wished to exclude the possibility that the results were 
biased by sub-optimal automated identification of sclerotic hippocampi. Therefore, SFS-RR 
was also separately applied using individualised Hammersmith atlases after the incorporation 
of manual delineation of each subject’s hippocampi into the MAPER-derived atlas. The 
hippocampi were delineated according to a previously described protocol (Niemann et al., 
2000), the same as used for the creation of the Hammersmith atlases, by a colleague (MF).  
 
5.3.4 Analysis of recovered PET data 
Analysis of PET data was by a ROI approach, in regions implicated in the pathophysiology of 
temporal lobe epilepsy and/or informed by the prior voxel-by-voxel study without PVE 
correction (Hammers et al. 2007). ROIs were the hippocampi, parahippocampal gyri, 
amygdalae, fusiform gyri, lateral temporal poles, and sub-genual anterior cingulate gyri.  
The [11C]DPN VT images of five of the healthy controls, selected at random using 
Random Sequence Generator (www.random.org), were also reversed. The VT images were 
then sampled via ‘tac-test’ (in-house software) using ROIs (object maps) created from the 
grey matter thresholded individual atlases. The ROI labels were left-right reversed after 
sampling for participants with a presumed right-sided epileptogenic focus, so that the focus 
was on the same side (left) in all eight participants with TLE.  
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As considerable inter-subject variability in global VT was evident, the average VT 
values within each ROI were scaled relative to the global VT according to the formula: 
 
 
(18) 
                                    
5.3.5 Statistical analyses  
Statistical analysis was performed using SPSS for (Microsoft) Windows version 16.0 (SPSS 
Inc., IBM Corporation, Somers, New York, USA). For all analyses, the threshold of 
significance was set at p < 0.05. 
 
5.3.6 Global [11C]DPN VT 
Global [11C]DPN VT values were computed as follows: the overall mean over the entire 
matrix was thresholded at 1/8 of its value to create a whole-brain mask; the mean over the 
entire matrix within this mask was then computed, using a MATLAB function derived from 
the SPM default global value calculation.  
Global [11C]DPN VT was compared between test (1
st) and re-test (2nd) control scans 
using the non-parametric Wilcoxon signed-ranks test. The influence of gender on global 
[11C]DPN VT was assessed by the non-parametric Mann-Whitney test (male versus female 
controls’ mean values). The effect of spontaneous seizures on global [11C]DPN VT was 
assessed by the Wilcoxon signed-rank test (post-ictal versus interictal) and separately by the 
Mann-Whitney test (post-ictal versus controls’ mean; interictal versus mean controls’ mean). 
The influence of hippocampal sclerosis on global [11C]DPN VT was assessed by 
Wilcoxon signed-ranks tests (post-ictal-HS versus interictal-HS; post-ictal-MRI-normal 
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versus interictal-MRI-normal) and Mann-Whitney tests (interictal-HS versus controls’ mean; 
interictal-MRI-normal versus controls’ mean).  
The mean of the global [11C]DPN VT over test and re-test scans was computed for the 
controls group. This data was used to quantify the relationship between age and global 
[11C]DPN VT as assessed by Spearman’s rho coefficient.   
 
5.3.7 Regional [11C]DPN VT 
The relationship between hippocampal [11C]DPN VT calculated using manually-delineated 
and MAPER-derived regions-of-interest was interrogated using Spearman’s rho coefficient. 
The same correlation was performed for the parahippocampal gyri (which were not manually 
delineated), to check the influence of manual hippocampal delineation on quantification of the 
nearby regions-of-interest. The delineation methods were also compared using a Tukey mean 
– difference plot.  
The effect of test – re-test on [11C]DPN VT was assessed for each ROI using Wilcoxon 
signed-ranks test. The relationships between age and [11C]DPN VT within each ROI (using the 
mean over left and right homologs) were assessed with Spearman’s rho coefficient.  
The effect of spontaneous seizures on [11C]DPN VT within each ROI was assessed 
using a full-factorial, multivariate general linear model (GLM) for repeated measures with 
‘scan’ (Scan 1; Scan 2’) as within-subjects factor and 6 pairs of [11C]DPN VT measures. 
Group (TLE; Controls) was specified as between-subjects factor. 
The effect of spontaneous seizures on [11C]DPN VT within each ROI was further 
assessed as described above for the global [11C]DPN VT analysis. As no significant difference 
in [11C]DPN VT was evidenced across test and re-test data (see ‘Results’), the mean VT over 
both scans was computed for each ROI, for each participant, to inform comparisons with the 
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interictal and post-ictal data. The influence of hippocampal sclerosis on regional [11C]DPN VT 
was also assessed as described above.  
Correction for multiple comparisons (6 ROIs x 2 hemispheres) was not performed for 
analyses relating to the hemisphere ipsilateral to the electroclinical focus, as the author had 
strong a priori hypotheses that an interictal decrease would be evident in sclerotic 
hippocampi, and that post-ictal increases would be evident in the (ipsilateral) temporal lobes 
of participants with TLE.  
 
5.4 Results 
A representative example of a [11C]DPN VT image prior to- and after application of SFS-RR 
is provided in Figure 24.  
 
5.4.1 Effect of SFS-RR on hippocampal and global [11C]DPN VT 
Global VTs in the recovered images were increased by a mean 10.0% (sd 2.9%) for 
participants with TLE, and 10.3% (sd 3.5%) for healthy controls, relative to the original 
uncorrected images (see Table 14).  
Small increases in VT were seen in the hippocampi (mean 3.3%, sd 5.6% in sclerotic 
hippocampi; 4.2%, 4.1% in the MRI-normal hippocampi of participants with TLE; 4.0%, 
1.3% in controls).  
All the global and regional [11C]DPN VT data presented subsequently are those 
generated after the application of SFS-RR.  
 
5.4.2 Effect of spontaneous seizures and other variables on global [11C]DPN VT  
There were no significant differences in global [11C]DPN VT between post-ictal, interictal, 
and control scans. There were also no significant differences in global [11C]DPN VT between 
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FIGURE 24: Parametric [11C]DPN VT images pre- (left) and post-SFS-RR (right).  
Improved visual contrast in seen in the post-SFS-RR image, with slight noise enhancement. DPN – 
Diprenorphine; L – Left; R – Right; SFS-RR – Structural and Functional Synergistic Resolution – Recovery; VT 
– Volume-of-distribution.  
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TABLE 14: Effect of SFS-RR on hippocampal and global [11C]DPN VT*. DPN – Diprenorphine; MRI – 
Magnetic resonance imaging; MAPER – Multi-atlas propagation with enhanced registration and decision fusion; 
sd – standard deviation; SFS-RR – Structural and Functional Synergistic Resolution – Recovery; ROI – Region-
of-interest; TLE – Temporal lobe epilepsy; VT – Volume-of-distribution; * – data was generated using MAPER-
derived ROIs. 
 
Region Group Hippocampi 
[11C]DPN VT 
uncorrected 
Mean (sd) 
[11C]DPN VT 
post-SFS-RR 
Mean (sd) 
% change in [11C]DPN 
VT with SFS-RR 
Mean (sd) 
Hippocampi TLE Sclerotic 13.1 (1.1) 13.5 (1.0) 3.3 (5.6) 
  MRI-normal 14.1 (2.0) 14.7 (2.1) 4.2 (4.1) 
  Combined 13.7 (1.8) 14.3 (1.8) 3.9 (4.6) 
 Controls MRI-normal 13.9 (2.4) 14.4 (2.5) 4.0 (1.3) 
      
Global TLE Sclerotic 10.4 (0.4) 11.3 (0.4) 8.3 (1.3) 
  MRI-normal 10.8 (1.2) 12.2 (1.3) 12.9 (2.4) 
  Combined 10.6 (0.8) 11.6 (1.0) 10.0 (2.9) 
 Controls MRI-normal 10.6 (1.7) 11.7 (1.9) 10.3 (3.5) 
 
test and re-test scans; between genders; or between participants whose TLE was associated 
with HS, participants with TLE associated with normal MRI, and controls.  
There was no significant correlation between age and global [11C]DPN VT for the 
control group.  
These findings indicated that epileptic seizures, epilepsy, gender, the presence of 
hippocampal sclerosis, and age did not significantly influence global [11C]DPN VT.  
 
5.4.3 Effect of manual delineation versus MAPER on hippocampal [11C]DPN VT  
Examples of regions of interest derived by MAPER- (top row) and manual (bottom row) 
delineation are provided in Figure 25.  
Quantification of [11C]DPN VT in manually-delineated hippocampi yielded very 
similar data to that obtained from hippocampi defined using MAPER (Table 15; Spearman’s 
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TABLE 15: Effect of manual delineation versus MAPER on hippocampal [11C]DPN VT (post SFS-RR; overleaf).  DPN – Diprenorphine; MAPER - Multi-atlas 
propagation with enhanced registration and decision fusion; mm – millimetres; n/a – non-applicable; sd – standard deviation; SFS-RR – Structural and Functional 
Synergistic – Resolution Recovery; TLE – Temporal lobe epilepsy; VT – Volume-of-distribution. 
Region Segmentation Group Lateralisation 
Volume mm3 mean 
(sd) 
VT mean (sd) 
Hippocampus MAPER TLE Ipsilateral 1782.0 (620.2) 14.1 (1.5) 
  TLE Contralateral 2190.0 (161.0) 14.4 (2.0) 
  Controls Left and right 2220.5 (314.9) 14.4 (2.4) 
 Manual TLE Ipsilateral 2420.1 (732.0) 14.1 (1.5) 
  TLE Contralateral 3117.5 (779.8) 14.1 (2.0) 
  Controls Left and right 2706.5 (473.2) 14.4 (2.3) 
      
Parahippocampal gyri MAPER TLE Ipsilateral 3333.0 (776.6) 14.8 (1.5) 
  TLE Contralateral 3780.0 (336.6) 14.8 (1.9) 
  Controls Left and right 3954.6 (550.3) 14.5 (2.7) 
 Manual TLE Ipsilateral 3015.1 (786.0) 14.9 (1.6) 
  TLE Contralateral 3333.2 (386.8) 15.0 (2.0) 
  Controls Left and right 3465.5 (406.0) 14.7 (2.7) 
      
Global MAPER TLE n/a n/a 11.6 (1.0) 
  Controls n/a n/a 11.7 (1.9) 
 Manual TLE n/a n/a 11.6 (1.0) 
  Controls n/a n/a 11.8 (1.9) 
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FIGURE 25: Examples of regions of interest derived by MAPER- (top row) and manual (bottom row) delineation for TLE group participant 5.  
Co-registered MR images (left) and [11C]DPN VT images (right; post-SFS-RR) are shown in radiological orientation. The hippocampi are delineated in red, the 
parahippocampal gyri in green, and the fusiform gyri in cyan. This participant’s MR images show evidence of left hippocampal sclerosis. DPN – diprenorphine; L – Left; 
MAPER - Multi-atlas propagation with enhanced registration and decision fusion; MR – magnetic resonance; R – Right; TLE – temporal lobe epilepsy; VT – volume-of-
distribution. 
L R 
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FIGURE 26: Comparison of [11C]DPN VT extracted from MAPER-derived and manually-delineated 
hippocampi.  
Tukey mean-difference plot (also known as Bland-Altman plot); a very slight bias towards overestimation is 
seen with MAPER for hippocampi with high VT. 
 
rho 0.948, p<0.001; Figure 26), despite differences in the volume of the structure. [11C]DPN 
VT was slightly reduced in the contralateral hippocampi of participants with TLE, with 
manual delineation.  
Manual delineation of hippocampi also had very little effect on quantification of VT in 
the nearby parahippocampal gyri (Spearman’s rho 0.983, p<0.001), or on the global VT. 
Therefore, all other regional data presented in this manuscript were obtained using the 
MAPER-derived ROIs.  
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5.4.4 Effect of scan on regional [11C]DPN VT  
The multivariate GLM analysis showed only within-subjects factor ‘scan’ to significantly 
influence regional [11C]DPN VT (p = 0.043). An alternate analysis using regional, scaled 
[11C]DPN VT showed both within-subjects factor ‘scan’ and between-subjects factor ‘group’ 
to significantly influence regional, scaled [11C]DPN VT (p = 0.006 and p = 0.021, 
respectively). A statistically-significant interaction was also observed between the ‘scan’ and 
‘group’ factors (p = 0.034). Univariate analyses showed this to be most evident in the 
fusiform gyri (p = 0.001), temporal poles (p = 0.003), and amygdalae (p = 0.022); a trend was 
observed in the parahippocampal gyri (p = 0.057).  
 Repetition of the alternate analysis with ‘gender’ (male; female) specified as an 
additional between-subjects factor, and ‘age’ (years) specified as a covariate, rendered the 
influence of the within-subjects factor ‘scan’ statistically non-significant (p = 0.803; Table 
16). However, the between-subjects factor ‘group’ was again observed to significantly 
influence regional, scaled [11C]DPN VT (p = 0.032). The influence of the ‘age’ covariate also 
reached statistical significance (p = 0.004). Moreover, an interaction was observed between 
the ‘group’ and ‘gender’ factors (p = 0.002); a trend was observed between the ‘scan’ and 
‘group’ factors (p = 0.056). Univariate analyses showed this interaction to be most evident in 
the temporal poles (p = 0.002), fusiform gyri (p = 0.005), hippocampi (p = 0.044) and 
amygdalae (p = 0.046); a trend was observed in the parahippocampal gyri (p = 0.051). 
 
5.4.5 Effect of test-re-test on regional [11C]DPN VT in controls  
There were no significant differences in [11C]DPN VT  between test and re-test conditions  for 
any of the ROIs in controls, indicating the test-re-test variability was low (e.g. Spearman’s 
rho 0.670, p=0.001 for hippocampi, left and right, and Spearman’s rho 0.604, p=0.003 for  
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TABLE 16: Full-factorial, multivariate GLM for repeated measures. ‘Scan’ as within-subjects factor, ‘Group’ and ‘Gender’ as between-subjects factors, ‘Age’ as 
covariate, and 6 pairs of scaled, regional [11C]DPN VT as dependent measures. Bold typeface denotes p < 0.005. df -  degrees of freedom. 
 
Effect Factor Measure Value 
F 
statistic 
Hypothesis 
df 
Error 
df 
Significance 
Partial Eta 
Squared 
Between Subjects Intercept Pillai's Trace 0.969 144.616 6 28 0.000 0.969 
 Age Pillai's Trace 0.470 4.145 6 28 0.004 0.470 
 Group Pillai's Trace 0.369 2.732 6 28 0.032 0.369 
 Gender Pillai's Trace 0.270 1.724 6 28 0.152 0.270 
 Group * Gender Pillai's Trace 0.506 4.783 6 28 0.002 0.506 
         
Within Subjects Scan Pillai's Trace 0.097 0.501 6 28 0.803 0.097 
 Scan * Age Pillai's Trace 0.088 0.449 6 28 0.840 0.088 
 Scan * Group Pillai's Trace 0.337 2.371 6 28 0.056 0.337 
 Scan * Gender Pillai's Trace 0.259 1.630 6 28 0.176 0.259 
 Scan * Group  *  Gender Pillai's Trace 0.084 0.430 6 28 0.853 0.084 
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fusiform gyrus, left and right). The mean VT over both scans was computed for each ROI, for 
each participant, to inform comparisons with the interictal and post-ictal data. 
 
5.4.6 Correlations between regional [11C]DPN VT and age 
There were no significant correlations between age and [11C]DPN VT for any of ROIs. 
 
5.4.7 Effect of spontaneous seizures and HS on regional [11C]DPN VT  
5.4.7.1 Effect of spontaneous seizures on regional [11C]DPN VT  
After spontaneous seizures and compared to the interictal state and controls, there was a 
significant increase in [11C]DPN VT in the parahippocampal gyrus (p=0.012 versus interictal; 
p = 0.032 versus controls; Table 17; Figure 27) ipsilateral to the electroclinical focus, which 
was not evident in the data prior to SFS-RR (p = 0.161 versus interictal; p = 0.246 versus 
controls). Ipsilateral post-ictal VT increases were also observed in the fusiform gyrus (p = 
0.012; p = 0.013) and the lateral temporal pole (p = 0.036; p>0.100 versus controls), after 
SFS-RR. These latter two increases were also evident in the uncorrected data, i.e. prior to 
SFS-RR.  
 There was no significant difference in [11C]DPN VT between post-ictal, interictal, and 
control scans in the ipsilateral hippocampus, amygdala, and sub-genual anterior cingulate 
gyrus.  
After spontaneous seizures compared to the interictal state and controls, there was a 
small increase in [11C]DPN VT in the fusiform gyrus (p = 0.017 versus interictal; p=0.012 
versus controls) contralateral to the electroclinical focus. A contralateral post-ictal VT 
increase was also observed in the temporal pole (p > 0.05 versus interictal; p = 0.012 versus 
controls). There were no significant differences in [11C]DPN VT between post-ictal, interictal,  
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TABLE 17: Effect of spontaneous seizures on regional [11C]DPN VT (post-SFS-RR). n/a – non-applicable; ROI – region-of-interest; sd – standard deviation; TLE – 
Temporal lobe epilepsy; VT – Volume-of-distribution; *  – p < 0.05 vs. Interictal; 
# – p < 0.05 versus controls. 
 
Region Group Lateralisation 
VT-ROI:VT-global post-ictal  
Mean (sd) 
VT-ROI:VT-global [TLE group – interictal  
Mean (sd) 
Parahippocampal gyrus TLE Ipsilateral 1.32 (0.08)*# 1.23 (0.10) 
  Contralateral 1.28 (0.11) 1.25 (0.07) 
 Controls Left n/a 1.24 (0.09) 
  Right n/a 1.23 (0.09) 
     
Fusiform gyrus TLE Ipsilateral 1.52 (0.13)*# 1.38 (0.15) 
  Contralateral 1.51 (0.10)*# 1.43 (0.11) 
 Controls Left n/a 1.36 (0.11) 
  Right n/a 1.37 (0.11) 
     
Lateral temporal pole TLE Ipsilateral 1.59 (0.13)* 1.43 (0.09) 
  Contralateral 1.62 (0.12)# 1.53 (0.03) 
 Controls Left n/a 1.42 (0.18) 
  Right n/a 1.42 (0.19) 
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FIGURE 27: Ipsilateral/left PHG scaled [11C]DPN VT post SFS-RR, across scan conditions.   
Participants with TLE are represented by red lines; the mean of the healthy controls group is represented by 
the blue line. DPN – Diprenorphine; PHG – Parahippocampal gyrus; SFS-RR – Structural and Functional 
Synergistic Resolution – Recovery; VT – Volume-of-distribution.   
 
and control scans within any of the other ROI homologs contralateral to the electroclinical 
focus.   
There were no significant post-ictal decreases in [11C]DPN VT in any region of 
interest, when compared against the interictal state or controls.  
 
5.4.7.2 Effect of HS on hippocampal [11C]DPN VT  
Across post-ictal and interictal conditions, [11C]DPN VT was (non-significantly) reduced in 
sclerotic hippocampi, relative to that seen in hippocampi of normal volume in participants 
with TLE and controls (see Table 18).  
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TABLE 18: Effect of spontaneous seizures on hippocampal [11C]DPN VT (post-SFS-RR) as a function of presence or absence of HS*. DPN – Diprenorphine; HS – 
Hippocampal sclerosis; MRI – Magnetic resonance imaging; n/a – non-applicable; ROI – Region-of-interest; ; sd – standard deviation; SFS-RR – Structural and 
Functional Synergistic – Resolution Recovery; TLE – Temporal lobe epilepsy; VT – volume-of-distribution; * - Data was generated using manually-delineated ROIs; # - p 
< 0.05 versus TLE-HS and controls groups.  
 
Region Lateralisation Group 
VT-ROI:VT-global  
post-ictal 
Mean (sd) 
VT-ROI:VT-global 
[TLE group – interictal] 
Mean (sd) 
Change in VT-ROI:VT-global 
[TLE: post-ictal – interictal; controls: test – retest] 
Mean (sd) 
Hippocampus Ipsilateral TLE-HS 1.18 (0.09) 1.19 (0.09) -0.01 (0.03) 
  TLE-MRI-normal 1.29 (0.01) 1.18 (0.03) 0.11 (0.05)# 
 Left Controls n/a 1.23 (0.10) -0.01 (0.09) 
      
 Contralateral TLE-HS 1.19 (0.11) 1.14 (0.09) 0.04 (0.04) 
  TLE-MRI-normal 1.29 (0.05) 1.28 (0.04) 0.01 (0.06) 
 Right Controls n/a 1.24 (0.10) -0.01 (0.08) 
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5.4.7.3 Effect of interaction between HS and spontaneous seizures on hippocampal 
[11C]DPN VT  
A non-significant post-ictal increase in ipsilateral hippocampal [11C]DPN VT was seen in 
the MRI-normal sub-group relative to the interictal state, those with TLE-HS, and controls 
(Table 19). 
 
5.4.7.4 Effect of interaction between HS and spontaneous seizures on regional 
[11C]DPN VT  
Post-ictal: interictal changes [11C]DPN VT did not differ significantly between MRI-
normal and  TLE-HS subgroups (Table 20). 
 
5.5 Discussion 
The author has demonstrated a post-ictal increase in [11C]DPN VT in the parahippocampal 
gyri in refractory TLE, which was not evident before multi-atlas segmentation and PVE 
correction.  
 The author was able to confirm previously reported increases in (scaled) opioid 
receptor availability of approximately 8% in the ipsilateral anterior temporal lobe 
following spontaneous seizures. After multi-atlas segmentation and application of SFS-RR, 
the magnitude of the post-ictal increases was increased to approximately 12 – 16% (Table 
16). Smaller increases were also identified in the contralateral fusiform gyri and temporal 
pole. Despite full quantification including arterial input functions and PVE correction, the 
post- ictal increases were only observed when differences in global mean were accounted 
for, in a manner analogous to SPM (voxelwise) analyses. Opioid peptide receptor binding 
per unit of grey matter was slightly decreased in sclerotic hippocampi, relative to MRI-
normal hippocampi of the TLE group, and to controls. Interestingly, a post-ictal increase  
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TABLE 19: Effect of hippocampal sclerosis on hippocampal [11C]DPN VT (post-SFS-RR).  DPN – Diprenorphine; MAPER - Multi-atlas propagation with enhanced 
registration and decision fusion; mm -  millimetres; ROI – region-of-interest; sd – standard deviation; SFS-RR – Structural and Functional Synergistic – Resolution Recovery; 
TLE – temporal lobe epilepsy; VT – volume-of-distribution.  
 
Segmentation Group Hippocampi VT mean (sd) VT-ROI:VT-global  mean (sd) Volume - mm
3 mean (sd) 
MAPER TLE Sclerotic 13.5 (1.0) 1.20 (0.11) 1672.6 (307.4) 
  MRI-normal 14.7 (2.0) 1.24 (0.11) 2282.0 (208.7) 
 Controls MRI-normal 14.4 (2.5) 1.23 (0.10) 2220.5 (314.9) 
      
Manual TLE Sclerotic 13.3 (0.9) 1.18 (0.08) 2480.5 (578.6) 
  MRI-normal 14.5 (2.1) 1.22 (0.09) 3113.0 (716.9) 
 Controls MRI-normal 14.4 (2.4) 1.23 (0.10) 2706.5 (473.2) 
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TABLE 20: Effect of spontaneous seizures on regional [11C]DPN VT (post-SFS-RR) as a function of presence or absence of  HS.  DPN – Diprenorphine; HS – 
Hippocampal sclerosis; MRI – Magnetic resonance imaging; n/a – non-applicable; ROI – Region-of-interest; sd – standard deviation; SFS-RR – Structural and Functional 
Synergistic Resolution – Recovery; TLE – Temporal lobe epilepsy; VT – Volume-of-distribution.  
 
Region Lateralisation Group Hippocampus 
VT-ROI:VT-global post-ictal 
Mean (sd) 
VT-ROI:VT-global [TLE group – interictal] 
Mean (sd) 
Parahippocampal gyrus Ipsilateral TLE Sclerotic 1.33 (0.09) 1.27 (0.09) 
   MRI-normal 1.31 (0.06) 1.16 (0.08) 
 Left Controls MRI-normal n/a 1.24 (0.09) 
      
Fusiform gyrus Ipsilateral TLE Sclerotic 1.56 (0.11) 1.42 (0.17) 
   MRI-normal 1.45 (0.14) 1.31 (0.11) 
 Left Controls MRI-normal n/a 1.36 (0.11) 
      
Lateral temporal pole Ipsilateral TLE Sclerotic 1.62 (0.11) 1.45 (0.09) 
   MRI-normal 1.53 (0.17) 1.40 (0.11) 
 Left Controls MRI-normal n/a 1.42 (0.18) 
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(9% relative to interictal) in opioid receptor availability was not seen in sclerotic hippocampi, 
while such an increase was seen in normal-sized, ipsilateral hippocampi. This trend did not 
reach statistical significance, and requires confirmation in a larger mTLE-HS and MRI-
normal cohort. If replicated, this trend would provide further evidence that pathophysiological 
mechanisms differ between these TLE sub-groups, as has also been suggested by studies 
using other techniques (Ho et al., 1996, Woermann et al., 1999). 
 The multi-atlas segmentation and RR techniques employed here allow the implication 
of several temporal lobe regions: parahippocampal gyrus, fusiform gyrus, and lateral temporal 
pole. The novel finding of post-ictal increases in the parahippocampal gyrus is notable, as 
previously only Rocha et al. (Rocha et al., 2007) had been able to identify altered opioid 
receptor binding in this region.  
 Interestingly, correction for global VT was necessary for the demonstration of focal 
post-ictal increases in [11C]DPN VT using a regions-of-interest approach. Across participants 
and test and re-test scans, there was a coefficient-of-variation in global VT of approximately 
16% for controls. The post-ictal increases identified in the ipsilateral temporal lobe might 
reflect preservation of opioid peptide receptor availability in the epileptogenic lobe coupled 
with a widespread post-ictal decrease in availability in other regions. Although small post-
ictal decreases in global [11C]DPN VT were observed for six of the eight participants, the 
groupwise the decrease did not reach statistical significance. 
 Participants were not excluded for making adjustments to their drug regimen during 
the course of the study. It was also not possible guarantee each of participant’s scans were 
acquired at the same time of day. Therefore, for the medicated participants in the TLE group, 
it is conceivable that between-scan variability in drug regimens could have influenced global 
VT.  
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 Correction for global uptake is routine in voxel-based analyses such as tests based on 
the comparison of parametric images. The finding suggests that it also should be considered 
for ROI-analyses to facilitate the identification of small but potentially meaningful alterations   
 in radioligand uptake/distribution.      
 
5.5.1 Opioid receptor availability in TLE 
Interpretation of PET studies of opioid receptor availability in TLE is challenging given the 
reports of mixed pro- and anti-convulsant properties of opioid peptides in animal models. 
Despite the appeal of a simple pro- or anti-convulsant concept, it is more likely that their 
effects are both context-specific (i.e. in relation to a seizure), receptor sub-type specific, and 
possibly even region-specific (Hammers et al., 2007a, Zieglgansberger et al., 1979).  
 A limitation of the single-injection PET technique lies in its inability to reveal the 
mechanism underlying any changes in the specific binding of a radioligand. Changes in VT 
can result from an altered affinity state of the receptor, down-regulation and internalisation of 
receptors - which can take place within minutes (Bohm et al., 1997) - or, on the other hand, 
increased surface receptor availability. For example, MOP-receptor recycling and resynthesis 
to 100% or more of control levels has been demonstrated within 30 minutes – 6 hours (Chen 
et al., 2003, Lecoq et al., 2004, Pfeiffer et al., 2003). Finally, release of endogenous ligands 
can account for changes in availability (Madar et al., 1997, Zubieta and Stohler, 2009).  
Given the above, comment on the pathophysiology responsible for this study’s 
findings, and also the net-effect of fluctuations in opioid peptide receptor neurotransmission 
on temporal lobe seizures, is speculative. Hammers et al. (2007) proposed an anticonvulsant 
model in which endogenous opioid peptide release occurs during seizures e.g. (Koepp and 
Duncan, 2000), as an innate, seizure-terminating response. Post-synaptic opioid peptide 
receptor up-regulation, proposed to contribute to the phenomenon of post-ictal seizure 
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suppression, was detectable by [11C]DPN PET at approximately 8 hours post-seizure, as 
reported here. The author elaborates the hypothesis by suggesting overshoot is followed by a 
gradual return to normal or low-normal levels of the KOP receptor (Theodore et al., 1992) in 
the interictal period; whereas MOP (Frost et al., 1988) and possibly DOP (Madar et al., 1997, 
Mayberg et al., 1991) receptor levels remain high, perhaps as a neuroprotective adaptation.  
The present study’s findings are concordant with this model and suggest increased 
OPR binding might contribute to post-ictal seizure suppression.  
 
5.5.2 Limitations  
The use of voxel-based techniques in earlier analyses (Hammers et al. 2007a) implies spatial 
transformations of the original imaging data and could arguably have induced artefacts. It is 
reassuring that post-ictal [11C]DPN VT increases in the ipsilateral fusiform gyrus and lateral 
temporal pole could be confirmed with the present technique in native data space.   
 The human cerebral cortex is approximately one to four millimetres thick, with 
considerable variation between regions (Han et al., 2006, Zilles, 1990, von Economo and 
Parker, 1929). The resolution of most PET cameras at the centre of the field of view can be 
approximated by a PSF of approximately 4 – 5 mm FWHM, with a reconstructed voxel size 
of approximately 2mm x 2mm x 2mm. It follows that the radioactivity concentration arising 
from the cerebral cortex will ‘spill-out’ into several surrounding voxels, leading to erroneous 
quantification. 
 SFS-RR can be used to improve the accuracy of quantification in cortex, but is limited 
by the accuracy of tissue-class (and anatomical) segmentation and co-registration, like other 
PVE correction methods that use MRI images (Tohka and Reilhac, 2008, Zaidi et al., 2006). 
The correction will be greatly undermined if smoothing is subsequently performed to enable 
voxelwise comparisons, as isotropic Gaussian filters are usually of at least 4 mm FWHM.   
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An additional limitation of the method is the need to specify a priori the degree of smoothing 
of the anatomical image that is equivalent to that of the PET image. Here, a filter of 4 mm 
FWHM was used, whereas the resolution of the PET camera used more closely resembles that 
of a 5 mm FWHM. A recent study suggests a discrepancy of -1 mm can be expected to result 
in a slight underestimation of signal, for example of approximately 3.5% in the caudate 
(Shidahara et al., 2012); this would not explain post-ictal – interictal increases within the 
same population, however. 
 Since the PVE affects the radioactivity distribution, the most direct approach to the 
PVE problem would consist in the application of the PVC methodology to the individual 
(dynamic image) frames. Whilst theoretically desirable, this is not feasible because of the 
very poor image-quality of the individual frames, and in particular those acquired just after 
radioligand injection. These frames are of such poor quality that even basic pre-processing 
steps such as frame-by-frame re-alignment are not possible. Moreover, the varying signal-to-
noise ratio across the time-length of the study would impose a varying degree of 
regularisation. This would be less troubling if the kinetic operators were linear, however, this 
is not the case for reversibly-bound radioligands like [11C]diprenorphine, where the target 
parameter is VT (or BP).   
The approach has been attempted (Reilhac et al., 2011) and further work in this field is 
of interest, but it has seldom, if ever, been used to analyse clinical datasets.  (Shidahara et al., 
2012) applied SFS-RR to two simulated, dynamic [11C]raclopride datasets in order to explore 
this approach. Whilst recovery of signal (BPND) in the caudate and putamen was impressive 
(up to 47%), considerable noise enhancement was observed. However, any bias introduced by 
the application of PVE correction procedures to parametric maps was negligible. These 
findings suggest that frame-wise PVE correction is unlikely to be a productive avenue to 
pursue. An alternative would be the incorporation of SFS-RR into iterative image 
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reconstruction schemes, and this will be investigated in the future. Here, SFS-RR was applied 
to VT images, rather than dynamic datasets, similar to many other PVE correction methods. 
The application of SFS-RR to parametric images rather than dynamic datasets is validated 
(Shidahara et al., 2009, Shidahara et al., 2012) and therefore should not diminish confidence 
in the findings. An advantage of this approach is that it facilitates the application of partial 
volume effect correction to previously reconstructed data, as in this thesis. 
The major limitation of the work is the limited sample size, due to the difficulties in 
recruiting for and performing post-ictal quantitative PET studies (Hammers et al., 2007a). The 
TLE group also includes participants with and without HS. Localisation was slightly tentative 
in TLE group participant 2, for whom ictal EEG data was not available. In addition, and as 
highlighted in the initial study (Hammers et al., 2007a), the exact duration of the interval 
between last seizure and PET scan was not quantified with certainty, as 
electroencephalography-telemetry was not available.  
 Another limitation is that [11C]DPN has quite a low volume-of-distribution in the 
hippocampus, when compared with that of surrounding regions; hence, the ability to reliably 
detect significant alterations in binding in this region may be reduced.   
 
5.6 Conclusion 
The findings provide further direct human in vivo evidence for post-ictal alterations of opioid 
peptide receptor availability in TLE. The author has demonstrated that resolution recovery 
and precise anatomical segmentation can extract valuable information from PET studies that 
would be missed with conventional post-processing procedures. Correction for global uptake 
can facilitate the identification of small but potentially significant alterations in radioligand 
distribution with regions-of-interest analyses. 
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6 GENERAL DISCUSSION  
In this thesis, the author reported the first use of [18F]GE-179 PET in healthy human control 
participants, and subsequently in participants with  frequent interictal epileptiform discharges. 
The author also reported the application of SFS-RR, a novel partial volume effect correction 
method, to post- and interictal [11C]DPN PET data acquired from participants with refractory 
temporal lobe epilepsy. The major theme of the work has been the advancement of the value 
of quantitative ligand PET imaging in the epilepsies, through the evaluation of novel tools.    
 
6.1 Summary of major findings 
The objectives (as defined in the Preface) were achieved, in addition to a thorough review of 
the relevant literature. The major findings were: 
1. [18F]GE-179 has high brain extraction in humans, with a relatively homogeneous and 
moderately-paced kinetics in grey matter, and is metabolised quite rapidly. 
Quantification of regional VT was feasible with a two-brain tissue, four-rate constants 
compartment model. Quantification was also feasible at the voxel level using rank-
shaping regularisation of exponential spectral analyses.  
2. Focal increases in [18F]GE-179 volume-of-distribution were identified in a minority 
(three) of 11 participants with frequent interictal epileptiform discharges. For two of 
the cases, the location of the largest increases roughly corresponded to the suspected 
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epileptogenic zone. However, similar increases were seen for three control 
participants, albeit smaller and less numerous. 
3. The application of the SFS-RR partial volume effect correction method enabled the 
novel detection of a post-ictal increase in ipsilateral parahippocampal gyral [11C]DPN 
volume-of-distribution. Previously reported post-ictal increases in the ipsilateral 
fusiform gyri and temporal pole were replicated. No significant abnormalities of 
[11C]DPN VT were identified in the hippocampi. 
 
6.2 Implications 
This thesis has characterised a novel PET radioligand and a novel PVE correction method.  
 
6.2.1 [18F]GE-179 
The findings from my [18F]GE-179 studies suggest that this radioligand may permit 
quantification of NMDA receptor activation in humans, in vivo. Moreover, they suggest that 
in a small proportion, e.g. 25%, of people with refractory focal epilepsy, NMDA receptor 
over-activation is detectable and focal. As such, this may contribute to epileptogenesis and 
neuronal excitability. 
 Further exploration of the utility of this radioligand as a research and clinical tool is 
therefore warranted. To find widespread application, the following remains to be 
demonstrated in larger cohorts: 
 Specificity for the NMDA receptor, in humans, in vivo 
 Low test – re-test intra-subject variability 
 Optimal quantification method 
 Sensitivity to identify epileptogenic (or other pathological) processes 
 Potential to localise epileptogenic (or other pathological) processes 
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 Potential limitations of the radioligand are the contribution of radiolabelled 
metabolites to the cerebral VT, and minimal heterogeneity with limited potential to detect 
focal increases (or decreases). The high global VT in seven participants with TLE, relative to 
controls, might suggests if excessive NMDA receptor-mediated neurotransmission is 
detectable, it might not be focal; in this case [18F]GE-179 PET would not have utility as a pre-
surgical evaluation. This would not necessarily preclude other potential applications, such as 
guidance of prognosis after traumatic brain injury, and monitoring of disease progression (not 
only in epilepsy, but in other neurological and psychiatric conditions).  
 
6.2.2 SFS-RR 
The findings from my application of SFS-RR to [11C]diprenorphine datasets highlight the 
value that can be added to PET studies through precise anatomical segmentation, and 
resolution recovery (PVE correction) techniques. The newly-identified post-ictal increase in 
the ipsilateral parahippocampal gyral VT may be significant in the mechanism of post-ictal 
seizure suppression; further work is required to address this. 
 SFS-RR has now been validated using a variety of clinical and simulated datasets 
(Shidahara et al., 2009, Shidahara et al., 2012). The simulations have demonstrated that 
application of the technique to parametric images significantly improves the accuracy of 
quantification. In this thesis, the author demonstrated in a real dataset acquired by a different 
PET camera and following injection of a different radioligand, that the application of SFS-RR 
(a) does not obscure foci of VT change identified through conventional analyses, and (b) 
facilitates the identification of novel, potentially relevant foci. The findings represent an 
important milestone, which now achieved, facilitate the permeation of SFS-RR into wider 
research and (hopefully) clinical use. Work in progress (Ying Hwey Nai, Image Analyst, 
Maccine Pte Ltd, Singapore) will develop a freely-distributed graphical user interface that 
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will allow the non-expert user to apply the technique with relative ease. SPM software is 
freely distributed; it and MATLAB (not freely-distributed) are widely used. Moreover, the 
computational and time demands are minimal. Potential applications abound in the epilepsies, 
neurological conditions such as Alzheimer’s disease, and psychiatric conditions such as 
schizophrenia, in which accurate quantification of distribution within small structures is vital.     
 
6.3 Limitations  
As for much in vivo clinical epilepsy research, the work presented in this thesis is limited by 
the small sample cohorts that were available for study. In the case of the [18F]GE-179 studies, 
the author intended to collate a larger dataset. Unfortunately, the PET centre, Hammersmith 
Imanet Limited, closed unexpectedly during the second year of this PhD research program 
before data acquisition could be completed. Data acquisition was also limited by the 
challenges of identification and recruitment of participants with sufficiently frequent IEDs. 
The SFS-RR study was limited by the difficulty in acquiring PET data within 24 hours of a 
participants’ seizure, and again when seizure-free for at least six days. MRI data was 
additionally no longer available for one of the nine participants with TLE, who was therefore 
excluded.   
Further limitations of the [18F]GE-179 studies are the considerable heterogeneity in 
the frequent IEDs group in terms of seizure frequency, extent of localising clinical data 
available, and site of presumed epileptogenic zone. Several of the participants were 
considered unsuitable for resective surgery due to a lack of concordant, localising data. As 
such, it is extremely difficult to evaluate the potential of [18F]GE-179 PET as a pre-surgical 
evaluation. However, the objective of this proof-of-principle study was rather to determine if 
focal increases in NMDA receptor activation were identifiable. In order to exclude the 
possibility of negative findings due to insufficient cortical excitability, only individuals with 
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extremely frequent IEDs were invited to participate. A consequence of the challenging cohort 
assembled, however, remains the difficulty in assigning clinical significance to the findings.  
Recruitment of well-localised cases without significant co-morbidity is challenging as such 
individuals have been investigated extensively as part of their clinical workup, are often 
invited to participate in multiple research studies, and where refractory, proceed to resective 
surgery rapidly.  
 To a lesser extent, the SFS-RR was also limited by a heterogeneous cohort; 
participants with TLE with or without hippocampal sclerosis. Thus, the sample presumably 
consists of a mixture of mesio-basal and neocortical epilepsies. These cannot necessarily be 
expected to share a common pattern of [11C]diprenorphine distribution and response to 
seizures. Indeed, and interestingly, hippocampal VT changes were suggested to differ between 
the subgroups – this requires further exploration in a larger study population. 
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7 FUTURE RESEARCH DIRECTIONS 
7.1 Future studies already feasible with data acquired  
The author intends to apply the SFS-RR PVE correction method to the [18F]GE-179 PET data 
reported in this thesis. This will improve the accuracy of quantification in smaller regions-of-
interest, thus facilitating characterisation of the radioligand and potentially identifying novel 
focal increases in [18F]GE-179 VT in the participants with frequent IEDs. 
 In the course of this thesis, the author applied SFS-RR PVE to a further three triplet 
[11C]diprenorphine datasets for three participants with severe, refractory depression. The 
scans were acquired before, midway through, and at the end of a course of electroconvulsive 
therapy. Several measures of affect and anxiety were obtained throughout the course of the 
study from these individuals, and also all the participants with epilepsy and the healthy 
controls who also had [11C]diprenorphine. The author intends to examine the relationship 
between [11C]diprenorphine VT, affect, and anxiety after correction for the PVE. 
 A graphical user interface is being developed for SFS-RR at present by the author’s 
collaborator (Ying Hwey Nai, Image Analyst, Maccine Pte Ltd, Singapore). The author (and 
his colleagues) will shortly test a beta-version of this software, before it is freely distributed. 
The influence of registration and segmentation errors on the accuracy of PVE correction with 
SFS-RR could be investigated with existing data; favourable data will facilitate uptake of the 
method.   
 In the course of this thesis, the author and a colleague acquired paired PET datasets 
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using [11C]MePPEP, a cannabinoid receptor type 1 radioligand from 12 participants with 
epilepsy (five with frontal lobe epilepsy, seven with temporal lobe epilepsy) and 14 healthy 
control subjects. 3T SPGR and diffusion-weighted imaging sequences were also acquired 
from each participant, along with several measures of anxiety, depression, memory (verbal- 
and non-verbal), and recreational drug use, amongst others. The author intends to examine 
post- and interictal cannabinoid receptor type 1 binding, as assessed by [11C]MePPEP, in 
participants with FLE. Subsequently, the relationships between [11C]MePPEP VT and the 
measures listed above will be examined. Finally, white matter integrity will be compared 
between participants with FLE and controls, with specific reference to the affective and 
cognitive measures. [Another colleague, Dr. Daniela Riaño Barros is analysing the TLE group 
at present]. 
 
7.2 Future prospective studies 
7.2.1 [18F]GE-179 and activated NMDA receptor availability 
The potential value of [18F]GE-179 as an in vivo marker of activated NMDA receptors could 
be further investigated in pre-clinical and clinical settings. Test – re-test studies in healthy 
controls will allow optimisation of quantification methods and scan protocol (e.g. perhaps 60 
minute scans would suffice). Positive findings such as low intra-subject variability would 
merit further exploration in larger patient cohorts.  
The specificity of radioligand for the NMDA receptor in humans in vivo will be 
particularly difficult to address, given that blockade of NMDA receptors is poorly tolerated 
(Forst et al., 2007). Thus, specificity of radioligand binding may need to be inferred from 
preclinical studies and slight reduction in VT with partial blockade in humans. The study of 
primates rather than humans might facilitate pre-treatment with competitive NMDA receptor 
antagonists (i.e. blocking studies), however, the use of anaesthesia is a potential confound. 
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Studies in primates might also provide a more relevant estimate of the concentration of 
radiolabelled metabolites in the brain. Evaluation of the localising capacity of [18F]GE-179 
PET in a larger, pre-surgical cohort with well-localised, symptomatic focal epilepsies offers 
the potential to corroborate VT estimates with intracranial EEG, NMDA receptor histology, 
and autoradiography in resected brain tissue. Such studies are being planned at present. 
Hippocampal NMDA receptors are implicated in consolidation of intermediate-term memory 
(for review see: (Foster, 2012), but resting-state [18F]GE-179 VT was low in this region. 
Therefore, further evidence of specificity of binding could be sought by through 
demonstration of an increase in hippocampal [18F]GE-179 VT with performance of a 
hippocampal-dependent, episodic memory paradigm, provided the influence of cerebral blood 
flow (i.e. K1) is accounted for in the analysis.  
If focal increases in [18F]GE-179 VT are hypothesised to depict actively discharging 
epileptic cerebral cortex, then co-localisation with EEG-fMRI-derived clusters and MEG 
source localisation might be expected. Concordance with measures of glutamate and 
glutamine concentration derived from magnetic resonance spectroscopy ((Otsuki et al., 2005, 
Pfund et al., 2000), for review see: (Petroff et al., 2000)) might also be expected. However, 
whilst such studies would be informative, methodological limitations apply to all three 
modalities, and interpretation will be limited be the lack of ‘ground truth’ in the population. 
Longitudinal studies could be performed in participants with new-onset epilepsies, or in 
participants with recent acute head injury, to assess the prognostic value of [18F]GE-179 VT.   
Alternative PET radioligands are also emerging that offer the potential to quantify 
expression of metabotropic receptors of the glutamatergic neurotransmission system 
(DeLorenzo et al., 2011). These should be explored and may hold greater value than [18F]GE-
179.  
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7.2.2   Opioid peptide receptor availability and SFS-RR 
The results of the SFS-RR study await replication in a larger cohort, scanned with modern 
PET and MRI cameras. The finding of ipsilateral post-ictal [11C]diprenorphine increases 
could be elaborated on by the acquisition of DOP-, KOP-, and MOP-selective PET data in the 
interictal, ictal, and post-ictal setting. Such a study is likely to be logistically challenging, 
however. An additional objective could be to compare ipsilateral temporal lobe opioid 
receptor availability between mTLE-HS and MRI-normal, neocortical temporal lobe epilepsy.    
PET is increasingly moving towards hybrid PET/MRI systems (for review see (Sauter 
et al., 2010, Zaidi and Del Guerra, 2011). As acquisition of structural MRI becomes near-
ubiquitous, the potential for application of SFS-RR will increase. Co-registration of PET to 
MRI data can be expected to improve, with consequential increase in the accuracy of partial 
volume effect correction with the SFS-RR method. The potential benefits of incorporating 
into the software more rigorous MRI registration and anatomical segmentation algorithms, 
such as DARTEL (Diffeomorphic Anatomical Registration using Exponentiated Lie algebra; 
(Ashburner, 2007)), should be examined. The DARTEL algorithm is implemented in SPM8 
and therefore has the advantage of compatibility with the existing SFS-RR components. 
Formal incorporation of MAPER into the software should be considered before widespread 
distribution. The limitation of atlas accuracy could be minimised by the incorporation of 
further regions of interest into the Hammersmith atlas (Hammers et al., 2003a), such as sub-
regions of the parietal lobes and of structures of the basal ganglia.  
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